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5-FU  5-fluorouracil
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LOOCV  Leave-one-out cross-validation
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NCBI  National Center for 
Biotechnology Information
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NRC  National Research Council
OECD  Organisation for Economic 
Co-operation and Development
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PC  Principal component
PCA  Principal component analysis
PenG  Penicillin G
RA  Retinoic acid
REACH  Registration Authorization and 
Evaluation of Chemicals
RIN  RNA Integrity Number
RMA  Robust Multichip Average
ROC  Receiver Operating 
Characteristic
RT-PCR  Real-time polymerase chain 
reaction
SACC  Saccharin
TDI  Triadimefon
VPA  Valproic acid
WARF  Warfarin
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General introduction 13
Alternative methods in developmental toxicology
Current developmental toxicity testing is via in vivo experimentation
The importance of testing for developmental toxicity became evident in the early 1960s 
due to the discovery of the teratogen thalidomide. Prescribed as a mild sedative to 
pregnant women, thalidomide exposure resulted in severe congenital malformations in 
more than 10,000 children [1]. This disaster illustrated the potential impact of prenatal 
chemical exposures and emphasized the importance of hazard identification of these 
compounds. In the 1980s, toxicity test guidelines established at the Organisation for 
Economic Co-operation and Development (OECD) have been implemented in order 
to improve the detection of the developmental toxic properties of compounds. These 
OECD guidelines cover the critical stages of reproduction and development, i.e. matu-
ration, mating and gestation, and are based on animal experimentation. Specifically 
regarding the assessment of developmental toxicity, at least two generations of ani-
mals are needed. Consequently, these studies are costly, time-consuming, and require 
considerable numbers of laboratory animals. Because the potential impact of develop-
mentally toxic effects of a compound is significant, studies evaluating developmental 
toxicity are of great importance. However, the continued use of relatively large numbers 
of experimental animals for toxicity testing raises ethical issues and is inconsistent 
with growing emphasis on reduction, replacement and refinement of animal use [2]. 
Moreover, the number of experimental animals that are needed for the assessment of 
potential toxicity is expected to increase because of the new EU regulation for Registra-
tion Authorization and Evaluation of Chemicals (REACH) [3]. Altogether, this motivates 
the design of alternative methods that could predict developmental toxicity at an early 
stage of compound development while requiring only a small volume of compound and 
a minimal number of experimental animals.
The Embryonic Stem cell Test as alternative testing model
Blastocyst-derived murine pluripotent embryonic stem cells (ESC) can be induced to 
differentiate in culture into a wide variety of cell types, including cardiomyocytes. This 
differentiation pathway is the basis of the Embryonic Stem cell Test (EST), which was first 
described by Spielmann et al. [4]. Cardiomyocytes have been selected as target cells due 
to the easy visual identification of contracting cells in differentiated ESC cultures. In ad-
dition, the in vitro differentiation into cardiomyocytes has been extensively investigated 
and standardized. Using the hanging drop culture technique [5], ESC form multicellular 
aggregates, named embryoid bodies (EB). EB resemble the egg-cylinder stage of a 
5-day-old embryo. Within the EB, the three germ layers endo-, ecto- and mesoderm can 
develop [6]. Further differentiation into cardiomyocytes can be induced by cultivation 
in suspension culture for two days followed by plating onto tissue culture plates. This 
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specific culture method results in EB with foci of contracting cardiomyocytes (Figure 1). 
Inhibition of differentiation is determined by microscopical inspection of contracting 
cardiomyocytes at day ten of differentiation. The effect of compound exposure on dif-
ferentiation of ESC into cardiomyocytes is regarded as a measure of the embryotoxicity 
of compounds. A standard protocol for the EST is available from the European centre for 
the validation of alternative methods (ECVAM) website [7].
Stem cell research dates back to the early 1970s, when pluripotent embryocarcinoma 
cells (ECC), the stem cells derived from teratocarcinomas, were established as cell lines 
[8, 9]. ECC can be induced to differentiate in culture into a wide variety of tissues. At first, 
these cells served as a model system to study early differentiation in the mammalian 
áÁ
áÁ
áÁ
áÁ
áÁ
áÁ
áÁ
Day 3: EB in suspension culture
Day 5: EB in tissue culture plates
Day 10: Evaluation contracting 
                cardiac muscle foci
Day X: Routine ESC culture
Day 0: Hanging drop culture
Figure 1. Differentiation protocol for embryonic stem cell (ESC) differentiation. Undifferentiated ESC 
are cultured as hanging drops. Single cell suspensions aggregate and form embryoid bodies (EB). EB are 
further cultured in suspension culture. At day 5, EB are plated on tissue culture plates. The morphology 
of routine culture and untreated EB at day 3, 5 and 10 is shown. The classical end point is microscopic 
evaluation of contracting foci.
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embryo. Later, the interference of teratogenic compounds with ECC differentiation was 
also studied [10]. ECC, however, may have chromosomal aberrations, may lose their 
ability to differentiate, or may differentiate in vitro only under specialized conditions 
and with chemical inducers [11]. After the isolation of the ESC from mouse embryos 
[12, 13] these problems could gradually be overcome and ESC have become the stan-
dard for studying cell differentiation in culture. Mouse ESC were initially grown under 
comparable conditions as ECC, in medium containing bovine serum on a layer of mouse 
embryonic fibroblasts (called ‘feeder cells’) to keep ESC pluripotent. The addition of the 
cytokine leukemia inhibitory factor (LIF) to serum-containing medium allows mouse ESC 
to proliferate without differentiation, the so-called self-renewal, in the absence of feeder 
cells [14]. Differentiation of ESC into all cell types of the three primary germ layers can 
be induced by withdrawal of LIF combined with specific culture conditions sometimes 
combined with addition of specific growth factors [15].
The EST is unique in that in a relatively simple cell-line-based assay it incorporates the 
entire differentiation pathways from pluripotent embryonic stem cell to differentiated 
cells including cardiac muscle cells. The variation of cell types in the assay at the end of 
culture, including ectoderm-, endoderm- and mesoderm-derived cells, stipulates that 
cell-cell interactions may play a crucial, though as yet undisclosed, role in the formation 
of cardiac cells in the EST [6]. Effects of compounds at any stage of the differentiation 
process can be studied. Furthermore, the test is devoid of experimental animal use and 
is based on mammalian cells. Recent research has shown that the test may be repro-
duced with human embryonic stem cell lines [16, 17]. On the other hand, the current 
single-lineage readout of the EST may confer a limitation to the assay. The assay by 
nature provides a reductionistic approach in view of the interaction among regulatory 
mechanisms and the complexity of pattern formation in embryogenesis which may 
reduce the applicability domain of the EST.
The EST in Chemical Evaluation
An interlaboratory study was carried out to assess the predictive capacity of the EST. A 
selection of 20 test compounds, assigned to three classes as non, weakly and strongly 
developmental toxicants, on the basis of an in vivo database [18] were tested under 
blind conditions in four different laboratories from governmental institutions and in-
dustry [19, 20]. An algorithm-based mathematical prediction model was developed to 
convert the in vitro results into a prediction of in vivo developmental toxicity. The EST 
achieved an overall accuracy of 78%. All strongly developmental toxicants were cor-
rectly identified, but the separation of non from weakly developmental toxicants was 
not convincing. The selected strongly developmental toxicants represented a limited 
number of mechanisms of toxicity, most of them affecting cell proliferation.
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Additional testing of developmental toxicants with other toxicological mechanisms 
could improve the reliability of EST for a broader range of compounds. The predictivity 
of the was also studied for in-house and marketed pharmaceuticals [21, 22]. Although 
receptor-mediated compounds were excluded from the validation set, the overall ac-
curacy for marketed pharmaceuticals showed to be 85% but for in-house compounds 
only 53%, mainly due to bad separation of non from weakly developmentally toxic phar-
maceuticals. Although the EST is a formally validated alternative test method, additional 
investigations are needed to further define the relevance of the EST [23]. An improved 
definition of the applicability domain, which is defined as the chemical classes and/or 
ranges of test method end points for which the model makes reliable predictions [23], is 
of importance to increase the mechanistic understanding of the EST. This is essential for 
defining the optimal use of the EST in a test strategy. In addition, the predictive capacity 
associated with the EST needs to be assessed to ensure reliable toxicity identification.
Trends in improving the EST
To improve the subjective end point evaluation of the EST, it has been suggested to 
replace the subjective morphological end point evaluation at day ten of differentiation 
by a reporter gene assay [24]. In this assay green fluorescent protein (GFP) is expressed 
under control of α-actin, a cardiac-specific promoter. By measuring the change in GFP 
expression, the effects of compounds on cardiac differentiation can be measured quickly 
and quantitatively. This method is therefore more suitable for high-throughput screen-
ing. Cardiomyocyte differentiation can be objectively quantified with flow cytometry 
using the cardiac-specific marker proteins Myosin and Actinin [25]. This illustrates the 
possibility to introduce molecular end points into the EST.
As an alternative to the late cardiomyocyte protein-marker evaluation, gene expres-
sion analysis could be used to detect early responses shortly after exposure, which may 
speed up the testing procedure. By implementation of transcriptome assays into the 
differentiation assay of the EST, developmentally-important pathways can be revealed 
that are activated during different phases of differentiation [26-29]. Changes on the 
gene expression level upon exposure to embryotoxic compounds could show inhibition 
of differentiation via effects on these specific pathways. In the EST, so far only changes in 
gene expression induced by compound exposure have been studied in a small selected 
group of genes [30, 31]. Whole genome microarrays have been used in other ESC-based 
models to identify valproic-acid-induced gene-expression changes [32]. These studies 
suggest that inclusion of selected target gene-expression markers allows prediction of 
developmental toxicity. Whole genome microarray analysis could lead to the identifica-
tion of predictive gene subsets, which can be utilized for routine screening applications.
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The use of toxicogenomics for predictive toxicology
Technical developments in molecular biology have resulted in tools that are capable 
of measuring thousands of end points in one single assay, such as transcriptomics that 
evaluates genome-wide gene expression. Transcriptomic approaches are currently 
widely employed in research in physiology, pathology and toxicology, and because 
this technique provides a specific evaluation of gene expression it extends the scale 
and depth of understanding biological processes. Transcriptomic profiling can be used 
for the identification of biomarkers that may improve the prediction of specific toxic 
effects. In addition, identified biomarkers may be used for improved discrimination of 
compound classes, because exposures that affect similar biological processes will likely 
share comparable gene expression changes. The application of genomics within toxicol-
ogy is commonly referred to as toxicogenomics.
Most studies that used toxicogenomics to study prediction of toxicity have been 
performed in the field of carcinogenesis [33-37]. Many investigations aimed at discrimi-
nating carcinogens from non-carcinogens based on their gene expression profile and at 
identifying biomarker genes for the prediction of carcinogenicity, mostly using in vivo 
models. Among the first studies in this field, Kramer et al. showed that gene expression 
profiles of rat livers exposed for five days to carcinogens could be discriminated from 
those of non-carcinogens [33]. This finding, supported by many others, showed the 
principle that gene expression profiling may be useful for the identification of carcino-
genicity. Other studies proved via cross-validation that small gene sets could success-
fully be used in the discrimination of carcinogens from non-carcinogens [34, 35]. Later, 
the great robustness of the use of gene signatures for the prediction of carcinogens was 
shown by the independent validation of identified gene sets [36, 37]. Besides the use 
of toxicogenomics for carcinogenicity prediction, this approach has also shown to be 
useful in predicting other toxic responses, including endocrine disruption [38], immune 
toxicity [39, 40], and developmental toxicity [32, 41].
To date, studies that use in vitro predictive toxicogenomics have been less frequently 
reported as compared to in vivo studies. It has been shown that gene expression pat-
terns of in vivo and in vitro models upon toxicant exposure were comparable, although 
differential gene expression levels were less extensive in in vitro cultured cells [42-44]. 
Also in in vitro toxicity prediction, the focus has been on prediction of carcinogenicity 
and hepatotoxicity. The ability to distinguish compounds with different mechanisms of 
action was demonstrated by Burczynski et al. using transcriptomic profiling on exposed 
HepG2 human hepatoma cells [45]. Later, successful attempts to predict potential toxic 
effects using transcriptomics have been described for hepatotoxicants [46], (hepato)
carcinogenic compounds [47] and sensitizing agents [48].
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Within the field of developmental toxicology, toxicogenomics has contributed to the 
understanding of developmental processes and mechanisms of action of a variety of 
developmental toxicants, such as compounds with estrogenic activity [49, 50], triazoles 
[51], valproic acid [52] and metals [53, 54]. However, limited studies have been published 
that addressed the prediction of potential developmental toxicity of existing and novel 
compounds using in vitro models. In a study of Robinson et al., gene expression profiling 
in compound-exposed whole embryo cultures showed distinct and relevant alterations 
in gene expression that precede developmentally toxic responses [55], indicating that 
transcriptomics-based alternative methods may also be successful to predict develop-
mental toxicity.
Analysis tools for transcriptomic data
Since transcriptomic studies generate large data sets, a challenging task is the interpre-
tation of the gene expression responses that are induced by compound exposure [56]. 
Normally, first differentially expressed genes are identified, since these genes reflect the 
biological processes changed by the experimental condition. These genes of interest 
can be selected by defining threshold values, such as p-value or false discovery rate 
(FDR) sometimes in combination with fold change. The genes differentially expressed 
above the threshold(s) are then selected for further biological interpretation. Different 
methods such as cluster analysis [57], principal component analysis (PCA) [58] and self-
organizing maps [59] can be useful tools to identify similar gene expression patterns 
of experimental groups or genes [60]. Because genes reacting similarly to a specific 
stimulus are expected to be functionally related, further study on biological functions of 
these genes will be a logical next step in data interpretation.
Information on the biology of individual genes can be derived from manual data-que-
ries in scientific literature and databases, such as Gene Ontology (GO) [61, 62], National 
Center for Biotechnology Information (NCBI) [63] and the Comparative Toxicogenomics 
Database (CTD) [64, 65]. These approaches are often used, but have the drawback that 
they are time-consuming and depend to a large extent on the researcher’s preferences 
and knowledge of biological mechanisms.
The biological functionality of the regulated genes can also come from analysis pro-
grams that calculate overrepresentation of genes annotated to biological processes or 
molecular function, such as DAVID [66, 67] or ErmineJ [68, 69]. Although these analyses 
result in lists of genes that share biology, function or location within the cell, they lack 
the level of biological information that provides the interrelation between genes, the 
‘ordered assemblies of functions’ that collaborate to produce a biological function [70]. 
Other approaches are available to describe interconnection between genes and pro-
teins in pathway format and to implement these into subsequent analyses. Examples of 
pathway analysis tools are the publicly available GenMAPP [71] and KEGG [72], and the 
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commercial MetaCore [73] and Ingenuity Pathway Analysis Tool [74]. Pathway analysis 
tools have shown to be useful in numerous studies [75-77], however ESC-related pro-
cesses such as self-renewal and differentiation are not yet sufficiently covered within 
these pathway tools. To overcome this limitation, 20 research groups of academia and 
industry combined their expertise in the ‘Functional genomics in embryonic stem cells’ 
(FunGenES) Consortium, resulting in the FunGenES database [78, 79]. This interactive 
database is based on data of 11 diverse settings representing 67 experimental condi-
tions, and organized with a number of novel features and search tools to promote 
studies in the biological properties of ESC. So far, several studies have taken advantage 
of the FunGenES database as a comprehensive resource for studies into ESC biology [80, 
81].Another strategy to study functional enrichment of genes is studying group-wise 
effects on gene sets, for example using Gene Set Enrichment Analysis (GSEA) [82] or 
T-profiler [83]. These methods include the complete gene expression data to test the 
expression changes of genes in the context of a functional set. This approach can target 
gene sets whose constituents show subtle but coordinated expression changes that 
might not be detected by the individual gene analysis. Although this approach lacks the 
level of biological information, which provides the interrelation between the genes, this 
method allows the identification of regulated gene sets of which the individual genes 
may not meet significance thresholds.
Objective and outline of this thesis
Objective of the thesis
There is a high demand for in vitro alternatives in the field of reproductive and devel-
opmental toxicity. Although the EST has been formally validated, several aspects of the 
assay need improvement to allow successful implementation of the EST as alternative 
testing method in regulatory toxicity testing. These aspects include the long culture 
duration and subjective end point scoring as well as the undefined applicability domain 
and undefined predictability of the EST model. Genomic technologies have incredibly 
enhanced the number of end points that can be evaluated simultaneously. The value of 
genomics within toxicology has been shown by identification of gene expression profiles 
reflective of compound-induced toxicity, such as those characteristic for carcinogenic 
compounds. It is expected that the implementation of genomics into the EST will pro-
vide a more detailed end point evaluation as compared to the classical morphological 
scoring of differentiation cultures. Therefore, genomics may contribute to the definition 
of the applicability domain of the EST leading to an improved predictive ability of the 
assay. Furthermore, the use of toxicogenomics may shorten the culture duration and 
enable objective end point evaluation. Therefore, the aim of this research is to optimize 
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the EST for identifying potential developmental toxicity of compounds using transcrip-
tomics. An overview of the experiments described in this thesis is provided in Figure 2. 
This transcriptomics-based EST may ultimately contribute to reduction and replacement 
of animal experimentation within developmental toxicity testing.
Outline of the thesis
A more detailed description of processes active during ESC differentiation may contrib-
ute to an improved definition of the relevance of the EST. In this regard, the intertwined 
relation of proliferation and differentiation in ESC differentiation has been extensively 
studied in chapter 2. The results were used to optimize the experimental procedures 
of the EST leading to a more specific evaluation of compound-induced effects on ESC 
differentiation, which is considered more specific for developmental toxicants.
To characterize ESC differentiation on the gene expression level, differential gene 
expression changes were identified by transcriptomics using cultures sampled at 6, 12, 
and 24h after the initiation of ESC differentiation as described in chapter 3. All genes 
up-regulated during this phase of ESC differentiation were combined in a gene set. 
Furthermore, gene expression analysis was performed using ESC differentiation cultures 
exposed for 6, 12, or 24h to the developmental toxicant monobutyl phthalate (MBP) 
to provide a proof-of-principle that developmental toxicants can be identified via their 
altered gene expression profile in ESC differentiation cultures.
Chapter 4 describes the gene expression of differentiating ESC 0, 24, 48, 72 and 96h 
after initiation of differentiation to further characterize ESC differentiation. A novel PCA-
based approach, the ‘differentiation track’ approach, was introduced to describe normal 
ESC differentiation in the EST. Furthermore, gene expression profiles of ESC differentia-
tion cultures exposed to the developmental toxicants MBP and 6-aminonicotinamide 
were analyzed by transcriptomics to study the possibility of identification of compound-
induced differentiation-modulating activities by deviation from the ‘differentiation track’.
The topic of chapter 5 is the optimization of the ‘differentiation track’ approach for the 
identification of developmental toxicants. Within this study, the transcription effects of 
six compounds were tested in the EST. The gene expression data was used to identify a 
novel biomarker gene set for developmental toxicity prediction using the ‘differentiation 
track’ method. Leave-One-Out cross validation was applied to validate this optimized 
approach.
In chapter 6, the identification of potential developmental toxicants using the ‘dif-
ferentiation track’ approach in the EST with predefined gene sets, described in chapter 3 
and 5, was evaluated. For this evaluation, ESC differentiation modulation of compounds 
with diverse modes of action and teratogenic effects were tested at single effective 
concentrations. Furthermore, the data revealed a correlation between ESC differentia-
tion inhibition and identification of developmental toxicants. Since ESC differentiation 
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Figure 2. Overview of experiments described within this thesis.
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inhibition is determined by compound concentration, it was expected that identifica-
tion of developmental toxicants will be improved by analyzing transcriptomic responses 
of compounds in a concentration-response design.
Concentration-related gene expression regulation is the subject of chapter 7. In this 
chapter, differentiation modulation of the developmental toxicant flusilazole was stud-
ied by analyzing concentration-dependent transcriptional responses in differentiating 
ESC.
The use of gene expression profiling to discriminate compound classes with distinct 
modes of action was described in chapter 8. Phthalates and triazoles were used in this 
proof of principle study. Three approaches were used to study class-characteristic gene 
regulation that may be useful for discrimination of compound classes. In addition, data 
of the phthalate compounds was used to study the identification of the developmentally 
toxic phthalates using a category approach.
All data described in chapter 5, 6 and 7 are combined in a new integrated analysis 
that is described in chapter 9. This study aimed at identifying a gene set that allows 
for improved prediction of developmental toxicity based on all available data. Random 
gene sets were sampled and evaluated to identify the best performing genes for predic-
tion of developmental toxicity using the ‘differentiation track’ approach.
Chapter 10 explores a new approach that takes gene sets from literature as input and 
uses gene co-occurrence for mapping a co-regulation network. Using this approach, 
novel genes, previously not associated with stem cell or organ development, were iden-
tified. The time-series described in chapter 4 were used to visualize the differentiation 
process.
Chapter 11 contains a summary of the results and the general discussion on the 
use of the EST combined with toxicogenomics for the identification of developmental 
toxicants. Furthermore, additional improvements necessary to bring the EST assay to 
the next level that will allow regulatory acceptation of the test were discussed.
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Disentangling cellular proliferation 
and differentiation in the Embryonic 
Stem cell Test, and its impact on 
the experimental protocol
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Abstract
The mouse Embryonic Stem cell Test (EST) was designed to predict embryotoxicity 
based on the inhibition of the differentiation of embryonic stem cells (ESC) into beat-
ing cardiomyocytes in combination with cytotoxicity data in monolayer ESC cultures 
and 3T3 cells. In the present study, we have tested a diverse group of chemicals in EST, 
applying different exposure durations, in an attempt to discriminate between effects on 
proliferation and differentiation within the EST protocol. Chemicals tested were mono-
butyl phthalate (MBP), 6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) and 5-bromo-
2’-deoxyuridine (BrdU). We showed that 5-FU and BrdU behaved principally different 
from MBP and 6-AN. 5-FU and BrdU specifically affected cell proliferation during the 
first three days of the EST protocol, as shown by EB size, protein concentration and cell 
cycle stage analysis. In addition, we studied the differentiation state of cells in the EST 
protocol with time to elucidate the transition of pluripotent ESC to more differentiated 
cell types. Analysis by flow cytometry of the pluripotency marker SSEA-1 in EST showed 
that although total SSEA-1 positive cells remained unchanged up to and including day 
5, the signal intensity already decreased from day 3 onwards. Furthermore, RT-PCR data 
showed an up-regulation of the mesodermal marker T at day 3, whereas the cardiac 
muscle marker Myh6 was up-regulated from day 5 onwards. These findings confirm 
that proliferation and differentiation of ESC in the EST are highly intertwined processes. 
Based on these findings we suggest an amended EST protocol which could more clearly 
discriminate between proliferation and differentiation effects of chemicals within the 
same EST differentiation protocol. This proposal includes a cytotoxicity assessment in EB 
at day 3 of the EST after day 0-3 exposure, and cardiac muscle foci counts after exposure 
from day 3-10 in the EST.
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Introduction
In the field of developmental toxicology, a range of in vitro methods has been developed 
with the aim to predict in vivo embryotoxicity whilst reducing animal experimentation. 
Among the spectrum of these tests are zebrafish embryo, rat whole embryo and organ 
cultures, and cell line based tests [19, 84-86]. Animal-free cell line based assays include 
the European centre for the validation of alternative methods (ECVAM) validated Em-
bryonic Stem cell Test (EST) which is probably the most extensively studied test in its 
class [19]. This method uses murine embryonic stem cells (ESC) which can be induced 
to differentiate into cardiomyocytes via formation of embryoid bodies (EB). EB bear 
similarities with the inner cell mass of egg-cylinder-stage embryos and develop cells 
of meso-, ecto-, and endodermal origin upon continued in vitro culture [6, 87]. This 
EB-based differentiation culture is therefore a powerful starting point for studying in 
vitro inhibition of embryonic cell differentiation, that may be used for the prediction of 
embryotoxicity of chemicals. In the EST, the extent of cardiomyocyte differentiation is 
microscopically evaluated after 10 days culture. In the standardized assay, cytotoxicity 
and differentiation inhibition data of the selected compound are combined to predict 
the degree of embryotoxicity using a mathematical prediction model. The interpreta-
tion of EST results is therefore highly dependent on the relative potency of a chemical 
as regards its cytotoxicity versus its differentiation inhibition. It is known that during dif-
ferentiation of ESC, proliferation gradually decreases and concomitantly differentiation 
increases [88, 89]. Consequently, when specific effects on differentiation are of interest, 
exposure should perhaps start later in the protocol. This would avoid inhibition of pro-
liferation in the EB formation stage during the first three days of the protocol and may 
provide a more specific differentiation-mediated response, less influenced by effects on 
cell proliferation, and possibly improving prediction.
To test this hypothesis, we selected four compounds based on the ECVAM test 
compound list for validation of embryotoxicity tests [90], and exposed the cells during 
different exposure periods. These compounds were selected on the basis of their in vivo 
and in vitro potency and because they do not need metabolic activation. Monobutyl 
phthalate (MBP) [91-93] and 6-aminonicotinamide (6-AN) [94-96] were selected as spe-
cific embryotoxicants, 5-fluorouracil (5-FU) [97, 98] and 5-bromo-2’-deoxyuridine (BrdU) 
[99-101] were selected as known proliferation inhibitors. We demonstrate that in EST 
5-FU and BrdU behave principally different from MBP and 6-AN in terms of cytotoxicity 
versus differentiation inhibitory potencies. In addition, we show new data indicating 
that differentiation in the EST is a gradual process, detectable as early as day 3 in the 
protocol, with beating muscle foci detectable at day 7 of culture. We discuss the possible 
consequences of these findings for the EST exposure protocol.
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Materials and methods
Pluripotent embryonic stem cell culture
Pluripotent mouse D3 embryonic stem cells (ESC; ATCC, Rockville, MD) were routinely 
subcultured every 2-3 days and grown as a monolayer in complete medium, consisting 
of Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL, Gaithersburg, MD) supple-
mented with 20% fetal bovine serum (Hyclone, Logan, UT), 1% non-essential amino ac-
ids (Gibco BRL, Gaithersburg, MD), 1% penicillin/ streptomycin (Gibco BRL, Gaithersburg, 
MD), 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD) and 0.1 mM β-mercapto-ethanol 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Leukemia inhibitory factor (LIF; Chemi-
con, Temecula, CA) was added directly to the culture disk in a final concentration of 1000 
units/ml. The cells were maintained in a humidified atmosphere at 37°C and 5% CO2.
Cardiomyocyte differentiation culture
Embryoid body (EB) formation was used as for the initial step for ESC differentiation 
cultures. EB were obtained via hanging drop culture in complete medium without LIF, 
carried out according to De Smedt et al. [102]. In brief, stem cell suspensions (3.75·104 
cells/ml) were placed on ice before the set up of the culture (Figure 1). Drops (20 µl) 
containing 750 cells were placed onto the inner side of the lid of a Petri dish filled with 
phosphate buffered saline (PBS; Gibco BRL, Gaithersburg, MD) and incubated at 37°C, 
90% relative humidity and 5% CO2. After 3 days of hanging drop culture EB had formed 
and these were subsequently transferred to bacterial Petri dishes (Greiner Bio-one, Frick-
enhausen, Germany). On day 5, 24 EB were plated one per well into 24-well tissue culture 
plates (TPP, Trasadingen, Switzerland). Differentiation was determined microscopically 
at day 10 of differentiation by inspection of EB outgrowths into contracting myocardial 
cells. EB were considered as cardiomyocyte positive if at least one contracting focus was 
present. The number of positive EB was expressed as fraction of total EB examined.
Derivation of concentration-response curves and determination of ID50 concentrations
Differentiation cultures were exposed to monobutyl phthalate (MBP; TCI Europe, 
Zwijndrecht, Belgium; CAS No. 131-70-4), 6-aminonicotinamide (6-AN; Fluka, Buchs, 
Switzerland; CAS No. 329-89-5), 5-fluorouracil (5-FU; Sigma-Aldrich, Zwijndrecht, The 
Netherlands; CAS No. 51-21-8), or 5-Bromo-2’-deoxyuridine (BrdU; Sigma-Aldrich, Zwijn-
drecht, The Netherlands; CAS No. 59-14-3). In addition, appropriate solvent concentra-
tions were tested in control differentiation cultures. The different exposures started at 
day 0, 3, 4, 5 or 7 and continued until the microscopical evaluation of the differentiation 
into contracting myocardial cells on day 10 (Figure 1). The incubations with MBP ranged 
from 0.045-4.5 mM diluted in dimethyl sulfoxide (DMSO) (Merck, Darmstadt, Germany), 
incubations with 6-AN ranged from 0.15-15 µM diluted in Dulbecco’s Modified Eagle 
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Medium (DMEM), incubations with BrdU ranged from 0.01-330 µM diluted in DMSO, 
and incubations with 5-FU ranged from 0.023-2.3 µM diluted in DMEM. Representative 
concentration-response curves were fitted using the log-logistic model, with PROAST 
software [103]. Differences of the concentration-response curves between cultures 
exposed from day 0 compared with exposure from day 3 onwards were assessed us-
ing all data regarding these exposure durations. We calculated the critical difference in 
log-likelihood values of the fit with PROAST software, and curves were considered to be 
significantly different when this difference exceeded the respective critical value at a 
5%-significance level.
The ID50 concentration, the concentration at which the number of beating EB was 
reduced to 50% of the control, was calculated based on the fit of the curve. Confidence 
intervals of the ID50 values were obtained by bootstrapping the data 1000 times using 
PROAST software.
Day 0
Day 3
Day 5
Day 10 Evaluation contracting 
cardiac muscle foci
áÁ
áÁ
áÁ
áÁ
áÁ
áÁ
Compound exposure
Figure 1. Schematic overview of experimental procedures. Hanging drops, containing single cel 
suspensions, were set up at day 0. The single cells form embryoid bodies (EB), which are transferred to 
suspension culture at day 3. At day 5, EB are plated out in a 24 wells plate. Microscopical evaluation for the 
presence of contracting foci is performed on day 10. 
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Resazurin cell proliferation assay
Hanging drops were set up as described above and exposed to a concentration 
range of MBP, 6-AN, 5-FU or BrdU. After 3 days, 50 EB were harvested per compound 
concentration, the EB were allowed to precipitate and supernatant was removed. EB 
were dissociated using non-enzymatic cell dissociation buffer (Gibco BRL, Gaithersburg, 
MD). Cells were resuspended in 700 µl complete medium, and 100 µl of this single cell 
suspension was pipetted per well (in sextuplicate) in a 96 wells plate and resazurin (Pro-
mega, Madison, WI) was added to each well. Resazurin dye reduction is a measure for the 
number of viable cells per well, and was measured after 4 hours of incubation at 37°C 
in the incubator at 530 nm (excitation) and 590 nm (emission) using FLUOstar Galaxy 
microplate reader (BMG Lab Technologies, Offenburg, Germany). After autofluorescence 
correction of measurements, the resazurin reduction of exposed cells relative to control 
measurement was calculated and plotted against the test concentrations using PROAST 
software [103]. For each compound a minimum of five concentrations were tested in 
three independent runs. The test concentration at which 50% of the cells were viable as 
compared to control (IC50) was calculated for each compound on basis of the fit of the 
curve and conficence intervals were obtained by bootstrapping the data 1000 times 
using PROAST software.
EB diameter measurements
Hanging drops were set up as described above and cells were exposed to the ID50 con-
centration of MBP, 6-AN, BrdU or 5-FU determined from concentration-response curves 
of differentiation cultures exposed from day 0 onwards. Appropriate solvent controls 
were included and penicillin G sodium salt (PenG; Sigma-Aldrich, Zwijndrecht, The Neth-
erlands; CAS No. 69-57-8) was used as negative control. The EB were harvested at the 
end of the hanging drop culture and photographed using the Olympus IX51 microscope 
with the UC30 colorview camera (Olympus, Zoeterwoude, The Netherlands). The diam-
eter of 24 EB per group was measured and difference between the means of exposed EB 
and control was determined using a one-sided Student’s t-test and presented as mean 
± sd.
Protein concentration determination
EB exposed to the ID50 concentrations of the selected compounds or solvent control 
were harvested at day 3 for the determination of protein concentration. Per group 100 
EB were used, EB were allowed to precipitate and supernatant was removed. EB were 
dissociated using non-enzymatic cell dissociation buffer (Gibco BRL, Gaithersburg, MD) 
and washed twice with PBS. Cells were permeabilized using 1% Triton-X100 (Merck, 
Darmstadt, Germany), protein concentration was determined using the micro BCA 
protocol according to the manufacturer’s instructions (Perbio Science, Etten-Leur, The 
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Netherlands). In short, cells were incubated with BCA working reagent for 30 minutes 
and absorbance was measured using SpectraMax 190 (Molecular Devices, Sunnyvale, 
CA) at 562 nm. Differences between the means of exposed cells and control were deter-
mined using a one-sided Student’s t-test and presented as mean ± sd.
Flow cytometric analysis of DNA content
EB were harvested at day 3 and 400 EB were pooled per group. EB were washed with PBS 
and dissociated into a single cell suspension by treatment with a non-enzymatic cell 
dissociation buffer. PBS was added to the single cell suspension and after centrifugation 
the cells were fixed by addition of 70% ethanol. After rehydration with PBS the cells were 
treated for 40 minutes with 0.1 mg/ml RNase A (Fluka, Buchs, Switzerland) and 50 µg/
ml propidium iodide (PI; Sigma-Aldrich, Zwijndrecht, The Netherlands). After centrifuga-
tion, cells were resuspended in FACSFlow (Becton Dickinson, Heidelberg, Germany). 
Fluorescence intensity was determined by flow cytometry on the FACSCalibur (Becton 
Dickinson, Heidelberg, Germany) in the Fl-2 channel. Non-viable cells and doublets were 
excluded by appropriate gating and each plot was made up of at least 10,000 viable cells. 
Data acquisition was performed with CellQuest software (Becton Dickinson, Heidelberg, 
Germany), and the percentages of G1-, S-, and G2-phase cells were calculated with the 
ModFit LT 3.0 software program.
Flow cytometric analysis of SSEA-1
The percentage SSEA-1 positive cells was determined in duplicate in pluripotent ESC 
and at day 3, 4, 5, 7 and 10 of differentiation. Cells were dissociated and 5×105 cells were 
suspended and washed twice with PBS/1mM EDTA (EDTA: Sigma-Aldrich, Zwijndrecht, 
The Netherlands). Next, the cells were incubated for 30 minutes with 1:100 mouse-
anti-SSEA-1 monoclonal antibody (Millipore, Ettenleur, The Netherlands) followed 
by a 30 minutes incubation with the second antibody, 1:100 goat anti-mouse-FITC 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). The cells were the then washed twice in 
PBS/0.5% BSA/5mM EDTA (BSA, Sigma-Aldrich, Zwijndrecht, The Netherlands). FACSFlow 
was added for FACS analysis on the FACSCalibur. The FITC-fluorochrome was detected 
in the Fl-1 channel. Non-viable cells were excluded by appropriate gating and each 
plot was made up of 10,000 viable cells. ESC, cells lacking primary antibodies, and the 
fibrosarcoma L929 cell line (ATCC, Rockville, MD) were used as controls. Data acquisition 
was performed with CellQuest software (Becton Dickinson, Heidelberg, Germany). We 
distinguished 3 intensities of SSEA-1 positivity as visualized in Figure 6A. Weakly positive 
staining corresponds with an intenstity of 101-102, medium positive staining with an 
intensity of 102-103, and strongly positive staining with an intensity of 103-104 detected 
in the Fl-1 channel. Statistical significance of the results was assessed using the Student’s 
t-test.
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Real-time PCR
ESC were induced to differentiate into beating cardiomyocytes as described above. 
Biological duplicates of nondifferentiated ESC and cells at days 3, 4, 5, 7 and 10 of dif-
ferentiation were collected in RNA protect (Qiagen, Venlo, The Netherlands) to stabilize 
RNA, and total RNA was isolated from the cell cultures using RNeasy protect cell mini kit 
(Qiagen, Venlo, The Netherlands) with an additional DNase treatment (RNase-Free DNase 
Set; Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. The 
quantity of RNA in each sample was measured using a NanoDrop spectrophotometer 
(ND1000; NanoDrop technologies, Wilmington, DE) and RNA integrity was determined by 
automated gel electrophoresis (Bioanalyzer 2100; Agilent technologies, Amstelveen, The 
Netherlands). cDNA was generated from RNA by using the high-capacity cDNA archive 
kit containing random hexamer primers (Applied Biosystems, Foster City, CA). mRNA 
presence was measured with Taqman gene expression assays (Applied Biosystems) on a 
7500 Fast Real-Time PCR System, with a two-step PCR procedure according to the manu-
facturer’s protocol. The thermal cycling conditions were: 95°C for 20 s for the first cycle, 
followed by 40 cycles of 95°C for 3 s and 60°C for 30 s. The mRNA markers we used were 
brachyury (T; Mm01318252_m1), which is one the earliest marker of mesodermal differ-
entiation [104, 105], alpha myosin heavy chain 6 (Myh6; Mm00440359_m1), a marker for 
cardiac myosine [106], and the housekeeping gene hypoxanthine guanine phosphoribo-
syl transferase 1 (Hprt1). Hprt1 was selected as housekeeping gene, since its expression 
was constant under the differentiation process and under compound exposure.
The custom made primers used for Hprt1 were as follows:
5’-GCC GAG GAT TTG GAA AAA GTG TTT A-3’
5’-TTC ATG ACA TCT CGA GCA AGT CTT T-3’.
The mRNA expression was normalized to the value of Hprt1 for each reaction according 
to the comparative Ct method [107] and expressed relative to the expression level in 
ESC.
Results
Exposure duration related inhibition of cardiomyocyte differentiation
The EST protocol was carried out with exposure to MBP, 6-AN, 5-FU or BrdU during dif-
ferent time windows. The exposures were started at day 0, 3, 4, 5 or 7 of the EST protocol 
and continued until the evaluation of the differentiation assay on day 10 (Figure 1). 
Concentration-response curves are given in Figure 2. These experiments showed that 
in most cases a later start of exposure of the differentiating cells to the 4 selected com-
pounds resulted in a decreased inhibition of differentiation towards cardiomyocytes. 
This included the concentration-response curves of day 0-10 versus day 3-10 exposures 
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for the cytostatic compounds 5-FU and BrdU, which were significantly different (p-
value<0.05). However, most remarkably, the day 0-10 and day 3-10 exposure curves of 
the embryotoxicants MBP and 6-AN were not significantly different. This difference in 
behaviour between the two compound groups suggests a difference in cytotoxic effect 
in the early EB formation stage of the protocol.
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Figure 2. Concentration-response curves of inhibition of cardiomyocyte differentiation by monobutyl 
phthalate (MBP), 6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) and 5-bromo-2’-deoxyuridine (BrdU) 
fitted with the log-logistic model on basis of data of at least two independent experiments (solvent 
controls on the left). Different exposures started at day 0, 3, 4, 5 or 7 and continued up to day 10 (see 
schematic overview of experimental procedures in Figure 1). 
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Proliferation inhibition during EB formation
We directly investigated inhibition of proliferation of the compounds in the EB formation 
stage (day 0-3) of the EST protocol (Figure 3). The IC50 concentrations of the proliferation 
inhibitors 5-FU and BrdU were significantly lower than the ID50 concentration of continu-
ously exposed cells (Table 1), indicating that in the day 0-10 EST protocol, inhibition of 
proliferation plays a major role in the cardiac differentiation inhibition effects of these 
compounds. In contrast, the IC50 concentrations of MBP and 6-AN were significantly 
higher compared with the ID50 concentrations of continuously exposed cells, suggesting 
a more specific differentiation-inhibitory effect for these compounds.
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Figure 3. Concentration-response curves of inhibition of cell viability by monobutyl phthalate (MBP), 
6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) and 5-bromo-2’-deoxyuridine (BrdU) (EST protocol, 
exposure day 0-3) fitted with the log-logistic model on basis of data of three independent experiments 
with a six technical replicates per experiment. The mean fraction of viable cells is shown per experiment.
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To further describe these effects, the diameters of EB, exposed during hanging drop 
culture, were measured at day 3 (Figure 4A and 4B). The diameters of PenG, MBP and 
6-AN exposed cells were not affected. On the other hand, the BrdU exposed cultures 
showed a non-significant decrease in EB size, and the diameter of 5-FU exposed EB was 
significantly decreased compared to control (p-value<0.05). Attempts to perform single 
cell counts of dissociated EB at day 3 were not informative due to large data variations. 
However, whereas protein concentrations of EB on day 3 after exposure to PenG, MBP 
Table 1. Summary of IC50 (EST protocol, exposure day 0-3, n=3) and ID50 concentrations (EST protocol, 
exposure day 0-10, n≥2) of monobutyl phthalate (MBP), 6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) 
and 5-bromo-2’-deoxyuridine (BrdU). Data is represented as mean (95% CI).
Compounds IC50 (95% CI) ID50 (95% CI)
MBP > 4.5 mM 1.3 mM (1.3-1.4)
6-AN 7.1 µM (6.9-7.4) 4.1 µM (3.4-5.0)
5-FU 0.15 µM (0.09-0.21) 0.30 µM (0.25-0.35)
BrdU 0.27 µM (0.15-0.47) 0.97 µM (0.65-1.42)
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Figure 4. Representive pictures of control and exposed EB at day 3 of the culture (magnification 20×) (A). 
Protein concentrations (black) and diameter (grey) of non-exposed EB (CON), and EB exposed to Penicillin 
G (PenG), monobutyl phthalate (MBP), 6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) or 5-bromo-2’-
deoxyuridine (BrdU) (B). Bar graphs represent mean ± sd, n=2 for EB protein concentration measurements, 
n=24 for EB diameter measurements. Asterisks indicate statistical significant changes between exposed 
and control cells (p-value<0.05).
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or 6-AN were not significantly different from control, the protein concentration was 
significantly lower when cells were exposed to BrdU or 5-FU (p-value<0.05), as expected 
(Figure 4B). These findings support the proliferation-inhibitory effects of 5-FU and BrdU 
during EB formation in the EST protocol and confirm the absence of such an effect of the 
remaining compounds tested.
Flow cytometric analysis of EB cell cycle structure
As the cell cycle structure is another indicator of proliferation rate, flow cytometry 
profiles of PI-stained cell samples were compared. The cell cycle structure of cells in 
standard pluripotent ESC culture appeared to be similar with that of day 3 EB (Figure 5). 
Furthermore, the cell cycle structure of exposed cells were compared with non-exposed 
cells at day 3. We observed a slight decrease in the percentage of cells in S-phase after 
exposure to MBP and 6-AN. However, 5-FU and BrdU exposed cells showed a clear S-
phase to G1-phase transition. A decrease of cells in S-phase with a factor 1.5 and 1.9 
compared to control was observed after exposure with 5-FU and BrdU, respectively, 
whilst the fraction of cells G1 phase increased with a factor 2.1 and 2.8 compared to 
control, respectively. These findings further support a proliferation-inhibitory effect of 
5-FU and BrdU, whereas MBP and 6-AN had marginal effects at most.
Transition of pluripotent ESC to differentiated cells
The pluripotent state of the cells in the EST protocol was monitored with time by flow 
cytometry using a fluorescence-labelled antibody to SSEA-1, a pluripotency marker. The 
total percentage of SSEA-1 positive cells was decreased at days 7 and 10 (p-value<0.001, 
Figure 6B). To further detail the analysis, we divided the SSEA-1 signal into three catego-
ries of intensity, corresponding to orders of magnitude (Figure 6A). In doing so, we ob-
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Figure 5. Cell cycle distribution of embryonic stem cells (ESC) and cells in embryoid body (EB) 
formation (day 3). During EB formation, cells were were exposed to monobutyl phthalate (MBP), 
6-aminonicotinamide (6-AN), 5-fluorouracil (5-FU) or 5-bromo-2’-deoxyuridine (BrdU) or non-exposed 
(CON). For each analysis 400 EB were pooled.
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served that the SSEA-1 signal per cell already diminished at day 3, as shown by a gradual 
decrease of the strongly positive cells (p-value<0.01, Figure 6E). As a consequence the 
percentages of medium positive cells at day 3 and 4 increased (p-value<0.01, Figure 6D), 
and a high percentage of weak positive SSEA-1 cells was present at day 5 (p-value<0.001, 
Figure 6C). At day 7 and 10 almost no SSEA-1 positive cells with a medium or strong 
signal were detected (p-value<0.001), and only a small population with a weak signal 
remained.
In view of the above, we wondered whether and how the early decrease in SSEA-1 
signal would be accompanied with the occurrence of early and late differentiation mark-
ers, respectively. RT-PCR analysis showed that the mRNA of one of the earliest markers 
for mesodermal differentiation, T, was highly expressed at day 3 as compared to its 
expression in pluripotent ESC. Subsequently, this early marker decreased rapidly with 
time, with only 23.6% of the peak value left at day 4 and decreasing further at later time 
points. In contrast, Myh6, an mRNA marker for cardiac myosin, showed up-regulation 
from day 5 onwards, with its peak expression at day 7 of cardiac differentiation (Figure 
7). At day 10, Myh6 expression was decreased to 76.7% as compared to day 7. These 
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Figure 6. A: Signal-intensity histogram for aspecific binding of FITC-labelled SSEA-1 antibody measured 
in the Fl-1 channel. Signal intensities were divided into three categories: weak: 101-102; medium: 102-103; 
and strong: 103-104. B-E: Percentage SSEA-1 positive cells per culture day (n=2) (B: all categories; C: weakly 
positive; D: medium positive; E: strongly positive). Bars represent mean ± sd. Statistical significance 
compared with embryonic stem cells (ESC) *=p-value<0.01, **=p-value<0.001.
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observations show that as early as day 3 of the EST protocol cells show markers of dif-
ferentiation, supporting the notion that in the EST proliferation and differentiation are 
highly intertwined.
Discussion
The EST was designed to determine the developmental toxicity of chemicals in an ani-
mal-free in vitro assay [4]. During an interlaboratory validation programme moderated 
by ECVAM, the assay was validated by four independent laboratories using 20 chemicals 
in a blinded study design. This study resulted in a prediction model, defined by inde-
pendent statisticians. In this model the ID50, the concentration inhibiting beating muscle 
foci formation by 50%, and two IC50 values, the concentrations inhibiting growth by 
50% in pluripotent embryonic stem cell monolayer culture and in the 3T3 fibroblastoid 
tumor cell line, were incorporated as parameters. This approach was successful in that it 
provided a 79% accuracy among the 20 chemicals tested [19]. Subsequent testing with 
additional compounds has not delivered the same success rate [21, 22]. In the prediction 
model of the EST the two most important biological parameters were included, namely 
cytotoxicity and inhibition of differentiation of ESC. However, in the EST the inhibition of 
differentiation could be obscured by effects on proliferation of the test compound, since 
proliferation and differentiation processes both occur in the EST. More specific testing of 
inhibition of cardiomyocyte differentiation could possibly improve the embryotoxicity 
prediction.
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Figure 7. Temporal expression pattern of the mesodermal marker T and the cardiac marker Myh6. 
Expression level is normalized against Hprt1 and compared with the expression level of ESC. Data is 
expressed as mean ± sd (n=2).
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In this study, we exposed cells during different exposure windows of the EST protocol 
and studied inhibition of cardiomyocyte differentiation. We show that the sensitivity of 
the EST decreases with delay of the onset of exposure, which in itself is not surprising. 
The remarkable finding of our study is that the difference between day 0-10 and day 
3-10 exposure appears to be chemical dependent. Whereas 5-FU and BrdU clearly show 
additional effects with the 0-10 day exposure protocol, the chemicals MBP and 6-AN 
do not show significantly different concentration-response curves with both exposure 
durations. Since 5-FU and BrdU are known cytostatic agents [97-101], and ESC in EB 
show rapid cell division, inhibition of cell proliferation could explain these differences. 
Therefore, IC50 concentrations of the test compounds were determined in cells exposed 
during the first 3 days of the EST. For 5-FU and BrdU IC50 values were significantly 
lower than their ID50 values, whereas for MBP and 6-AN the IC50 values were significantly 
higher than their ID50 values. This indicates that BrdU and 5-FU mediated inhibition of 
cell proliferation observed at day 3 occurs at lower concentrations than inhibition of 
cardiomyocyte differentiation monitored at day 10. As a consequence, in the enhanced 
inhibition of cardiomyocyte differentiation when cells were exposed to 5-FU or BrdU 
from day 0-10 as compared to day 3-10, inhibition of cell proliferation probably plays a 
major role.
We have further substantiated the day 3 effects by determining EB size, protein 
content and cell cycle characteristics. Both 5-FU and BrdU caused decreases in EB size 
and protein content, indicating effects on EB growth. A high proliferation rate is a well-
known characteristic of ESC together with an unusual cell cycle structure composed of 
a rather large S-phase and a truncated G1-phase [108, 109]. As ESC differentiate, their 
cell cycle structure changes dramatically and the length of the G1 phase increases 
substantially [89, 110]. DNA content analysis showed that the cell cycle profile of day 
3 EB was similar to that of ESC, which suggests the presence of a pure pluripotent cell 
population at the end of EB formation. Furthermore, the data of DNA content analysis 
showed that both 5-FU and BrdU exposed cells displayed an S- to G1-phase transition. 
This effect could be expected as a result of proliferation inhibition. These results confirm 
our hypothesis that 5-FU and BrdU affect cell proliferation during the first 3 days of car-
diomyocyte differentiation. This inhibition of proliferation explains the differences in the 
concentration-response curves of differentiation cultures exposed to these cytostatic 
agents from day 0-10 versus day 3-10.
When evaluating the proliferation and differentiation processes in the EST we showed 
that the percentage of cells positive for SSEA-1 was not decreased until day 7. This sup-
ports the hypothesis that the cells start differentiating after completion of EB formation. 
However, although the total number of SSEA-1 positive cells remain constant up to day 
5, the signal intensity per cell decreased from day 3 onwards (Figure 6E). Analyses of 
earlier time points were not possible in view of limited cell numbers available in these 
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cultures at day 1 and 2. In combination with the RT-PCR results in which the expres-
sion of T is observed at day 3, this implies that the transition from rapidly proliferating 
pluripotent cells to differentiating cells is a gradual process which seems to start at or 
even before day 3 of the differentiation culture. The transcription factor T is one of the 
earliest markers of cardiomyocyte differentiation [104, 105, 111], it is briefly and tran-
siently up-regulated when mesodermal differentiation starts [112]. The first indication of 
differentiation of cardiac muscle cells appears at day 5, as observed by Myh6 expression. 
This marker is not found at day 3 and 4 in the EST, confirming that this differentiation 
event occurs well after EB establishment. In addition, we observed that exposure of cells 
in the EST from day 7-10 hardly if at all affected the fraction of EB containing contracting 
cardiomyocyte foci, indicating that cardiomyocyte differentiation is accomplished by 
day 7. This was confirmed by our RT-PCR results which showed the highest expression 
level of the cardiac marker Myh6 at day 7. The decrease of the Myh6 expression level at 
day 10 may be explained by preferential growth of other cell types in the culture, which 
was also shown by Seiler et al.[25]
It is well known that the formation of cardiac muscle cells is preceded by several differ-
entiation steps, such as endoderm formation and mesoderm induction in an area where 
ectoderm and endoderm are adjacent [6, 113]. Our finding that the mesodermal marker 
T is already expressed at day 3 shows that critical steps in differentiation occur early in 
the EST. On the other hand, as cardiac myocytes do not begin to appear until day 5, this 
allows day 3 as a possible day to start compound exposure in search for specific effects 
on final cardiac muscle formation that are less influenced by effects on proliferation dur-
ing EB formation. Our present results with MBP and 6-AN as opposed to 5-FU and BrdU 
support this notion.
The nature of IC50 determination in the prediction model is a returning discussion 
point [21, 22]. In the standardized EST protocol, the IC50 for ESC is derived in monolayer 
culture, which may have a different sensitivity to chemicals as compared to EB which are 
used in EST for ESC differentiation. The other cytotoxicity end point in EST, the IC50 for 3T3 
includes a completely different cell line, which may also have a different sensitivity that 
may or may not be relevant for the prediction of embryotoxicity. To avoid the principal 
and practical complications of the incorporation of additional culture systems, we have 
approached the issue of cytotoxicity by studying it within the EST protocol. We show 
that this approach is able to discriminate among different mechanisms of inhibition of 
cardiac muscle differentiation.
This study confirms that the proliferation and differentiation of ESC in the EST are 
co-occurring processes that are not simply separated in time. In vivo these processes 
are also coupled to coordinate growth and differentiation. The first example of this oc-
curs in the early embryo, which grows at a rapid rate until a critical embryonic mass is 
generated at the time when gastrulation normally occurs [114, 115]. Thus, both effects 
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on proliferation as well as direct effects on differentiation, can affect embryonic devel-
opment. When translating this knowledge to the design of the EST, both proliferation 
and differentiation inhibition are important mechanisms of developmental toxicity and 
therefore both need consideration as relevant parameters for inclusion in the predic-
tion model. In conclusion, this means that for studying a more specific differentiation-
mediated response, cells in the EST protocol should be exposed from day 3 onwards. 
Furthermore, it is worthwile to consider replacing the two IC50 measures currently used 
in the prediction model for a single IC50 (EB day3) based on the resazurin assay or a simi-
lar assay. This would at least provide a comparison between EB inhibition of proliferation 
and inhibition of cardiac muscle differentiation within the same culture system. These 
biologically relevant parameters could then be used to predict embryotoxicity and 
could possibly improve the accuracy of the model. Our recent work relating in vitro ID50 
values to in vivo benchmark doses shows promising correlations [116, 117]. On the other 
hand, any in vitro-in vivo translation will also need to consider differences in compound 
kinetics in both systems [118]. Future prediction models should probably additionally 
include such information to further improve prediction of in vivo effects on the basis of 
in vitro findings.
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Early gene expression changes during 
embryonic stem cell differentiation 
into cardiomyocytes and their 
modulation by monobutyl phthalate
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Abstract
The Embryonic Stem cell Test (EST) is an in vitro alternative test designed for the predic-
tion of embryotoxicity. The end point of the test is the interference with mesoderm-
derived cardiac muscle differentiation observed under the microscope as beating 
muscle foci. The relative subjectivity of this end point, as well as the applicability do-
main and related predictivity need further to be defined to facilitate implementation 
of the EST into regulatory strategies. The use of transcriptomic techniques to monitor 
differentiation-related gene expression changes in the EST might improve the EST in 
each of these aspects. Therefore, we studied the gene expression profile in embryonic 
stem cells (ESC) in the early phase of differentiation and its modulation by exposure 
to the well known embryotoxicant monobutyl phthalate (MBP). Cells were exposed 
from the early embryoid body stage onwards and RNA was collected after 6, 12 and 24h 
of exposure. Samples were hybridized to spotted microarrays, containing 21,997-mer 
oligonucleotides. Differential gene expression patterns were analyzed. A total number 
of 43 genes that were found to be up-regulated in this study as a consequence of induc-
tion of cardiomyocyte differentiation were combined in a gene set, named ‘Van_Dar-
tel_heartdiff_24h’. Gene set enrichment analysis (GSEA) comparative analysis using 
multiple gene set collections clearly showed that temporal changes in gene expression 
were functionally related to cardiomyocyte differentiation. Furthermore, exposure of 
embryoid bodies to MBP increased expression of pluripotency-, proliferation- and non-
mesodermal differentiation-related gene sets, which indicates inhibition of mesodermal 
differentiation. The inhibition of mesoderm-derived cardiomyocyte differentiation by 
MBP exposure was most obvious through the down-regulation of our novel gene set 
identified in this study, ‘Van_Dartel_heartdiff_24h’, which specifically describes the niche 
of early cardiomyocyte differentiation. The gene set defined in this study might serve as 
a starting point for defining a dedicated gene set for early detection of embryotoxicity 
in the EST. Such a gene set may serve as an improved end point in the EST as compared 
to morphology, and will allow a more detailed definition of the applicability domain and 
predictivity of EST.
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Introduction
Toxicological risk assessment of chemicals is based primarily on animal testing accord-
ing to internationally agreed protocols. Animal use for hazard identification is especially 
high in reproductive toxicity testing. Estimations show that under the new European 
chemicals legislation Registration Authorization and Evaluation of Chemicals (REACH) 
more than 60% of experimental animals will be used to assess reproductive toxicity 
[119]. The need for alternative methods reducing animal use, cost and time is likewise 
high. In the area of developmental toxicology many alternative tests have been devel-
oped during recent decades, none of which has yet acquired regulatory acceptance. 
The European centre for the validation of alternative methods (ECVAM) validation study 
of three alternatives [20] has been the most advanced achievement toward regulatory 
acceptance, and standard protocols are available on the ECVAM web site. However, the 
relevance and predictivity of these assays are still not sufficiently addressed to allow 
regulatory implementation.
Of the three validated alternatives for developmental toxicity, the Embryonic Stem 
cell Test (EST) is the only one which is completely animal-free. Briefly, it employs a con-
tinuous murine embryonic stem cell line which is cultured under conditions stimulating 
differentiation to beating cardiomyocyte foci. The extent of differentiation is scored 
under the microscope after 10 days culture. Compounds inhibiting differentiation are 
considered as potential developmental toxicants. Disadvantages of the current protocol 
include the long duration of culture and the scoring by eye of cardiomyocyte differ-
entiation. Furthermore, the applicability domain in terms of developmental processes 
incorporated is not well-described in the assay. In addition the limited number of car-
diomyocytes at the end of culture is hampering the interpretation of results since other 
cell types are present and may be affected themselves and/or play a role in inducing 
cardiomyocyte differentiation. Mesoderm-derived cardiomyocytes are among the first 
cells acquiring functionality in the embryo.
The mesodermal germ layer develops by induction between the ectoderm and endo-
derm germ layers. Understanding this complex sequence of steps in the differentiation 
process requires a comprehensive assessment of the underlying molecular events. 
Therefore the application of molecular approaches may improve the EST in each of the 
aspects mentioned above. Seiler et al. have shown that cardiomyocytes can be quanti-
fied with flow cytometry on day 7 of culture using specific protein markers [25]. Analysis 
of gene expression changes using transcriptomics would in principle allow an even ear-
lier detection of differentiation events [120] and in addition may reveal cell type specific 
effects within the various lineages of embryonic cell differentiation, which may be used 
to further define the applicability domain and increase the predictivity of the test.
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In this study we exposed the differentiating cells to monobutyl phthalate (MBP), 
which is the embryotoxic metabolite of butylbenzyl phthalate (BBP) and dibutyl 
phthalate (DBP). These and other phthalate esters are produced in high volume as 
plasticizers and are used in vinyl floors, food wraps, cosmetics, medical products, and 
toys. Consequently, much research has focused on the health effects of these widely 
distributed chemicals. The most severe adverse effects observed appear to be effects on 
reproduction and development. Results from a series of animal studies suggest that the 
monoester metabolite of the parent compound is responsible for adverse reproductive 
and developmental effects of phthalates [121]. The developmental effects of MBP and its 
parent compounds depend on the embryonic age at the time of exposure and exposure 
duration. The effects are mainly on mesodermal structures and include cleft palate, car-
diovascular, urogenital, and skeletal malformations [91-93, 122]. Other observed effects 
are neural tube closure defects such as exencephaly. Since structures affected by MBP 
are mainly of mesodermal origin, inhibition of (mesodermal) cardiac differentiation by 
MBP exposure might be demonstrable on the gene expression level. Because the class 
of phthalates contains both embryotoxic and non-embryotoxic structures, these phthal-
ates are interesting in search for specific gene expression profile changes predictive of 
embryotoxicity.
Cardiomyocyte differentiation of embryonic stem cells (ESC) was induced by specific 
culture conditions. The cells were exposed to MBP from the embryoid body (EB) stage 
onwards. At this stage the EB are in suspension culture and resemble the egg-cylinder 
stage of a 5-day old embryo [6]. The cells were exposed for 6, 12 or 24h to study early 
compound-induced gene expression changes [75, 120]. We demonstrate that early 
differentiation of ESC can successfully be monitored by transcriptomics. Furthermore, 
inhibition of cardiomyocyte differentiation by MBP could be demonstrated already after 
24h of differentiation using a defined gene set specifically related to embryonic devel-
opment. These findings offer possibilities for further application of the transcriptomic 
approach to improve the assessment of the applicability domain and the predictivity of 
the EST, whilst reducing the exposure duration from 10 days to 24 h.
Materials and methods
Embryonic stem cell culture
Mouse D3 ESC (ATCC, Rockville, MD) were routinely subcultured every 2-3 days and 
grown as a monolayer in Dulbecco’s Modified Eagle Medium (DMEM) medium (Gibco 
BRL, Gaithersburg, MD) supplemented with 20% fetal bovine serum (Hyclone, Logan, 
UT), 1% non-essential amino acids (Gibco BRL, Gaithersburg, MD), 1% penicillin/ strep-
tomycin (Gibco BRL, Gaithersburg, MD), 2 mM L-glutamine (Gibco BRL, Gaithersburg, 
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MD) and 0.1 mM β-mercapto-ethanol (Sigma-Aldrich, Zwijndrecht, the Netherlands). 
Leukemia inhibiting factor (LIF) (Chemicon, Temecula, CA) was added directly to the 
culture disk in a final concentration of 1000 units/ml. The cells were maintained in a 
humidified atmosphere at 37°C and 5% CO2.
Cardiomyocyte differentiation culture
Differentiation of ESC was carried out in hanging drops according to De Smedt et al. 
[102]. In brief, stem cell suspensions (3.75·104 cells/ml) were placed on ice before the 
set up of the culture (Figure 1). Drops (20 µl) containing 750 cells were placed onto the 
inner side of the lid of a Petri dish filled with phosphate buffered saline (PBS) (Gibco 
BRL, Gaithersburg, MD) and incubated at 37°C, 90% relative humidity and 5% CO2. 
After 3 days of hanging drop culture embryoid bodies (EB) had formed and these were 
subsequently transferred to bacterial Petri dishes (Greiner Bio-one, Frickenhausen, 
Germany). On day 5, EB were plated one per well into 24-well tissue culture plates (TPP, 
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Figure 1. Schematic overview of experimental procedures. Hanging drops, containing single cell 
suspensions, were set up at day 0. The single cells form embryoid bodies (EB), which are transferred to 
suspension culture at day 3. At day 5, one EB is plated per well in a 24-wells plate. At day 10 each EB is 
microscopically evaluated for the presence of contracting foci. Differentiating cells were exposed from 
suspension culture onwards. For transcriptomic analysis, samples were isolated after 6, 12 and 24 hours of 
monobutyl phthalate (MBP) exposure.
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Trasadingen, Switzerland). Differentiation was determined by microscopical inspection 
of EB outgrowths into contracting myocardial cells at day 10 of differentiation.
Determination of ID50 concentration MBP
Differentiation cultures were exposed to monobutyl phthalate (MBP) (CAS No.131-70-4) 
or 0.25% dimethyl sulfoxide (DMSO) from suspension culture onwards to day 10 (Figure 
1) and differentiation into contracting myocardial cells was microscopically determined. 
The incubations with MBP (TCI Europe, Zwijndrecht, Belgium) ranged from 0.045-4.5 
mM diluted in DMSO. A representative concentration-response curve of MBP was fitted 
using the log-logistic model, with PROAST software [103]. The ID50 concentration, the 
concentration which corresponds with the concentration at which 50% of the EB were 
inhibited to differentiate towards contracting cardiomyocytes, was calculated based on 
the fit of the curve.
Resazurin cell viability assay
Hanging drops were set up as described in the section cardiomyocyte differentiation. 
After 3 days, EB were harvested, dissociated en resuspended in complete medium. 
Single cells were divided in the wells of a 96 wells plate and resazurin (Promega, Madi-
son, WI) was added to each well. After 4h of incubation at 37°C in the incubator, resa-
zurin dye reduction was measured at 530 nm (excitation) and 590 nm (emission) using 
FLUOstar Galaxy microplate reader (BMG Lab Technologies, Offenburg, Germany). After 
autofluorescence correction of measurements, significance of differences in reduction 
of exposed cells relative to the control measurement was analyzed by Student’s T-test, 
using data of two independent runs.
RNA isolation and processing
For microarray analysis, cells were exposed to the ID50 concentration of MBP (1.35 mM) 
or 0.25% DMSO at day 3. EB were harvested 6, 12 and 24h later (Figure 1). The cells were 
directly collected in RNA protect (Qiagen, Venlo, the Netherlands) to stabilize RNA, and 
total RNA was isolated from the cell cultures using RNeasy protect cell mini kit (Qia-
gen, Venlo, the Netherlands) with an additional DNase treatment (RNase-Free DNase 
Set; Qiagen, Venlo, the Netherlands) according to the manufacturer’s instructions. The 
quantity of RNA in each sample was measured using a NanoDrop spectrophotometer 
(ND1000; NanoDrop technologies, Wilmington, DE) and RNA integrity was determined 
by automated gel electrophoresis (Bioanalyzer 2100; Agilent technologies, Amstelveen, 
the Netherlands).
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Transcriptomic profiling
Microarray analysis experiments were performed as described previously by Janssen et 
al. [123]. In brief, total RNA samples were processed in randomized order using one RNA 
sample per array and with a mix of all samples as common reference. Of the correspond-
ing RNA samples (7-8 replicates per group) 1 µg was amplified using the Amino Allyl 
MessageAmp II aRNA kit (Ambion, Austin, TX). Next, 5 µg of control or exposed sample 
aRNA was labeled with Cy3, and equal amounts of reference pool with Cy5 (CyDye Post 
Labeling Reactive Dye Pack; Amersham Biosciences, Buckinghamshire, UK) according 
to the manufacturer’s instructions. Volumes of the labeled and purified aRNA samples, 
containing 150 pmol of the respective dye, were reduced to 9 µl by vacuum drying. 
Thereafter, the aRNA was fragmented (RNA Fragmention Reagents; Ambion, Austin, TX), 
combined with an aliquot of reference pool aRNA and total volume was adjusted to 25 
µl with milliQ water.
Microarray slides were spotted at the Microarray Department of the University of 
Amsterdam. The slides contain 21,997 65-mer oligonucleotides from the Sigma-Com-
pugen Mouse nucleotide library, as well as appropriate controls and blank spots. The 
slides were prehybridized at 42°C for at least 30 min in 5× SSC (Invitrogen, Breda, the 
Netherlands), 0.1% SDS (Ambion, Austin, TX), and 1% BSA (Sigma–Aldrich, Zwijndrecht, 
the Netherlands) dissolved in milliQ and sterilized by filtering through a 0.22  μm 
filter (Millipore, Amsterdam, The Netherlands). Subsequently, the slides were washed 
and dried by centrifugation. Next, hybridization mixture, containing 50% formamide 
(Sigma–Aldrich, Zwijndrecht, the Netherlands), 10× SSC, and 0.2% SDS, was added to 
the combined sample and reference pool. This mixture was pipetted onto a slide and 
spread evenly by application of a cover slip. After 16h incubation at 42°C in the dark in 
humid hybridization chambers, the slides were washed. Immediately after centrifuga-
tion, the microarray slides were scanned using a ScanArray 4000XL microarray scanner 
(Perkin-Elmer, Waltham, MA) with appropriate laser and photomultiplier tube settings.
Data analysis and statistics
Array Vision software (Imaging Research, St. Catherines, Ontario, Canada) was used to 
determine median Cy3 and Cy5 signal intensities for each separate spot and background 
signal. Quality control was performed on raw data by means of a scatter plot and MA-
plot as well as a normal probability plot to assess signal distribution. The control and 
blank spots present on the slide were used for quality control, but excluded in the 
further analysis.
Data normalisation and statistical analysis were carried out using the R statistical 
software environment (www.r-project.org). Raw microarray signal data were normal-
ized using a three-step approach as described by Janssen et al.[123]. Genes that were 
differentially expressed between any of the experimental groups were identified by a 
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one-way ANOVA on the normalized data. P-values were corrected for multiple testing by 
calculating the false discovery rate (FDR) according to Benjamini and Hochberg [124]. 
An FDR significance threshold of 0.20 was used to select differentially expressed genes. 
Gene expression patterns were visualized by hierarchical clustering (based on Euclidian 
Distance and Ward linkage) using GeneMaths (Applied Maths, St-Martens-Latem, Bel-
gium). Functional annotation and Gene Ontology (GO) term enrichment were examined 
with tools on the DAVID website (http://david.abcc.ncifcrf.gov) [67].
Gene set enrichment analysis (GSEA) was performed to discover the differential ex-
pression of biologically relevant sets of genes that share common biological function 
or regulation [82]. Gene sets were considered being significantly affected when the p-
value was below 0.05 and the FDR below 0.15. GSEA was followed by molecular concept 
analysis, in which the gene sets are visualized within a network based on their overlap in 
genes [125]. The overlap among the gene sets were calculated on the genes that were 
responsible for a gene set being significant. For this, either the top-20% of the ranked 
gene list for up-regulated genes or the bottom-20% of the ranked gene list for down-
regulated genes was used. The significance of overlap between gene sets was calculated 
based on the binomial distribution using the program Venn-Mapper [126]. Genes that 
showed significant overlap at p<0.05 (Z-value>1.96) were considered connected in a 
network that was subsequently visualized using Cytoscape [127].
For the GSEA we used five gene set collections. Two general gene set collections, C2 
and GO, were available from open sources. The curated gene sets C2 were from the 
Molecular Signature Database of the GSEA developers (http://www.broad.mit.edu/
gsea/msigdb/msigdb_index.html), and gene sets for GO (mouse gene symbols) were 
downloaded from the GO Consortium (http://www.geneontology.org/). In addition, 
a Tissue Specific gene set collection was created using expression microarray data of 
tissues [128]. Genes in sets of this collection were considered to be tissue specific when 
its expression was at least 100-fold higher than the median expression in all tissues. 
Furthermore, a gene set collection Cell Cycle was included, which contains genes that 
are specifically up-regulated during a cell cycle stage. These gene sets were taken from 
the supplementary data of two studies [129, 130]. The fifth gene set collection, named 
ESC_Cardiac, contains gene sets derived from microarray studies on gene expression 
changes during the differentiation of ESC to cardiomyocytes [27, 28, 131-135] or vascu-
lar tissues [136]. Gene sets affected by Hmga1 in ES cells as described by Martinez-Hoyos 
et al. [137] were also included in the ESC_Cardiac gene set collection. Furthermore, gene 
sets related to ‘ES cells and heart development’ or ‘ES cells and fetal heart’ derived from 
literature using the text-mining tool Anni 2.0 [138] were included. Finally, the genes 
that were found to be up-regulated in this study as a consequence of cardiomyocyte 
differentiation were combined in a gene set, named ‘Van_Dartel_heartdiff_24h’.
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Results
Inhibition of cardiomyocyte differentiation by MBP
A concentration-response curve for MBP in the differentiation assay of the EST is given in 
Figure 2. The ID50 concentration of MBP derived from the curve was rounded to 1.35 mM 
and this concentration was used in the transcriptomic experiment. At this ID50 viability of 
exposed cells was 90.7 ± 3.4% (p-value<0.05) compared to control as determined using 
resazurin reduction, suggesting minimal cytotoxicity at the tested concentration.
ESC differentiation related gene expression changes
Gene expression data of all samples were compared by a one-way ANOVA. An FDR of 
<0.20 was applied to select genes that were differentially expressed in at least one of 
the experimental groups. This yielded 48 genes which were differentially expressed 
after 24h of suspension culture compared to the samples isolated after 6 and 12 h, in 
the combined control and MBP-exposed samples (Figure 3). In total, 43 genes were up-
regulated, and 5 genes were down-regulated. Analysis of GO term enrichment showed 
that these genes are enriched for ‘development’ (p-value 5.1E-5), ‘embryonic develop-
ment’ (p-value 4.0E-3) and ‘morphogenesis’ (p-value 1.5E-2). All up-regulated genes were 
included in the new gene set ‘Van_Dartel_heartdiff_24h’.
Regulation of gene sets by differentiation of ESC
Data were further analyzed using the GSEA tool testing the following five gene set col-
lections, C2, GO, Tissue Specific, Cell Cycle and ESC_Cardiac and the gene set ‘Van_Dar-
tel_heartdiff_24h’. The samples isolated after 6 and 12h were combined in this analysis 
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Figure 2. Concentration-response curve of monobutyl phthalate (MBP), fitted with the log-logistic model on 
the basis of data from three independent experiments. The ID50 is calculated on the basis of the fit of the curve.
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since minimal gene expression changes were observed between these groups (Figure 
3). In total, 24 gene sets were found to be regulated by the differentiation process of ESC, 
as analyzed by comparing the samples after 24h of suspension culture to the control 
samples after 6 and 12 h. These significantly regulated gene sets are presented in Table 
1. None of the gene sets from C2, Tissue Specific and Cell Cycle gene set collections 
were regulated as a consequence of differentiation. Two gene sets of the GO collection 
were down-regulated. Furthermore, five GO gene sets were up-regulated, including 
‘development’ and ‘somitogenesis’. The majority of the regulated gene sets is from the 
ESC_Cardiac collection (16/24).
As expected the gene set ‘Van_Dartel_heartdiff_24h’ is significantly up-regulated, the 
respective GSEA calculated p-value is <1E-3 and the FDR is <1E-3 (Table 1), and based on 
a paired t-test, p-value 2.9E-4.
The significance of overlap among regulated gene sets in gene content, shown as connec-
tions, is visualized in Figure 4. In this molecular concept analysis the high degree of overlap 
between these up-regulated gene sets from the ESC_Cardiac gene set collection is shown, 
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Figure 3. Clustering of differentially expressed genes after 24h of suspension culture. Cells were exposed 
for 6, 12 or 24h to monobutyl phthalate (MBP) or solvent control (CON). Per group the mean regulation of 
7-8 replicates is shown. Gene expression changes are indicated by the color bar, where white represents 
down-regulation and black up-regulation. For color figure, see Color figures section.
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thereby illustrating that these particular gene sets play a role in related biological processes. 
In addition, the gene set derived from this study showed to have the highest overlap with 
other up-regulated gene sets. Also, the two down-regulated gene sets from the study of 
Behfar et al., included in the ESC_Cardiac gene set collection, have a significant overlap with 
each other. The overlap between the regulated GO gene sets with other sets was minimal.
Table 1. Regulated gene sets in ESC cardiomyocyte differentiation cultures.
Gene Ontology gene set collection # genes/ set NOM p-val FDR q-val
Downregulated
Glutathione_transferase_activity 21 <1.00E-04 7.53E-02
Response_to_unfolded_protein 37 3.96E-03 1.21E-01
Upregulated
Development 328 <1.00E-04 1.43E-01
Ribosome 138 <1.00E-04 1.16E-01
Structural_constituent_of_ribosome 160 <1.00E-04 8.34E-02
Regulation_of_progression_through_cell_cycle 119 1.92E-03 1.46E-01
Somitogenesis 21 3.84E-03 4.49E-02
ESC Cardiac gene set collection
Downregulated
Behfar_pluripotent_markers 243 <1.00E-04 <1.00E-04
Behfar_heartdiff_day7 264 <1.00E-04 7.64E-02
Upregulated
Alexandrovich_early_heartdiff 28 <1.00E-04 9.46E-03
Anni_heart_development_and_ES_cell 117 1.95E-03 1.37E-01
Anni_heart_development_and_fetal_heart 64 <1.00E-04 3.33E-02
Beqqali_heartdiff_day3 81 <1.00E-04 4.34E-04
Beqqali_heartdiff_day3_with_T 26 <1.00E-04 3.47E-04
Beqqali_mid_heartdiff 199 <1.00E-04 5.26E-02
Beqqali_early_heartdiff 426 1.96E-03 9.35E-02
Christoforou_heartdiff_day7-8 64 <1.00E-04 2.84E-04
Faustino_heart/vascular_diff 65 <1.00E-04 5.03E-03
Martinez_Hmga1_Ko 28 <1.00E-04 9.03E-04
TFs_regulating_ESC_lit 61 <1.00E-04 3.60E-02
Van_Dartel_heartdiff_24h 42 <1.00E-04 <1.00E-04
Wang_Flk1Pos_day8_ 34 <1.00E-04 4.43E-04
Wang_Flk1Pos_84h_vs_8d_up 237 <1.00E-04 8.52E-03
Wang_Flk1Pos_95h_vs_8d_up 244 <1.00E-04 1.68E-03
Novel gene set (this study)
Upregulated
Van_Dartel_heartdiff_24h 42 <1.00E-04 <1.00E-04
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MBP-induced gene expression changes in differentiating ESC
The gene expression profiles of the MBP exposed samples were not significantly differ-
ent from their time-matched controls based on the analysis of changes in the expression 
of individual genes. However, an overall trend towards inhibition of differentiation by 
MBP seemed present as can be observed in Figure 3.
GSEA analysis showed that 30 gene sets were regulated by MBP treatment after 24h 
of exposure (Table 2). No gene sets from C2 and Tissue Specific gene set collection 
were regulated. The regulated gene sets were from the GO gene set collection (n=11) 
and the Cell Cycle gene set collection (n=1), but most regulated gene sets were from 
the ESC_Cardiac gene set collection (n=16). All these gene sets were up-regulated, 
whereas our own gene set, ‘Van_Dartel_heartdiff_24h’ was uniquely down-regulated. 
Among the regulated gene sets from the GO collection was the up-regulated set ‘telo-
mere_maintenance’. In addition the cell cycle related gene sets ‘DNA_replication’ and 
‘condensed_chromosome’ were up-regulated, as well as ‘Bar-Joseph_fibroblasts_G1_S’ 
from Cell Cycle gene set collection. Two sets from ESC_Cardiac gene set collection, 
‘Behfar_pluripotent_markers’ and ‘Behfar_heartdiff_day7’ were up-regulated after MBP 
exposure. Furthermore, the sets, ‘Wang_Flk1_84h_vs_8d_up’ and ‘Wang_Flk1_95h_
vs_8d_up’ were also up-regulated by MBP exposure.
These ESC_Cardiac sets have overlap in gene content as shown in Figure 5. The gene 
sets from the study of Zhou and co-workers showed the highest similarity. None of the 
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Figure 4. Molecular concept analysis of regulated gene sets in differentiation. Per set the top 20% 
highest affected genes were used. The size of the gene set corresponds with the size of the node, and the 
boldness of the connecting lines indicates the degree of overlap between the respective gene sets. For 
color figure, see Color figures section.
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Table 2. Regulated gene sets in monobutyl phthalate exposed ESC differentiation cultures.
Gene Ontology gene set collection # genes/ set NOM p-val FDR q-val
Upregulated
Dna_replication 93 <1.00E-04 1.36E-01
Symporter_activity 74 2.04E-03 1.35E-01
Neural_crest_cell_migration 16 4.23E-03 1.22E-01
Protein_heterodimerization_activity 59 4.33E-03 1.28E-01
Telomere_maintenance 19 4.35E-03 1.35E-01
Response_to_unfolded_protein 37 5.98E-03 1.38E-01
Early_endosome 23 1.02E-02 1.31E-01
GABA-a_receptor_activity 29 1.28E-02 1.30E-01
Protein_ubiquitination 25 1.64E-02 1.19E-01
Condensed_chromosome 17 1.86E-02 1.39E-01
Germ_cell_development 19 2.07E-02 1.41E-01
Cell Cycle gene set collection
Upregulated
Bar-Joseph_fibroblasts_G1_S 133 1.00E-03 1.34E-01
Esc_Cardiac gene set collection
Upregulated
Alexandrovich_EC_cells_day4_Gata6 57 2.27E-03 1.32E-01
Behfar_pluripotent markers 243 <1.00E-04 1.43E-01
Behfar_heartdiff_day7 264 <1.00E-04 1.25E-01
Behfar_slow diff 124 2.18E-03 1.47E-01
Christoforou_low in cardiomyocytes 67 4.28E-03 1.34E-01
Wang_Flk1Neg_95h 107 <1.00E-04 3.42E-02
Wang_Flk1Pos_84h_vs_8d_up 239 <1.00E-04 1.34E-01
Wang_Flk1Pos_95h_vs_8d_up 244 <1.00E-04 1.46E-01
Wang_Flk1Pos_84h_vs_95_up 56 6.48E-03 1.29E-01
Zhou_Oct4_Sox2_Nanog_network 334 <1.00E-04 1.17E-01
Zhou_Oct4_activation_Pou5F1 subset 219 <1.00E-04 8.12E-02
Zhou_target_Nanog 410 <1.00E-04 1.38E-01
Zhou_target_Oct4 195 <1.00E-04 1.36E-01
Zhou_Oct4_activation_5-8 TF subset 43 2.08E-03 1.39E-01
Zhou_Oct4_activation_Nanog subset 96 2.20E-03 1.29E-01
Zhou_Oct4_activation_Esrrb subset 60 8.40E-03 1.09E-01
Zhou_Oct4_activation_Stat3 subset 59 1.02E-02 1.27E-01
Novel gene set (this study)
Downregulated
Van_Dartel_heartdiff_24h 42 <1.00E-04 1.68E-03
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regulated gene sets from the GO or Cell Cycle collections had overlap with any of the 
other regulated sets (Figure 5). Since the gene set ‘Van_Dartel_heartdiff_24h’ was the 
only gene set down-regulated by MBP treatment, there was no overlap between this 
gene set and the other regulated gene sets.
Discussion
ESC differentiation and gene expression changes
Gene expression analysis of differentially expressed genes showed that based on 
48 genes we could discriminate the samples isolated after 24h in EST differentiation 
cultures from the samples isolated earlier. This gene set showed to be enriched for 
‘development, ‘embryonic development’ and ‘morphogenesis’ as analyzed with GO 
enrichment analysis. This enrichment confirms that our gene set enables the detection 
of early embryonic differentiation in ESC differentiation culture within a 24 hour culture 
period, in the absence of cytotoxic effects. This assessment after 24h exposure precludes 
the need for 10 day differentiation culture and subsequent time-consuming beating 
cardiomyocyte scoring.
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Figure 5. Molecular concept analysis of regulated gene sets in monobutyl phthalate exposed 
differentiation cultures. Per set the top 20% highest affected genes were used. The size of the gene set 
corresponds with the size of the node, and the boldness of the connecting lines indicates the degree of 
overlap between the respective gene sets. For color figure, see Color figures section.
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For the detection of more subtle effects at the level of gene sets we analyzed our data 
with GSEA [82]. This analysis works without initial filtering of the dataset to select for sig-
nificantly differentially expressed genes. GSEA first ranks all genes based on fold changes 
in expression between two groups of samples. Subsequently, by using pre-defined sets 
of associated genes based on prior biological knowledge, GSEA calculates whether sets 
as a whole are enriched at the top or bottom of the fold change-based ranking list, or 
are randomly distributed. This enables the detection of significantly affected gene sets, 
while the fold change of expression of the individual genes can be relatively modest.
We used two collections from open sources, C2 and GO, that are commonly used 
for GSEA analysis in the literature. Two additional gene set collections were included, 
namely Tissue Specific and Cell Cycle gene set collection to allow for detection of tissue 
differentiation or effects on cellular proliferation. These collections were not specific for 
the cardiomyocyte differentiation of ESC. Therefore, we designed a fifth collection, the 
ESC_Cardiac gene set collection, in which gene sets derived from transcriptomic stud-
ies during cardiomyocyte or vascular differentiation of ESC were included. Using GSEA, 
testing these five gene set collections and the set ‘Van_Dartel_heartdiff_24h’, temporal 
changes in regulation of gene sets were revealed. None of the gene sets of the C2, Cell 
Cycle and Tissue Specific collections were affected by differentiation. Furthermore, only 
seven gene sets from the GO collection were up-regulated, of which 5 gene sets play a 
role in general processes, such as protein synthesis (‘ribosome’ and ‘structural constitu-
ent of ribosome’) or protein response (‘response to unfolded protein’). Just 2 gene sets 
related to differentiation were regulated, namely ‘development’ and ‘somitogenesis’. 
Up-regulation of these differentiation-related GO sets shows that using universal gene 
set collections it is possible to demonstrate effects on differentiation. However, these 
collections contain few gene sets for specific differentiation routes. Studying effects on 
specific differentiation processes using universal gene set collections does not give in-
sight into the specific niche of our interest. For this reason these gene set collections are 
not the most suitable ones for studying cardiomyocyte differentiation-related processes.
GSEA with the ESC_Cardiac gene set collections showed regulation of 16 gene sets. 
This indicates that dedicated gene sets allow for detection of cardiomyocyte differentia-
tion related effects. The majority of these gene sets were up-regulated and are related to 
heart differentiation. The gene sets ‘Anni_heart_development_and_ES_cell’ and ‘Anni_
heart_development_and_fetal_heart’ were made using the Anni 2.0 text-mining tool 
[138]. These gene sets comprise genes which are most significantly co-published with the 
concept ‘heart development’ and respectively ‘ESC and ‘fetal heart’. The up-regulation of 
these text-mining based heart development-related gene sets indicate that the ESC dif-
ferentiate towards cardiomyocytes. Beqqali et al. studied cardiomyocyte differentiation 
of human ESC. They identified and validated time-dependent gene expression patterns 
[28]. The gene set ‘Beqqali_early_heartdiff’ contains genes up-regulated in day 3 isolated 
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differentiation cultures compared to the reference pool, which contains samples of day 
1, 3, 6, 9 and 12 cardiomyocyte differentiation and human fetal heart as positive control. 
The gene sets ‘Beqqali_heartdiff_day3_with_T’ and ‘Beqqali_heartdiff_day3’ comprises 
genes which are up-regulated after 3 days of differentiation culture, respectively with 
and without co-expression of the mesodermal marker T, compared to the reference 
pool. These three gene sets are characteristic for the first phase of cardiomyocyte dif-
ferentiation, which is similar to the differentiation period we describe in this study.
The up-regulation of the sets ‘Wang_Flk1pos_day8’, ‘Wang_Flk1pos_84h_vs_8d_up’ 
and ‘Wang_Flk1pos_95h_vs_8d_up’ in the control samples isolated after 24h is caused 
by the genes associated with the cardiomyocyte lineage present in these sets. The 
strongest regulated genes in this set by cardiomyocyte differentiation are the mesoder-
mal markers T and Mesp1, furthermore other mesodermal and cardiac differentiation 
related genes contributed to the significance of these gene sets.
As shown in the molecular concept analysis (Figure 4), there is a high overlap be-
tween the gene sets related to cardiac differentiation. Because our gene set ‘Van_Dar-
tel_heartdiff_24h’ includes genes that mark early cardiomyocyte differentiation, it has a 
high overlap with other gene sets characteristic for cardiac differentiation.
Besides up-regulation of cardiac differentiation-related gene sets, two gene sets were 
down-regulated. These gene sets include genes characteristic for the pluripotent state 
of stem cells. The down-regulation of the pluripotency-associated gene sets after 24h of 
suspension culture indicates loss of the pluripotent state of the cell because of initiation 
of cardiomyocyte differentiation. The down-regulated set ‘Behfar_pluripotent_markers’ 
contains genes which were down-regulated after induction of differentiation by adding 
a differentiation inducing cocktail compared to cultured cells without differentiation 
induction. The down-regulated set ‘Behfar_heartdiff_day7’ contains genes which are 
down-regulated at day 7 of cardiomyocyte differentiation compared with day 12 [132]. 
Most likely, these genes were first down-regulated when differentiation was initiated, 
and become up-regulated at the latest phase of the differentiation protocol. This ef-
fect is also shown in the transcriptomic study of Bruce et al.[29]. They showed a large 
group (>1000 genes) of stem cell genes to be down-regulated from day 3 onwards, 
when the cells loose their pluripotency, and become up-regulated again from day 12 
onward. Nanog, one of the transcription factors of the pluripotent marker trio Pou5f1-
Sox2-Nanog, was significantly down-regulated after initiation of differentiation and was 
up-regulated again from day 6 onwards [29]. Nanog is also present in the ‘Behfar_heart-
diff_day7’ gene set. Furthermore the genes in this gene set showed overlap with the 
‘Behfar_pluripotent_markers’ gene set, which indicates that the ‘Behfar_heartdiff_day7’ 
gene set contains genes which are normally highly expressed in pluripotent stem cells.
In summary, GSEA shows temporal up-regulation of gene sets related to cardiac dif-
ferentiation, including our novel gene set ‘Van_Dartel_heartdiff_24h’, whereas gene sets 
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related to pluripotency are down-regulated. These findings are mechanistically concor-
dant and indicate that early cardiac differentiation of ESC in culture can effectively be 
monitored within the 24h period studied.
MBP related gene expression changes in differentiating ESC
At the individual gene level, no significant MBP-related gene expression changes were 
found. This is most likely due to the presence of different cell types in the EB, which 
considerably decreases the power of the analysis. Seiler et al. observed that at day 7 
of the differentiation protocol the highest percentage of cardiomyocytes was present 
in the culture, namely 17% [25]. Likewise, in our study the detection of subtle changes 
on the level of single gene expression specific for such a small subset of cells appeared 
difficult. However, an overall trend towards inhibition of differentiation by MBP seemed 
present (Figure 3). For detection of subtle gene expression changes induced by MBP we 
performed GSEA pathway level analysis using five gene set collections as well as the set 
‘Van_Dartel_heartdiff_24h’. No significantly regulated gene sets were found in the C2 
and Tissue Specific gene set collection. In the GO gene set collection, 11 gene sets were 
found to be regulated as a consequence of a 24h MBP treatment of EB in suspension 
culture. Regulation of most gene sets could not be explained from a biological point of 
view by inhibition of cardiomyocyte differentiation by MBP. However, the up-regulation 
of the set ‘telomere_maintenance’ is indicative of inhibition of early cardiomyocyte 
differentiation, because normally telomerase activity becomes down-regulated during 
differentiation [139]. The higher expression of this gene set in the MBP-treated samples 
points towards inhibition of differentiation. Furthermore, two gene sets, ‘DNA_replica-
tion’ and ‘condensed_chromosome’, were up-regulated. This up-regulation implies an 
increased proliferation rate in MBP exposed samples. Doss et al. previously showed 
down-regulation of proliferation-related gene sets, under which these two sets, in 15-
day old cardiomyocyte differentiation cultures compared with undifferentiated ESC [26]. 
From this study it remains unclear in which phase of differentiation the proliferation rate 
decreases. It was shown recently that down-regulation of Nanog, which occurs when 
cells start to differentiate, impaired cell proliferation [140]. Since we know from literature 
that Nanog is repressed from initiation of differentiation onwards [29], we expect the 
cells to mainly proliferate in the early phase of the differentiation protocol, and that the 
proliferation rate decreases when the cells become more specialized. Additionally, the 
Cell Cycle set, ‘Bar-Joseph_fibroblasts_G1_S’, was up-regulated in these samples, which 
also points towards an increased proliferation rate in these MBP exposed samples. A 
higher proliferation rate in the MBP exposed differentiation culture is therefore an indi-
cation for inhibition of differentiation.
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The gene sets ‘Behfar_pluripotent_markers’ and ‘Behfar_heartdiff_day7’ were up-
regulated by MBP exposure. As discussed, these sets were down-regulated during dif-
ferentiation and contained pluripotent-associated genes.
The molecular concept analysis shows the high overlap between the different gene 
sets originally described in the study of Zhou et al. [131]. These gene sets contain genes 
that are targets of specific transcription factors known to play a role in the molecular 
circuitry of pluripotency. These transcription factors do not necessarily up-regulate 
pluripotency associated genes, but can also inactivate or repress differentiation related 
genes. From literature it is known that genes that are activated by a combination of 
transcription factors present in ESC are expressed in the pluripotent state and become 
repressed upon differentiation [141]. The high interaction of the regulated gene sets of 
Zhou et al. indicates that these transcription factors coregulate the expression of these 
target genes. This means that the top 20% of the regulated genes in these sets are ex-
pected to be expressed in pluripotent cells. The higher expression of these pluripotency 
associated gene sets from the study of Zhou et al. in the MBP-exposed samples confirms 
the inhibition of differentiation by the treatment.
Besides the higher pluripotent state of the MBP treated cells, also more nonmeso-
dermal differentiation was observed. The genes in the regulated gene sets that are 
derived from the study of Wang et al. are genes which are higher expressed in Flk1+ 
cells after both 84 and 95h of differentiation than in Flk1- cells. Flk1+ cells were used for 
endothelial differentiation in the study of Wang et al., however these Flk1+ cells can also 
differentiate towards the hematopoietic and cardiac lineage [136]. The genes in these 
sets contain genes specific for endothelial, hematopoietic and cardiac differentiation, 
but furthermore genes not specific for mesodermal differentiation were present in these 
sets. The up-regulation of these gene sets as a consequence of MBP treatment, is ex-
plained by the higher expression of nonmesodermal Flk1+ related genes. Up-regulation 
of nonmesodermal genes in MBP exposed samples also causes up-regulation of the gene 
sets ‘Christoforou_low_in cardiomyocytes’ and ‘Alexandrovich_EC_cells_day4_Gata6’.
The inhibition of cardiomyocyte differentiation by MBP-exposure was most obvious 
through the down-regulation of our novel gene set, ‘Van_Dartel_heartdiff_24h’, which 
specifically describes the niche of early cardiomyocyte differentiation. This cardiomyo-
cyte differentiation related gene set was down-regulated after MBP exposure, with a 
GSEA calculated p-value of <0.001 and an FDR of 0.002.
In summary, the MBP induced inhibition of beating cardiomyocytes scored at day 10 
of culture was parallelled by gene expression changes observed as early as 24h after ex-
posure onset. These changes included increased expression of pluripotency-, prolifera-
tion- and nonmesodermal differentiation related gene sets and most significantly, the 
unique down-regulation of our novel gene set identified in this study, which specifically 
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describes the niche of early cardiomyocyte differentiation. The combination of these 
findings show a consistent pattern of cardiomyocyte differentiation inhibition (Figure 6).
We showed that, besides our novel gene set ‘Van_Dartel_heartdiff 24h’, other gene 
sets showed temporal regulation (Table 1) functionally related to cardiomyocyte 
differentiation. However, these sets were not down-regulated after MBP exposure, in 
spite of the overlap of genes present in these sets with the ‘Van_Dartel_heartdiff_24h’ 
gene set (Figure4). Our novel identified gene set contained well known genes involved 
in mesodermal and early cardiomyocyte differentiation, such as T, Fgf8, Mesp1 and 
Mixl1. These genes were only present in some of the gene sets that had significant 
overlap with ‘Van_Dartel_heartdiff_24h’. In addition, the set ‘Van_Dartel_heartdiff_24h’ 
contained several genes involved in mesodermal and early cardiomyocyte differentia-
tion that were not present in any of the temporally regulated gene sets that showed 
overlap with ‘Van_Dartel_heartdiff_24h’. Furthermore, among the MBP-regulated genes 
of the set ‘Van_Dartel_heartdiff_24h’, genes are present which are related to inhibition 
of cell proliferation. The unique combination of the genes present in the ‘Van_Dar-
tel_heartdiff_24h’ gene set was essential for identification of cardiomyocyte inhibition 
by MBP at this early stage of differentiation.
In conclusion, we demonstrated cardiomyocyte differentiation of ESC at the level of 
gene expression at an early stage in the differentiation process. With GSEA, using gene 
sets that specifically apply to the system studied, including our novel gene set ‘Van_Dar-
tel_heartdiff_24h’, the sensitivity of the analysis was greatly improved. MBP induced 
changes in gene expression profile were demonstrated mainly as an up-regulation of 
gene sets after 24h of suspension culture relative to the nonexposed timed control. 
These gene sets were related to pluripotency, cell proliferation and nonmesodermal dif-
ferentiation, respectively. Direct evidence for inhibition of cardiomyocyte differentiation 
was given by the down-regulation of (mesoderm-derived) cardiac differentiation genes 
observed with our gene set (‘Van_Dartel_heartdiff_24h’). It is known from in vivo studies 
that MBP causes mainly malformations of tissues of mesodermal origin [91-93, 122]. 
Pluripotent ESC
Cells of 
non-mesodermal
origin
Cardiomyocytes
Expression 
of our gene set
Proliferation
MBP MBP
MBP
MBP
MBP
Figure 6. Summary scheme of monobutyl phthalate regulated inhibition (MBP) of ESC cardiomyocyte 
differentiation as observed in this study.
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MBP induced inhibition of mesoderm-derived cardiac differentiation as demonstrated 
on the gene expression level is therefore in line with in vivo embryotoxicity. The gene 
set defined in this study might serve as a starting point for defining a dedicated gene 
set for detecting embryotoxicity in the EST. More specifically, comparison with other 
phthalates could lead to a gene set for the prediction of embryotoxicity of the chemical 
class of phthalates. In addition, these findings offer possibilities for further application 
of the transcriptomic approach to define the applicability domain and the predictivity 
of the EST.
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Abstract
The Embryonic Stem cell Test (EST) predicts developmental toxicity based on the inhibi-
tion of cardiomyocyte differentiation of embryonic stem cells (ESC). The subjective end 
point, the long culture duration together with the undefined applicability domain and 
related predictivity need further improvement to facilitate implementation of the EST 
into regulatory strategies. These aspects may be improved by studying gene expression 
changes in the ESC differentiation cultures and their modulation by compound exposure 
using transcriptomics. Here, we tested the developmental toxicants monobutyl phthal-
ate and 6-aminonicotinamide. ESC were allowed to differentiated, and cardiomyocyte 
differentiation was assessed after 10 days of culture. RNA of solvent controls was 
collected after 0, 24, 48, 72 and 96h of exposure, and RNA of developmental-toxicant-
exposed cultures was collected after 24 and 96h. Samples were hybridized to DNA 
microarrays, and 1355 genes were found differentially expressed among the unexposed 
experimental groups. These regulated genes were involved in differentiation-related 
processes, and Principal Component Analysis (PCA) based on these genes showed 
that the unexposed experimental groups appeared in chronological order in the PCA, 
which can therefore be regarded as a continuous representation of the differentiation 
track. The developmental-toxicant-exposed cultures appeared to deviate significantly 
from this differentiation track, which confirms the compound-modulating effects on 
the differentiation process. The incorporation of transcriptomics in the EST is expected 
to provide a more informative and improved end point in the EST as compared with 
morphology, allowing early detection of differentiation modulation. Furthermore, this 
approach may improve the definition of the applicability domain and predictivity of 
the EST.
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Introduction
Alternative methods for hazard identification in developmental toxicology have been 
the subject of extensive research over the last three decades. This research has been 
driven partly by the relatively high animal use in developmental toxicity testing and the 
call for reduction, replacement and refinement of animal testing. This has stimulated 
the design of alternative methods that could predict developmental toxicity at an early 
stage of compound development while requiring only a small volume of compound and 
a minimal number of experimental animals. The designed alternative tests vary from 
whole embryo cultures of rat or zebrafish, and organ cultures to continuous cell-line-
based tests [19, 84-86].
Cell-line-based tests are completely animal-free, and include the Embryonic Stem cell 
Test (EST), which was validated by the European Centre for the Validation of Alternative 
Methods (ECVAM) [19]. The EST uses a continuous murine embryonic stem cell (ESC) 
line, which can be induced to differentiate into contracting cardiomyocytes, via the 
formation of embryoid bodies (EB). Within EB, cells of ecto-, meso-, and endodermal 
origin develop upon continued in vitro culture [6, 87]. This resembles the in vivo situation 
in which the mesodermal germ layer develops between the ectoderm and endoderm 
germ layers [113], and stipulates that cell-cell interactions may play a crucial role in the 
formation of cardiac cells in the EST.
In the EST protocol the extent of differentiation is evaluated microscopically after 
10 days of culture. Compound induced inhibition of cardiomyocyte differentiation 
combined with cytotoxicity data is then used for the prediction of embryotoxicity. 
Disadvantages of this protocol are the subjective scoring of contracting cardiomyocyte 
outgrowths, the duration of culture and the limited basis of the existing prediction 
model in terms of compounds tested [22]. In addition, the current model misses the 
opportunity to study effects on different developmental processes which accompany 
and may be mediating the development of beating cardiomyocytes. Information about 
these processes could help to define the applicability domain of the EST and could lead 
to improved predictivity.
A series of studies have revealed important developmental pathways, which are 
activated during different phases of cardiomyocyte differentiation [26-28, 111, 132-135, 
142-145]. However, most of these studies describe genes involved in late stages of dif-
ferentiation. Recently, we identified a set of genes (‘Van_Dartel_heartdiff_24h’) that was 
regulated during the first 24h of cardiomyocyte differentiation [111]. We showed that 
this gene set was down-regulated when differentiation cultures were exposed to the 
developmental toxicant monobutyl phthalate (MBP). Chemical embryotoxicity in ESC 
differentiation cultures monitored by gene expression have been studied before, but 
only with small selected groups of genes [30, 31].
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The application of gene expression analysis to detect effects on the differentiation 
process has shown promising results [111, 120, 146] and could be used to improve the 
model in each of the aspects mentioned above. In the present study, differentiation 
cultures were exposed to MBP or 6-aminonicotinamide (6-AN). Both compounds mainly 
affect structures of mesodermal origin. For MBP these effects include cleft palate, cardio-
vascular, urogenital, and skeletal malformations [91-93, 122], and 6-AN has been shown 
to induce cleft palate and skeletal malformations [147-149]. Given that 6-AN is a much 
more potent developmental toxicant than MBP and likely induces malformations via a 
different mechanism, it is interesting to study if inhibition of cardiomyocyte differentia-
tion in the EST by both compounds can be detected using a common set of genes.
Cardiomyocyte differentiation of ESC was induced through specific culture condi-
tions, based on the ECVAM EST protocol [7]. RNA from control cultures was isolated after 
0, 24, 48, 72 and 96h from the EB-stage onward. We identified 1355 genes that were 
significantly regulated among the time points, which collectively describe the ‘differen-
tiation track’ in a Principal Component Analysis (PCA). Differentiation cultures exposed 
to MBP or 6-AN from the EB-stage onward for 24 or 96h showed RNA expression pat-
terns statistically significantly deviating from the differentiation track. We show that the 
identified gene set, which is regulated during ESC differentiation, can be used to detect 
differentiation-disrupting effects of the two diverse developmental toxicants tested. The 
implications for further development of the assay are discussed.
Materials and methods
Pluripotent embryonic stem cell culture
Pluripotent murine D3 embryonic stem cells (ESC; ATCC, Rockville, MD) were routinely 
subcultured every 2-3 days and grown as a monolayer in complete medium, consisting 
of Dulbecco’s Modified Eagle Medium (Gibco BRL, Gaithersburg, MD) supplemented 
with 20% heat-inactivated fetal bovine serum (Hyclone, Logan, UT), 1% non-essential 
amino acids (Gibco BRL, Gaithersburg, MD), 1% penicillin/ streptomycin (Gibco BRL, 
Gaithersburg, MD), 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD) and 0.1 mM 
β-mercapto-ethanol (Sigma-Aldrich, Zwijndrecht, The Netherlands). Leukemia inhibi-
tory factor (LIF; Chemicon, Temecula, CA) was added directly to the culture disk in a final 
concentration of 1000 units/ml. The cells were maintained in a humidified atmosphere 
at 37°C and 5% CO2.
Cardiomyocyte differentiation culture
Embryoid body (EB) formation was used as the initial step for ESC differentiation cultures 
(Figure 1). EB were obtained via hanging drop culture in complete medium without 
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LIF as described earlier [7, 102]. In brief, stem cell suspensions (3.75·104 cells/ml) were 
placed on ice before the set up of the culture. Drops (20 µl) were placed onto the in-
ner side of the lid of a Petri dish filled with phosphate buffered saline (PBS; Gibco BRL, 
Gaithersburg, MD) and incubated in a humidified atmosphere at 37°C and 5% CO2. After 
3 days of hanging drop culture, EB had formed and these were subsequently transferred 
to bacterial Petri dishes (Greiner Bio-one, Frickenhausen, Germany). On day 5, EB were 
plated one per well into 24-well tissue culture plates (TPP, Trasadingen, Switzerland). 
Differentiation was determined by microscopical inspection of EB outgrowths into 
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Figure 1. Hanging drops, containing single cell suspensions, were set up at day 0. The single cells formed 
embryoid bodies (EB), which were transferred to suspension culture at day 3. At day 5, one EB was 
plated per well in a 24 wells plate. At day 10, each EB was microscopically evaluated for the presence 
of contracting foci. Cultures were exposed from day 3 onwards to monobutyl phthalate (MBP) or 
6-aminonicotinamide (6-AN). RNA was collected at selected exposure durations as indicated.
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contracting myocardial cells after 10 days of culture. EB were considered cardiomyocyte 
positive if at least one contracting focus was present.
Test compounds and inhibition of cardiomyocyte differentiation
ESC differentiation cultures were exposed from the EB stage at day 3 onwards to 
monobutyl phthalate (MBP; TCI Europe, Zwijndrecht, Belgium; CAS No. 131-70-4), 6-ami-
nonicotinamide (6-AN; Fluka, Buchs, Switzerland; CAS No. 329-89-5) or vehicle (0.20% 
dimethyl sulfoxide (DMSO)). MBP and 6-AN were tested at their ID50 concentration, the 
concentration at which the number of EB containing contracting foci was reduced to 
50% of the control. We determined these noncytotoxic ID50 concentrations previously 
[150], and tested MBP at 1.4 mM, and 6-AN at 4.4 µM.
To confirm the ID50 of MBP and 6-AN, parallel exposed cultures were microscopically 
evaluated at day 10 of the culture and others were used for gene expression analysis at 
various time points as described below.
RNA isolation and gene expression profiling
MBP and 6-AN exposed cultures were sampled after 24h (culture day 4) and 96h (culture 
day 7) after the start of exposure. Vehicle control differentiation cultures were harvested 
after 0, 24, 48, 72 and 96h (culture days 3, 4, 5, 6 and 7) from the EB-stage at day 3 
(Figure 1). Cells were directly collected in RNA protect (Qiagen, Venlo, The Netherlands) 
to stabilize RNA, and total RNA was purified using the RNeasy mini kit (Qiagen, Venlo, 
The Netherlands) with an additional DNase treatment (RNase-Free DNase Set; Qiagen, 
Venlo, The Netherlands) according to the manufacturer’s instructions. The quantity of 
RNA in each sample was measured using a NanoDrop Spectrophotometer (NanoDrop 
technologies, Wilmington, DE). RNA integrity was assessed on the 2100 Bioanalyzer 
(Agilent Technologies, Amstelveen, The Netherlands), and good quality RNA was used 
for gene expression analysis (RNA Integrity Number (RIN) >8).
Microarray analysis experiments were performed as described previously with minor 
changes [75, 111]. In brief, as it was not practically feasible to process all samples simulta-
neously, RNA samples were randomized and processed over several experimental days, 
using one RNA sample per array and with a mix of all samples as common reference. All 
samples were run within a 2-week time period. Of the RNA samples (7-8 independent 
biological replicates per group), 1.5 µg was amplified using the Amino Allyl MessageAmp 
II aRNA kit (Ambion, Austin, TX). Next, 10 µg of control or exposed sample aRNA was 
labeled with Cy3, and equal amounts of reference pool with Cy5 (CyDye Post Labeling 
Reactive Dye Pack; Amersham Biosciences, Buckinghamshire, UK). The labeled and puri-
fied aRNA samples were fragmented and combined with reference pool. The samples 
were hybridized to microarray slides which were spotted at the Microarray Department 
of the University of Amsterdam. The slides contain 21,997 65-mer oligonucleotides from 
Dorien BW v12.indd   70 12-05-11   14:07
Introduction ‘differentiation track’ approach 71
the Sigma-Compugen Mouse nucleotide library, as well as positive and negative con-
trols. The microarray slides were scanned using a ScanArray 4000XL microarray scanner 
(Perkin-Elmer, Waltham, MA) with appropriate laser and photomultiplier tube settings. 
Array Vision software (Imaging Research, St. Catherines, Ontario, Canada) was used to 
determine median Cy3 and Cy5 signal intensities for each separate spot and background 
signal. Quality control was performed on raw data by means of a scatter plot and MA-
plot as well as a normal probability plot to assess signal distribution. The positive and 
negative controls present on the slide were used for quality control, but excluded from 
further analysis.
Data analysis and statistics
Data normalisation and statistical analysis were carried out using the R statistical soft-
ware environment [151]. Raw microarray signal data were normalized using a three-step 
approach as described previously [123]. For each gene maximal fold ratios (FR) in gene 
expression between the experimental groups were determined by comparing the aver-
age normalized signal values per group and were calculated as the maximum/minimum 
ratio. Genes that were differentially expressed between any of the experimental groups 
were identified by a one-way ANOVA on the normalized data. A p-significance threshold 
of 0.001 and FR>1.5 was used to select differentially expressed genes. Arrangement of 
differentially expressed genes in expression group clusters was achieved by hierarchical 
clustering based on Euclidian distance and Ward linkage, using GeneMaths (Applied 
Maths, Sint-Martens-Latem, Belgium).
To explore matching concept profiles of these significantly regulated gene clusters 
with concept profiles of biological processes in the Gene Ontology Database, we used 
the text-mining tool Anni 2.0 [138]. This tool calculates the overall matching score, the 
cohesion score, between each gene of the gene cluster with the concept profiles of GO 
biological processes. The concept with the highest sum of cohesion scores is defined as 
the predominant gene cluster function.
Analysis of gene set regulation using GSEA
Gene Set Enrichment Analysis (GSEA) was performed to detect differential expression of 
biologically relevant sets of genes that share common biological function or regulation 
[82, 152]. For the GSEA analysis, we used the default parameters and 1000 permutations. 
Gene sets were considered being significantly affected when the p-value was<0.01 and 
the False Discover Rate (FDR)<0.05. GSEA was followed by molecular concept analysis, in 
which overlap of genes between gene are visualized within a network [125]. The overlap 
between the gene sets was calculated as we described previously [111]
For the GSEA we used the gene set collection, named ESC_Diff, which we created 
ourselves. As basis for this gene set collection we used the gene set collection ESC_Car-
Dorien BW v12.indd   71 12-05-11   14:07
72 Chapter 4
diac, described earlier [111], which contains 103 gene sets. We extended this gene set 
collection with 145 gene sets involved in differentiation presented in the literature. 
Gene sets were included using data on ESC cardiomyocyte differentiation and cardiac 
development [26, 27, 133, 142-145]. Also gene sets specific for different stages of em-
bryonic development and stem cells were included [153]. Furthermore, gene sets that 
are related to mesodermal differentiation were included. These sets were derived from 
a transcriptomic study in which the expression profile of BMP2+ EB was compared with 
control EB and ESC [154]. Furthermore, gene sets were included from studies in which 
target genes of pluripotency-related transcription factors, such as Nanog, Pou5f1 and 
Sox2, were identified [140, 141, 155-157]. More gene sets related to the pluripotent 
cell state were included from a meta-analysis study [158] and a common expression 
analysis of 6 ESC lines, and of 5 ESC and 2 embryonal germ cell lines [159, 160]. Gene 
sets involved in pluripotency and differentiation were obtained from studies in which 
gene expression patterns of ESC were compared with DMSO and retinoic acid-induced 
differentiated ESC and differentiation of ESC by LIF-removal [161-164]. Also gene sets 
related to ESC differentiation derived from literature using the test-mining tool Anni 
2.0 were included [138]. In addition, also gene sets were included from transcriptomic 
studies that describe non-cardiomyocyte differentiation, including neural, pancreatic 
and renal differentiation [29, 165, 166].
Definition of the differentiation track
To visualize the differences between the experimental groups, we applied a novel 
approach based on Principal Component Analysis (PCA) [58]. PCA is a mathematical 
algorithm that describes the data on the basis of their (dis)similarity, so that a greater 
distance corresponds with a greater dissimilarity. In this analysis, a principal component 
is defined as a mathematically derived combination of genes and their expression 
characteristics that can be used to describe part of the process observed. A number of 
principal components that are mutually independent can be derived which in combina-
tion describe the process under study. Here, we first performed PCA using the genes 
that were identified to be differentially expressed when ESC differentiate. Secondly, the 
different time points of the differentiation process in culture could be connected with a 
curve in the PCA-plot obtained, which is therefore a continuous representation of ESC 
differentiation based on the dynamics of gene expression. This representation will be 
further referred to as the ‘differentiation track’.
Coordinates along the first and second principal component, after PCA transforma-
tion, were calculated for each sample. Deviation of compound exposed cultures from the 
PCA-derived ‘differentiation track’ was analyzed by a t-test on the first and second prin-
cipal components coordinates compared to these of the time-matched control cultures. 
Cultures were considered to deviate statistically significant from the track, if p<0.05.
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Results
Inhibition of cardiomyocyte differentiation
The presence of contracting cardiomyocyte foci in EB after exposure to either MBP or 
6-AN at their ID50 was assessed at day 10 of the culture. We confirmed the ID50 con-
centration of MBP and 6-AN as previously determined [150]. Exposure showed that the 
number of MBP or 6-AN exposed EB containing contracting cardiomyocytes was de-
creased with 44% and 40%, respectively, compared to control (data not shown). Parallel 
cultures were used for RNA transcript analysis, as described below.
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Figure 2. Heatmap of all 1355 significantly regulated genes (fold ratio >1.5 and p<0.001) transcriptionally 
responsive to cardiac differentiation. Each row represents the relative expression of a single gene throughout 
the differentiation. Seven clusters are discriminated based on temporal gene expression of these regulated 
genes. The predominant function of each cluster is given. For color figure, see Color figures section.
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ESC differentiation related gene expression changes
Gene expression data of control samples were compared by a one-way ANOVA. Using 
the cut-off criteria of a p-value of<0.001 and a FR>1.5, 1355 regulated genes were dif-
ferentially expressed among the chemically unexposed experimental groups. The clus-
tering of these genes is presented in Figure 2. Broadly seven clusters of gene expression 
profile can be distinguished on the basis of their expression dynamics with time (Figure 
2, clusters 1-7 and Supplemental Table 1).
The predominant gene cluster functions of the seven clusters as determined by Anni 
2.0 text-mining analysis are presented in Figure 2. For two gene clusters, cluster 4 and 
5, no predominant gene cluster function could be identified. For cluster 4, several con-
cepts with equal sums of the cohesion scores were identified, while for cluster 5 the sum 
of the cohesion scores relative to the number of genes present in this cluster was low (< 
0.0065), this indicates that no enriched biological process could be identified.
GSEA was performed to further study the progress of differentiation towards the time 
points at which exposed cultures were sampled (24 and 96 h). After 24h of suspension 
culture, 51 gene sets were up-regulated and 91 gene sets were down-regulated com-
pared with the samples isolated after 0h of suspension culture (Supplemental Table 2). 
The significance of overlap among up-regulated gene sets in gene content, shown as 
connections, is visualized in Figure 3. All up-regulated gene sets were connected in one 
network. These gene sets are enriched in genes involved in differentiation processes, 
including cardiac differentiation, and includes cluster 4 (‘Cl4_24h_up’). Of the down-
regulated gene sets, 87/91 were connected in one network. These sets comprise genes 
which are up-regulated in pluripotent ESC and at the early stage of ESC differentiation, 
including the gene set ‘Van_Dartel_heartdiff_24h’ (Figure 3A).
GSEA of gene sets regulated between 96h and 0h in unexposed cultures revealed up-
regulation of 72 gene sets and down-regulation of 73 gene sets. Of all up-regulated gene 
sets, 71/72 have significant overlap in gene content with at least one other up-regulated 
gene set (data not shown). These gene sets are characteristic for differentiation, and in par-
ticular cardiac differentiation. Most of these gene sets were already up-regulated after 24h 
Table 1. Significance of deviation from the ‘differentiation track’ on the first (PC1) and second 
(PC2) principal component of cultures exposed for 24 or 96h to monobutyl phthalate (MBP) or 
6-aminonicotinamide (6-AN). * p<0.05.
Compound Exposure duration p-value PC 1 p-value PC 2
MBP 24h 0.041* 0.096
MBP 96h 0.059 0.493
6-AN 24h 0.164 0.031*
6-AN 96h 0.587 0.017*
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(45/72). The majority of the additional up-regulated gene sets are described to be related 
to later stages of cardiomyocyte differentiation. All down-regulated gene sets showed 
significant overlap in genes responsible for the significance of the gene set regulation, 
and together form one network (data not shown). These gene sets describe pluripotency 
and early differentiation stages. A majority of these gene sets were already significantly 
down-regulated after 24h (68/73). The additional down-regulated gene sets include sets 
comprising genes described to be down-regulated at later stages of differentiation, a gene 
set containing targets of transcription factors that maintain pluripotency, and another 
pluripotency-related set. In general, these GSEA results show that as early as 24h after 
plating EB, ESC differentiation can be detected by up-regulation of differentiation gene 
sets and down-regulation of pluripotency-related gene sets. The 96-h time point only adds 
the up-regulation of gene sets describing later stages of cardiomyocyte differentiation.
ESC cardiac differentiation track
Principal Component Analysis (PCA), on the basis of all 1355 significantly regulated 
genes, showed that 93.8% of all variance between experimental groups could be de-
scribed using the first and second principal components of the PCA analysis. The remain-
ing principal components had minor contributions to total gene expression variance 
and produced no significant shifts between experimental groups. The two-dimensional 
PCA-plot showed that replicates within different experimental groups clustered togeth-
er and different groups appeared in chronological order in the PCA (Figure 4). The arc 
connecting these experimental groups can therefore be regarded as a representative 
description of the ‘differentiation track’ by gene expression changes.
VAN_DARTEL_HEARTDIFF_24H
CL4_24H_UP
Cardiac gene set; downregulated
Pluripotency gene set; upregulated
Figure 3. Molecular concept analysis of regulated gene sets after 24h of differentiation. Per set the top 
20% highest affected genes were used. The size of the gene set corresponds with the size of the node, and 
the width of the connecting lines indicates the degree of overlap between the respective gene sets. For 
color figure, see Color figures section.
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Figure 4. Principal Component Analysis (PCA) of the control cultures after 0, 24, 48, 72 and 96h of 
differentiation, and cultures exposed to monobutyl phthalate (MBP) or 6-aminonicotinamide (6-AN) for 
24 or 96 h. The PCA is based on the 1355 regulated genes. The mean values per experimental group are 
indicated by the large circles and the ‘differentiation track’ is shown by the dashed line. For color figure, 
see Color figures section.
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Figure 5. Molecular concept analysis of regulated gene sets (A) after 24h monobutyl phthalate exposure 
in differentiation cultures and (B) after 24h 6-aminonicotinamide exposure in differentiation cultures. Per 
set the top 20% highest affected genes were used. The size of the gene set corresponds with the size of 
the node, and the width of the connecting lines indicates the degree of overlap between the respective 
gene sets. For color figure, see Color figures section.
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Compound-induced gene expression changes in differentiating ESC
Comparison of gene expression profiles of differentiation cultures exposed to MBP or 
6-AN with their time-matched controls revealed no significant changes in the expression 
of individual genes. However, GSEA showed that exposure of differentiation cultures 
to MBP or 6-AN resulted in significant effects at the level of gene set regulation. MBP 
exposure induced the up-regulation of 14 gene sets that comprise genes involved in 
pluripotency and differentiation (Figure 5A and Supplemental Table 2). Further analysis 
using Anni 2.0 revealed that genes that contributed to the significance of this gene 
set were enriched for processes involved in adhesion, stress, and apoptosis. The seven 
down-regulated gene sets were mainly enriched for genes involved in early differentia-
tion. Cluster 4 (‘Cl4_24h_up’, Figure 2), including genes up-regulated after 24h in unex-
posed differentiation cultures, was significantly down-regulated by 24-h MBP treatment 
(p-value<0.001 and FDR<0.001).
6-AN exposure of differentiation cultures resulted in up-regulation of 115 gene sets af-
ter 24h in comparison to unexposed cultures (Supplemental Table 2). Molecular concept 
analysis revealed that these sets have a significant overlap in gene content as shown in 
Figure 5B. These gene sets were predominantly involved in either pluripotency or early 
differentiation. The only gene set down-regulated in cultures exposed to 6-AN for 24h 
was cluster 4 (‘Cl4_24h_up’, Figure 2; p-value<0.001 and FDR<0.001).
GSEA results of the 96-h exposed cultures were not used for the interpretation of 
exposure effects because the ‘differentiation track’ is less dynamic at that time point 
than at the 24h point, as illustrated by the relatively small changes in expression pattern 
between 72 and 96h (Figures 2 and 4).
Compound exposed differentiation cultures deviate from differentiation track
Inhibition of cardiomyocyte differentiation was further studied by analyzing the 
compound-induced deviation from the ‘differentiation track’ defined by PCA. Both com-
pounds showed statistically significant deviations from the differentiation track. The 
differentiation cultures exposed for 24h to MBP deviated statistically significantly from 
the first principal component of the ‘differentiation track’ (p-value<0.04), however after 
96h of exposure the deviation was not significant anymore (p-value <0.06). Alternatively, 
the 6-AN exposed differentiation cultures at both time points resulted in a statistically 
significant deviation from the second principal component of the ‘differentiation track’ 
(24 h: p-value <0.03, 96 h: p-value <0.02; Figure 4 and Table 1). These results show that 
using the ‘differentiation track’ of ESC differentiation cultures in the PCA-plot can be used 
to identify differentiation-modulating effects of two diverse developmental toxicants.
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Discussion
ESC differentiation and gene expression changes
Gene expression analysis during a 96-h period of unexposed ESC differentiation revealed 
1355 statistically significantly regulated genes, which could be divided into seven clus-
ters dependent on their gene expression profile in time. We identified the predominant 
function of these gene clusters in relation to ESC differentiation as described earlier 
[27, 109, 131, 167]. Analysis of gene function generally indicated loss of pluripotency 
and gain of cardiac differentiation. This supports the notion that in our gene expression 
analysis we are clearly monitoring cardiac differentiation.
To our knowledge, this is the most comprehensive analysis to date of gene expression 
in the early phase of cardiomyocyte differentiation, represented by the 24 and 48h time 
points. This period of the differentiation trajectory appeared to be highly dynamic, as 
both at 24- and at 48-h (clusters 4 and 5 respectively in Figure 2) transiently up-regulated 
genes were identified. Although genes known to be involved in development were pres-
ent in cluster 4, such as Hoxb6, Hand1, and BMP4, various groups of genes with the same 
abundance but with alternative functional characteristics were identified on the basis 
of the current literature. This indicates that cluster 4 includes genes involved in several 
biological processes, apparently related to development, which have not been previ-
ously described in literature. For cluster 5 no predominant function could be identified, 
indicating that we have encountered a cluster with a novel functionality for the genes 
involved.
In a previous study of early cardiac differentiation in ESC, we identified a gene set, 
‘Van_Dartel_heartdiff_24h’, containing 43 genes up-regulated after 24h from suspen-
sion culture onwards as compared with the 6- and 12-h differentiation time points 
[111]. In the present study we found that 22 of these 43 genes were already statistically 
significantly down-regulated at the individual gene level at the 24-h compared to the 
0-h time point. This shows that the differentiation process in the present study was 
further advanced as compared to our previous study [111]. The discrepancy between 
both studies can be explained by the rapid, brief and transient up-regulation of the 
‘Van_Dartel_heartdiff_24h’ gene set, similar to the dynamics of cluster 4 (‘Cl4_24h_up’) 
at 24h of differentiation in the present study. No less than 79% of the genes in the 
‘Van_Dartel_heartdiff_24h’ gene set were also found statistically significantly regulated 
in the current study. Further studies will enable the selection of the most reliable genes 
in terms of reproducible expression changes as a robust set of differentiation markers. 
Together, these findings show that monitoring differentiation in this model that is 
characterized by rapidly changing gene expression should not rely on just a single gene 
cluster defined by time-dependent regulation only. Rather, improved description of dif-
ferentiation process should be based on a combination of gene clusters with different 
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expression dynamics in time, giving a more informative picture of the differentiation 
stage of the cell population in the assay.
The gene set identified in this study contains 1355 genes that were expressed at dif-
ferent stages of cardiomyocyte differentiation. From literature we identified 83 gene sets 
in which regulation of genes related to cardiomyocyte differentiation were described 
[26-28, 111, 132-135, 142-145]. The overlap in gene content with our 1355 genes was 
relatively low, only 3 gene sets contained >50% overlap with our gene set. These sets 
include the set ‘Van_Dartel_heartdiff_24h’ [111] and two sets from a study of Masino et 
al. [142] with respectively, 79%, 55% and 50% of the genes also present in our current 
set. This relatively high overlap in gene content, appears to be caused by overlap with 
a specific cluster within our gene set (cluster 1, 7, and 6 respectively). The majority of all 
gene sets contained genes that correspond with the gene clusters up-regulated after 
72 and 96h of differentiation (culture days 6 and 7) in this study. Besides the gene sets 
identified in this study, no other gene set was found that contained genes regulated 
after 0, 24 or 48h of differentiation (culture days 3, 4, or 5). Combination of gene sets 
derived from the same article still does not result in a gene set that describes these 
stages of differentiation. Therefore, our gene set is currently the most complete one 
available to study the ESC differentiation dynamics.
We studied the ESC differentiation dynamics by performing PCA on the dataset using 
the 1355 regulated genes, which showed a continuous PCA trajectory that defines the 
differentiation track. Using these genes not only the classical end point of cardiomyocyte 
differentiation is included, but also other biological processes which proceed and/or 
accompany cardiomyocyte differentiation are incorporated in this differentiation track. 
Interference with these additional identified biological processes may finally lead to dis-
turbed cardiomyocyte differentiation, and therefore inclusion of genes involved in these 
other processes may improve the developmental toxicity prediction. This ‘differentiation 
track’ was subsequently used as a differentiation fingerprint for the discrimination of 
developmental toxicant-exposed cultures. This method was also used in other studies to 
discriminate experimental groups. Van de Waterbeemd et al. [168]used this PCA-method 
to study the optimal harvest point in bacterial vaccine production, and Liu et al. [169] 
described the detection of endogenous signalling activation pathways by an oncogenic 
stimulus.
Compound-induced gene expression changes in differentiating ESC
Studying regulation of individual genes induced by developmental toxicant exposure 
has shown to be insufficient in developmental models. Developmental modulation 
restricted to specific cell types may not necessarily lead to statistically significant single 
gene expression changes because of the dilution of effects occurring in a single cell 
type within the whole sample that contains a variety of cell types. Kultima et al. [146] 
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found only nine genes regulated in day 8 p.c. embryos after exposure to cadmium. In our 
previous study on differentiation modulation, no individual genes were regulated after 
MBP exposure [111], and in the present study again no individual genes were regulated 
after MBP or 6-AN exposure. Therefore, we studied the modulation of the cardiomyocyte 
differentiation process by analyzing the deviation of MBP or 6-AN exposed cultures from 
the ‘differentiation track’ defined by PCA. The PCA approach combines all gene expres-
sion data and therefore greatly increases the statistical power of the analysis. When the 
exposed differentiation cultures were projected onto the two-dimensional expression 
space delineated by the 1355 differentiation-related genes, it appeared that both MBP 
and 6-AN deviated significantly from the ‘differentiation track’ after 24h of exposure, 
confirming the modulating effects of these developmental toxicants on the cardio-
myocyte differentiation process. In the early phase of cardiomyocyte differentiation, 
the differentiation-induced gene expression regulation appeared to be more dynamic 
as compared to the later phase, which results in a better detection of developmental 
toxicants after the relatively short exposure duration of 24 h, compared to 96 h.
The GSEA analysis reveals effects on differentiation after 24h of compound exposure, 
using the time-matched cluster 4 (‘Cl4_24h_up’) defined in the present study. This 
gene set was strongly down-regulated by both MBP and 6-AN. The gene set ‘Van_Dar-
tel_heartdiff_24h’, down-regulated after 24h of differentiation in our previous study, 
was not down-regulated in cultures exposed for 24h to MBP and was even up-regulated 
after 24h of exposure to 6-AN (Figure 5A and 5B). This can be explained by the fact that 
differentiation stage of the cultures between experiments can vary, as discussed above 
[111]. Since GSEA relies on a comparison of only two groups, only time-matched ex-
posed and control groups can be compared to study exposure effects. This cross-section 
approach is therefore less suitable to identify effects on a dynamic differentiation 
model. In addition, the genes responsible for significant regulation of the gene set do 
not per definition have to be involved in the biological process for which the gene set 
was identified. This was observed in some of the up-regulated gene sets after 24h of 
exposure to MBP compared to control. These gene sets were derived from studies in 
which gene sets involved in cardiac differentiation were described [133, 145]. Further 
analysis of the genes within the set responsible for the significant regulation revealed 
that genes involved in processes as adhesion, stress, and apoptosis contributed to the 
significance of gene set up-regulation in the MBP exposed cultures. However, in this 
analysis cardiomyocyte-specific genes within the set, such as Pln, Myl3, and Creld1, did 
not contribute to the significance of the gene set regulation. Taken together, GSEA does 
support the rationale that differentiation-related gene sets are affected by compound 
exposure.
The differentiation track, defined by PCA, described in this study is a more powerful 
starting point to detect differentiation-related gene expression changes. A significant 
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improvement of this ‘differentiation track’ approach is that genes are included that are 
regulated at different stages during the entire 96h of monitored differentiation. This 
removes the necessity of using time-matched gene sets for separate experiments. In 
addition, this makes the model more flexible, as variation in differentiation progression 
between experiments will not hamper the interpretation of results. Furthermore, when 
deviation from the ‘differentiation track’ is studied, effects on all biological processes 
represented in the assay are included in the analysis. This is a wider assessment than 
that of the ‘classical’ EST, which is focusses exclusively on inhibition of cardiomyocyte 
differentiation, which is only a single end point of the developmental cascade. Thus, 
the ‘differentiation track’ approach may lead to an improved applicability domain and 
increased sensitivity of the EST.
In conclusion, the PCA-derived ‘differentiation track’ approach appeared to be a 
suitable method to describe the dynamics of the cardiomyocyte differentiation. Fur-
thermore, this approach provides an important proof-of-principle by showing that the 
effects of both MBP and 6-AN in the EST could be described by a statistically significant 
deviation from the ‘differentiation track’ defined by gene expression changes. It is known 
from in vivo studies that both MBP and 6-AN cause effects on tissues of mesodermal 
origin, probably via a different mechanism. The deviation of the compound-exposed 
cultures from the ‘differentiation track’ is therefore in line with the in vivo embryotoxicity. 
Additional testing of non-embryotoxic and embryotoxic compounds that affect tissues 
of nonmesodermal origin might lead to refinement of the gene set for the prediction 
of embryotoxicity. Further refinement might be achieved by focussing on the early and 
highly dynamic phase of the differentiation track.
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Monitoring developmental toxicity 
in the Embryonic Stem cell Test 
using differential gene expression 
of differentiation-related genes
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Abstract
The Embryonic Stem cell Test (EST) has been designed to predict developmental toxicity 
based upon compound-induced inhibition of embryonic stem cell (ESC) differentia-
tion. The end point scoring, the test duration, and the definition of the predictivity and 
the applicability domain require improvements to facilitate implementation of the 
EST into regulatory testing strategies. The use of transcriptomics to study compound-
induced differentiation modulation may improve the EST in each of these aspects. 
ESC differentiation was induced and cell samples were collected after 0, 24 and 48h of 
differentiation. Additionally, samples were collected that were 24h-exposed to one of 
five developmentally-toxic compounds or a non-developmentally-toxic compound. All 
samples were hybridized to Affymetrix GeneChips, and analyses revealed that 26 genes 
were significantly regulated both during ESC differentiation and by exposure to each 
of the developmentally-toxic compounds tested. Using Principal Component Analysis 
we defined a ‘differentiation track’ on the basis of this gene list, which represents ESC 
differentiation. We showed that significant deviation from the ‘differentiation track’ was 
in line with the developmental-toxic properties of the compounds. The significance 
of deviation was analyzed using the Leave-One-Out cross validation, which showed a 
favorable prediction of toxicity in the system. Our findings show that gene-expression 
signatures can be used to identify developmental-toxicant induced differentiation 
modulation. In addition, studying compound-induced effects at an early stage of dif-
ferentiation combined with transcriptomics leads to increased objectivity in determin-
ing differentiation inhibition and to a reduction of the test duration. Furthermore, this 
approach may improve the predictivity and applicability domain of the EST.
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Introduction
The implementation of the new EU regulation for Registration, Evaluation and Autho-
rization of Chemicals (REACH) in 2007 will bring about the assessment of the potential 
toxicity of thousands of chemicals within the coming years. The current regulatory 
guidelines for the toxicological hazard identification require large numbers of experi-
mental animals. As the highest number of experimental animals are currently being 
used in regulatory reproductive and developmental toxicology [119], the demand for in 
vitro alternative test methods is particularly high in that field. Various alternative testing 
methods for the prediction of developmental toxicity have already been developed. 
These tests vary from whole embryo cultures of rat or zebrafish, and organ cultures, to 
continuous cell-line-based tests, such as the Embryonic Stem cell Test (EST) [19, 84-86].
To effectively reduce the demand for experimental animals, in vitro alternative test 
methods need regulatory acceptance. The validation by the European Centre for Vali-
dation of Alternative Methods (ECVAM) of the EST, the rat Whole Embryo Culture and 
the MicroMass as alternative testing methods has been an important exercise towards 
this regulatory acceptance so far. Of these three tests, the EST is the only one that is 
completely animal-free. However, while the EST is considered a promising alternative 
assay for developmental toxicity, it has several weaknesses as recently discussed in an 
ECVAM Workshop [170]. Aspects that need optimization to allow successful regulatory 
implementation include culture duration, end point scoring, and the definition of its 
predictivity and its applicability domain.
The EST predicts developmental toxicity based on the inhibition of the differentiation 
of embryonic stem cells (ESC) into cardiomyocytes. However, besides these mesoder-
mal-derived cardiomyocytes, cells derived from both the ecto- and endodermal germ 
layers also develop within these differentiation cultures [6, 87]. This resembles the in vivo 
situation in which cells from each of these three germ layers are present in the develop-
ing embryo [171]. The prediction of developmental toxicity by the EST could possibly be 
optimized if compound-induced interference with each of the cell types present in the 
EB would be taken into account.
The use of molecular techniques in toxicology has enabled the early detection of 
changes in gene and protein expression [172, 173]. In addition, these methods can help 
in our understanding of the mechanisms of action of toxicity [174, 175]. Small-scale 
molecular techniques, such as real-time polymerase chain reaction (RT-PCR), can be 
used to study modulations of the expression of specific genes by a toxicant expected 
on the basis of knowledge of the mode of action. More advanced techniques, including 
transcriptomics, can be used to study gene expression alterations in the whole genome, 
not necessarily requiring prior mechanistic knowledge. The transcriptomic technique 
has shown promising results in toxicology. Waring et al. [176] revealed a correlation 
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between gene expression profiles of hepatoxins and mechanisms of toxicity. In the 
field of developmental toxicology, Robinson et al. [54] and Jergil et al. [52] showed that 
compound-induced gene expression changes in in vivo and in vitro systems, respectively, 
were related to teratogenic effects observed in vivo.
The implementation of transcriptomics in the EST may optimize this test as a success-
ful in vitro model for predicting developmental toxicity. Analyses of gene-expression 
changes have shown to be feasible within an abbreviated experimental protocol [111, 
177]. Furthermore, ESC differentiation-related genes have been identified in these stud-
ies, which could help us to define the applicability domain and improve the predictivity 
of the EST.
In this study, we investigated the possibility of predicting developmental toxicity by 
the implementation of transcriptomics into the EST. We applied Principal Component 
Analysis (PCA) of gene expression dynamics to define the ‘differentiation track’ in dif-
ferentiating ESC in the EST protocol as previously described [177]. In the present study, 
we show that five developmental toxicants caused significant deviation from the dif-
ferentiation track, whereas a non-developmental-toxic negative-control compound 
did not deviate from the differentiation track. We identified a set of 26 differentiation-
regulated genes of which the expression was changed both during ESC differentiation 
and after exposure to each of the five developmental toxicants but not necessarily after 
exposure to the non-developmentally-toxic compound. Moreover, application of the 
Leave-One-Out method showed a favorable prediction of toxicity in the system. These 
findings show that gene expression signatures can be used to describe and possibly 
predict developmental toxic responses in the EST.
Materials and methods
Test compounds
Test compounds used in this study were monobutyl phthalate (MBP; CAS No. 131-
70-4, TCI Europe, Zwijndrecht, Belgium), methoxyacetic acid (MAA; CAS No. 625-45-6, 
Sigma-Aldrich, Zwijndrecht, The Netherlands), valproic acid (VPA; CAS No. 1069-66-5, 
Sigma-Aldrich), and retinoic acid (RA; CAS No. 302-79-4, Fluka, Buchs, Switzerland), 
which were dissolved in dimethyl sulfoxide (DMSO), and 5-fluorouracil (5-FU; CAS No. 
51-21-8, Sigma-Aldrich), and Penicillin G (PenG; CAS No. 69-57-8, Sigma-Aldrich), which 
were dissolved in phosphate-buffered saline (PBS).
Resazurin cell proliferation assay
Compound-induced effects on cell number were determined using resazurin dye reduc-
tion, which is a measure for the number of viable cells per well [178], as described previ-
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ously [150]. In short, hanging drop cultures were set up using pluripotent murine D3 
embryonic stem cells (ESC; ATCC, Rockville, MD) and exposed to a concentration range 
of the selected test compounds. After 3 days, embryoid bodies (EB) were harvested per 
compound concentration and resazurin (Promega, Madison, WI) was added to the cells. 
The resazurin reduction by the cells was measured after incubation at 37°C at 530 nm 
(excitation) and 590 nm (emission) using a FLUOstar Galaxy microplate reader (BMG Lab 
Technologies, Offenburg, Germany). The resazurin reduction of exposed cells relative 
to control measurement was calculated and plotted against the test concentrations 
using PROAST software [103]. For each compound a minimum of five concentrations 
were tested in three independent runs. The cell survival at the concentration used in the 
transcriptomic experiment was calculated for each compound on basis of the curve fit.
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Figure 1. Schematic overview of experimental procedures of cardiomyocyte differentiation. Hanging 
drop cultures containing a suspension of single embryonic stem cells were set up at day 0. The dissociated 
cells formed embryoid bodies (EB), which were transferred to suspension culture plates at day 3. At day 
5, EB were plated one per well into 24-well tissue culture plates. At day 10, each EB was microscopically 
evaluated for the presence of contracting cardiomyocyte foci. Differentiating cells were exposed to test 
compounds from day 3 onwards. For transcriptomic analysis, non-exposed control samples were isolated 
after 0, 24, and 48h of exposure, and compound-exposed cultures were sampled after 24h of exposure.
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Pluripotent embryonic stem cell culture and cardiomyocyte differentiation
D3 ESC were cultured in a monolayer in complete medium supplemented with leukemia 
inhibitory factor (LIF; Chemicon, Temecula, CA), as described previously [7, 177]. Embry-
oid bodies (EB) were obtained via hanging drop culture in complete medium without LIF 
[7, 102, 177] as is visualized in Figure 1. These EB cultures were used as the primary step 
for ESC differentiation. The cardiomyocyte differentiation was considered successful if in 
at least 21 out of the 24 evaluated control EB, at least one contracting focus was present.
Inhibition of cardiomyocyte differentiation by compound exposure
ESC differentiation cultures were exposed from the EB-stage at day three onwards to 
concentrations that were calculated (on the basis of historic data) to inhibit cardiomyo-
cyte differentiation with 50% compared to control cultures. All cultures were exposed 
to 0.2% DMSO for comparability reasons. Cultures were microscopically evaluated at 
day 10 of the culture to assess the inhibition of cardiomyocyte differentiation (Figure 1), 
while parallel cultures were used for gene expression analysis at earlier time points as 
explained below.
RNA isolation and whole genome gene expression profiling
RNA of compound-exposed cultures was isolated 24h after the start of exposure, which 
corresponds with culture day 4 (6-8 replicates per group). dimethyl sulfoxide (DMSO)-
exposed control differentiation cultures were harvested after 0, 24 and 48h from the EB-
stage at day 3, which corresponds with culture day 3, 4, and 5 (12 replicates per group) 
as is visualized in Figure 1. Cells were directly collected in RNA protect (Qiagen, Venlo, 
The Netherlands) to stabilize RNA, and total RNA was purified using the RNeasy mini kit 
(Qiagen, Venlo, The Netherlands) with an additional DNase treatment (RNase-Free DNase 
Set; Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. The 
quantity of RNA in each sample was measured using a NanoDrop Spectrophotometer 
(NanoDrop technologies, Wilmington, DE) and RNA integrity was assessed on the 2100 
Bioanalyzer (Agilent Technologies, Amstelveen, The Netherlands) using the RNA 6000 
Nano Chip Kit (Agilent Technologies) and good quality RNA was used for gene expres-
sion analysis (RNA Integrity Number (RIN) >8). Of the corresponding RNA samples, 250 
ng was amplified and fragmentated using the Affymetrix GeneChip® 3’IVT Express 
Kit (Affymetrix, Santa Clara, CA) according to manufacturer’s instructions on the Xiril 
Neon 150 robotic system (GC-Biotech, Alphen a/d Rijn, The Netherlands). Next, 250 µl 
hybridization cocktail was added to 12.5 µg fragmented aRNA and 200 µl of this cocktail 
was applied to the Mouse Genome 430 2.0 arrays (Affymetrix) and hybridized for 16h at 
45°C in a Genechip Hybridization Oven 640 (Affymetrix). After hybridization the arrays 
were washed and stained with a Genechip Fluidics Station 450 (Affymetrix) using the 
Genechip hybridization wash and stain kit. Thereafter, the arrays were scanned using 
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the Genechip scanner 3000 (Affymetrix). Quality controls were performed according to 
the manufacturer’s instructions and showed to be within acceptable limits for all arrays, 
except for one RA-exposed sample that was excluded for further analysis.
Data analysis and statistics
Affymetrix CEL files were normalized using the Robust Multichip Average (RMA) 
algorithm [179] using RMAexpress [180]. For probe to gene mapping, a custom Chip 
Description File (CDF) was used according to the recent assembly by de Leeuw et al. 
(http://mad-db.science.uva.nl/~wdeleeuw/HybridAnnot/version6.html) [181]. Of the 
hybrid probe-set definitions included in the custom annotation, 16,331 probe sets 
defined by the Brainarray custom CDF version 11 (http://brainarray.mbni.med.umich.
edu/Brainarray/Database/CustomCDF) [182] and 4,648 additional probe sets defined by 
Affymetrix chip annotation 26 were used in further analyses, giving a total of 20,979 
probe sets. Probe sets for Affymetrix internal controls or probe sets that did not cor-
respond to an Entrez Gene ID were not used in further analyses. Raw and normalized 
data are deposited at ArrayExpress (http://www.ebi.ac.uk/arrayexpress) under accession 
number E-TABM-903.
Statistical analyses were carried out using the R statistical software environment [151] 
using log-transformed values. For each gene, maximal fold ratios (FR) in gene expression 
between the experimental groups were determined by comparing the average normal-
ized signal values per group and were calculated as the maximum/minimum ratio. Genes 
that were differentially expressed between any of the experimental groups were identi-
fied by a one-way ANOVA on the normalized data. A p-significance threshold of 0.001 
and FR>1.5 was used to select genes that were significantly differentially expressed 
when ESC differentiate. A p<0.001 without FR restriction was applied for the identifica-
tion of significantly differentially expressed genes caused by compound exposure.
Arrangement of the genes that were significantly differentially expressed in the ESC 
differentiation cultures in expression clusters was achieved by hierarchical clustering 
based on Euclidian distance and Ward linkage, using GeneMaths XT (Applied Maths, 
Sint-Martens-Latem, Belgium). Functional annotation and enrichment for Gene Ontol-
ogy (GO) biological processes were studied using the tools on the DAVID website [183]. 
Only genes with FR>1.5 were used to study this enrichment due to DAVID’s limitation on 
the length of the gene-list input. In order to perform functional annotation of individual 
genes, we used the Entrez gene database on the NCBI website (http://www.ncbi.nlm.
nih.gov/gene/).
Definition of the differentiation track
Using the genes significantly differentially expressed in ESC differentiation, we defined 
the ‘differentiation track’ of normal ESC differentiation as we described previously [177]. 
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This approach is based on Principal Component Analysis (PCA) [58], which is a math-
ematical algorithm that describes the data on the basis of their (dis)similarity, so that 
a greater distance corresponds with a greater dissimilarity. In this analysis, a principal 
component is defined as a mathematically derived combination of genes and their 
expression characteristics that can be used to describe part of the process observed. A 
number of principal components that are mutually independent can be derived which 
in combination describe the process under study. At first a gene list was defined, which 
comprised the genes that were identified to be significantly differentially expressed 
among the ESC differentiation groups sampled at different stages of ESC differentia-
tion. Next, PCA analysis was performed using this gene list, using R. We connected a line 
between the average array gene expression at 0, 24 and 48h on our PCA plot to display 
the continuous representation of the ESC differentiation based on the dynamics of 
gene expression. This curve was defined as the ‘differentiation track’. Later, the number 
of genes on this list was reduced by selecting the genes that were both regulated in 
ESC differentiation and by compound exposure. Finally, this refined gene list was used 
to describe the ESC differentiation by means of the PCA-derived differentiation track. 
Coordinates along the first and second principal component were calculated for each 
sample. Deviation of compound exposed cultures from the ‘differentiation track’ was 
analyzed by applying a Hotelling T-test to these coordinates compared to those of time-
matched control cultures. Significant deviation from the ‘differentiation track’ (p<0.05) 
was considered characteristic for developmental toxicants.
To cross-validate the classification by the obtained gene list using the ‘differen-
tiation track’ approach, we used the Leave-One-Out validation test. Expression data of 
compound-exposed experimental groups were left out one-by-one to obtain the genes 
that were regulated in ESC differentiation as well as after exposure to all other develop-
mental toxicants. These gene lists were used to define the ‘differentiation track’ and for 
each compound-exposed experimental group the statistical significance of deviation 
from these differentiation tracks was calculated.
Results
Compound-induced effects on cell proliferation and differentiation
Differentiating ESC were exposed to single test compound concentrations, selected on 
the basis of historic data from our laboratory. Effects on proliferation and differentiation 
were scored in cultures parallel to those analyzed for gene expression. The effects on 
proliferation at day three of hanging drop culture and on cardiac foci scoring at termina-
tion (day 10) of EST culture are given in Figure 2. PenG, VPA and MBP did not affect 
cell survival, whereas RA, MAA and 5-FU reduced cell numbers in varying degrees. All 
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compounds affected differentiation, with PenG and VPA as the least effective and 5-FU 
as the most effective compound tested. The remaining three compounds showed dif-
ferentiation inhibition of around 50%.
Differentiation-related gene expression changes
The gene expression profiles of the samples of unexposed differentiation cultures at 
0, 24, and 48h were compared by means of a one-way ANOVA analysis, using cut-off 
criteria of p<0.001 (corresponding False Discovery Rate=0.0017) and FR>1.5. We identi-
fied 3579 genes showing statistically significant differential expression with time. This 
gene expression pattern showed the dynamics of early cardiomyocyte differentiation 
as shown in Figure 3A. Broadly, three main gene clusters were observed based on the 
gene expression dynamics of the differentiating ESC, representing the highest differen-
tial gene expression values among the time points studied. These gene clusters were 
enriched for developmental-related terms, including cell differentiation (0 h), somito-
genesis (24 h), developmental process (24h and 48 h), and tube development (48 h). The 
gene cluster up-regulated at 0h was also enriched for cell proliferation and metabolism. 
Furthermore, the term extracellular matrix was found to be significantly related to the 
identified gene cluster at 48h (Figure 3A).
Principal Component Analysis (PCA), using the 3579 transcriptionally responsive 
genes, showed that 94.0% of all variance between the unexposed experimental groups 
could be described using only two principal components of the PCA (Figure 3B). Addi-
tional principal components had a minor contribution to total gene expression variance 
and produced no significant shifts between these experimental groups. The PCA plot 
clearly shows the differentiation dynamics, and indicates that the variance within experi-
mental groups is relatively very small as compared to the variance between time points 
in ESC differentiation (Figure 3B). In addition, the experimental time points appeared 
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Figure 3. (A) Clustering of the 3579 genes transcriptionally responsive to ESC differentiation between 0, 
24 and 48 h. Each row represents the relative expression of a single gene throughout differentiation.  
(B) Principal Component Analysis of unexposed control cultures (CON) after 0, 24 and 48h of 
differentiation using the 3579 differentiation-related genes. The arrow connecting these experimental 
groups represents the differentiation track. For color figure, see Color figures section.
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in chronological order in the PCA plot and a curve connecting these points showed a 
continuous PCA trajectory which can be considered as the differentiation track.
Compound-induced gene expression changes
Comparison of the gene expression profiles of the compound-exposed experimental 
groups with the time-matched control group revealed the significantly differentially 
expressed genes per treatment (p<0.001; Table 1). The highest numbers of genes were 
affected by exposure to MAA (8477 genes) and 5-FU (7839 genes). Furthermore, the ex-
pression of a relatively high number of genes was changed after exposure to VPA (4069 
genes), RA (3276 genes), and MBP (918 genes), while the non-developmental toxicant 
PenG exposure altered the regulation of only 486 genes.
GO enrichment revealed down-regulation of developmental-related processes for all 
exposures, except for cultures exposed to MBP and to the negative control PenG. Be-
sides this down-regulation, developmental-related processes were also up-regulated in 
RA-and VPA-exposed cultures, such as pattern specification process (RA), regionalization 
(RA), and neurite development (VPA), which is clearly indicative for these compound-
induced differentiation disturbances. Among the down-regulated genes in MAA- and 
5-FU-exposed cultures we observed a significant enrichment in proliferation-related 
genes, which is in line with their observed decrease in cell number after exposure.
For all developmental-toxicant exposed groups a significant proportion (23-36%) of 
the regulated genes showed overlap with the 3579 genes that were found to be differ-
entially expressed in ESC differentiation (Table 1), whereas this percentage of common 
genes was limited to 18% in PenG-exposed cultures. Evaluating the common genes 
regulated by compound exposure and by differentiation using only the more exten-
sively regulated genes (FR>1.5) supported these observations. At least 50% of the genes 
regulated by developmental toxicants shared overlap with the genes regulated in differ-
entiation. In contrast, in the PenG-exposed cultures no single gene was regulated with 
FR>1.5, and subsequently no overlap could be calculated (data not shown). Moreover, 
significant overlap was found between the significantly differentially expressed genes of 
any two compounds tested (Table 1).
Compound-induced deviation from differentiation track
Differentiation modulation by compound exposure was further studied using the 
‘differentiation track’ approach. First, the deviation from time-matched non-exposed 
cultures was calculated for all exposed groups (Table 2). The significance levels of the 
p-values correlated with the level of differentiation inhibition observed via morpho-
logical scoring. The cardiomyocyte differentiation of cultures exposed to VPA was only 
decreased to 73.5%, this was mimicked by the borderline non-significant deviation of 
this experimental group from the ‘differentiation track’ (p=0.053). On the other hand, the 
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high significance values for 5-FU and MAA also correlated with their strong inhibition of 
the differentiation in parallel cultures scored for morphology at day 10.
Secondly, we defined a minimal subset of genes regulated in both ESC differentia-
tion and by exposure to each of the developmental toxicants. Using these criteria we 
defined a subset of 26 genes out of the 3579 that were changed during differentiation 
(Table 3). Gene functions in the gene set include development, transcription and cellular 
proliferation. For 10 of the 26 genes no information about gene function was available.
Table 3. Overview of the 26 genes transcriptionally responsive to both ESC differentiation and 
developmental toxicant exposure.
Entrez 
Gene ID
Gene Symbol Gene Name Function
109857 Cbr3 Carbonyl reductase 3 Xenobiotic metabolism
664968 2210411K11RIK RIKEN cDNA 2210411K11 gene Unknown
211896 Depdc7 DEP domain containing 7 Unknown
107515 Lgr4
Leucine-rich repeat-containing G protein-
coupled receptor 4
Development
66995 Zcchc18 Zinc finger, CCHC domain containing 18 Unknown
19301 Pxmp3 Peroxisomal membrane protein 2 Unknown
114714 Rad51c RAD51 homolog c (S. cerevisiae) DNA repair
19183 Psmc3ip
Proteasome (prosome, macropain) 26S 
subunit, ATPase 3, interacting protein
Unknown
66953 Cdca7 Cell division cycle associated 7 Cell division
18045 Nfyb Nuclear transcription factor-Y beta Transcription
72672 Zfp518 Zinc finger protein 518 Transcription
22249 Unc13b Unc-13 homolog B (C. elegans) Apoptosis
53868 Rab25 RAB25, member RAS oncogene family Unknown
17349 Mlf1 Myeloid leukemia factor 1 Cell differentiation, proliferation
329727 Dennd2c DENN/MADD domain containing 2C Unknown
16173 Il18 Interleukin18 Immune response
69635 Dapk1 Death associated protein kinase 1 Development, apoptosis
193796 Kdm4b lysine (K)-specific demethylase 4B Unknown
56786 Tmem9b TMEM9 domain family, member B Unknown
13823 Epb4.1l3 Erythrocyte protein band 4.1-like 3 Cytoskeleton
20913 Stxbp4 Syntaxin binding protein 4 Metabolism
242362 Manea Mannosidase, endo-alpha Protein glycosylation
14958 Hif0 H1 histone family, member 0 Histone
74134 Cyp2s1
Cytochrome P450, family 2, subfamily s, 
polypeptide 1
Xenobiotic metabolism
213819 Casd1 CAS1 domain containing 1 Unknown
53860 Sept9 Septin9 Cell division
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Figure 4. (A) Clustering of the 26 genes that are both transcriptionally responsive to ESC differentiation 
with time and are also regulated by exposure to all developmental-toxic compounds tested. (B) Principal 
Component Analysis of the non-exposed cultures (CON) (individual samples, circles) at different stages of 
differentiation and compound-exposed cultures (mean of n=8 samples, asterisks) using the 26 biomarker 
genes. For color figure, see Color figures section.
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Gene expression dynamics of differentiating ESC could effectively be visualized in a 
PCA plot using the subset of 26 genes (Figure 4A and B). The deviation of the compound-
exposed differentiation cultures from the ‘differentiation track’ based on these 26 genes 
was calculated and visualized (Table 2, Figure 4B). Using the subset of 26 genes, all 
developmental toxicants deviated significantly from their time-matched controls on the 
differentiation track. Furthermore, the negative developmental toxicant, PenG, showed 
no statistically significant deviation from the 24 h-controls on the differentiation track.
Leave-One-Out prediction of developmental toxicity
We analyzed the predictivity of this gene expression dataset for the compounds tested 
by a Leave-One-Out cross validation (Table 2). Gene subsets were derived composed 
of the genes that were both regulated in ESC differentiation and by all compounds 
except the one left out. This resulted in gene subsets of 29 (MAA left out) to 220 (MBP 
left out) commonly affected genes. Testing the left-out compound on the basis of the 
gene set generated with the remaining compounds showed that all developmental 
toxicants studied were scored as significantly deviating from the time-matched controls 
on the ‘differentiation track’ (Table 2, numbers in bold) except for MBP (p=0.066). The 
significance of differentiation-track deviation of the remaining 25 experimental groups 
were in line with their expected developmental toxicity except for two of the predictions 
related to the non-developmental toxicant PenG, with p-values of 8.4E-03 and 0.020, 
respectively.
Discussion
In the present study we have applied transcriptomics as a tool to study ESC differentia-
tion and its modulation by a variety of developmental toxicants. We hypothesized that 
differential gene expression would objectivate effect assessment in the EST. In addition, 
predictivity might potentially be improved and the applicability domain expanded as 
gene expression changes include all cell lineages present in the culture. Finally, with this 
approach culture duration could be abbreviated. Since transcriptomics has been shown 
to be an attractive approach to study the toxicity of compounds [52, 54, 176, 177], we 
further studied the implementation of this technique in the EST to improve the model in 
the above-mentioned aspects.
Genes transcriptionally responsive to ESC differentiation
In the present study we uncovered more than 3500 genes that were regulated in 
response to ESC differentiation, and this expands the findings of previous microar-
ray studies [28, 111, 132, 135, 142, 177]. The enrichment of this group of genes for 
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developmental-related processes, including cell differentiation, gastrulation and tube 
development, confirms that our model shares important characteristics with in vivo 
development. These genes may thus provide a good basis for developing a gene set 
that could be used as a biomarker for developmental toxicity prediction.
Furthermore, despite fundamental differences in experimental design with our pre-
vious studies [111, 177], a large fraction (84.2% and 70.5%, respectively) of the genes 
regulated in early ESC differentiation in those studies were also present in the set of 3579 
genes identified in the present study. In addition, a similar pattern of ESC-expression 
dynamics in time and GO enrichment was observed in the current study as compared 
to our previous studies, which illustrates the robustness of this differentiation model.
Compound-induced gene expression changes
All compounds tested in the present study induced alterations in gene expression, 
however major differences in the number of the regulated genes and the extent of 
regulation were present. The negative control PenG caused the regulation of 486 genes, 
however the induction of those genes was modest, i.e. no genes were regulated with a 
FR>1.5. In contrast, the developmental-toxic exposures caused a high number of genes 
to be regulated and at a higher induction magnitude.
5-FU and MAA, which were demonstrated to affect cell survival and proliferation at 
the tested concentration, caused large alterations in individual gene expression. Analy-
ses of the significantly regulated genes revealed that the down-regulated genes were 
enriched for proliferation-related processes. This confirmed that 5-FU and MAA affected 
cell survival and/or proliferation as is known from literature [97, 98, 184, 185]. In addition, 
5-FU and MAA exposure also affected developmental-related processes, which confirms 
their modulating effects on the ESC differentiation process. Although 5-FU and MAA 
may indirectly affect differentiation via inhibition of cell proliferation, the detection of 
such compounds as developmental toxicants is of great relevance.
RA, VPA, and MBP caused the regulation of a relatively high number of genes, 
which was associated with their differentiation modulating activities as observed via 
microscopical evaluation of ESC differentiation cultures. GO enrichment analyses using 
these regulated genes revealed that both up- and down-regulated genes in RA- and 
VPA-exposed cultures were significantly enriched for developmental-related processes. 
This clearly illustrates the differentiation-modulating properties of these compounds 
as described earlier [186-188]. In contrast, MBP-exposed cultures did not reveal disrup-
tion of developmental-related processes using these enrichment analyses. We showed 
previously that incomplete functional annotation of differentiation-related genes may 
hamper detection of gene function enrichment using standard GO-based tools, includ-
ing DAVID [111]. Therefore, in that study, we defined a novel defined gene set involved 
in early differentiation to successfully identify the MBP-induced differentiation-modula-
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tion. This present study also shows regulation of a large portion of ESC differentiation 
related genes by MBP (23%). This confirms that customized gene sets have a significant 
added value in revealing differentiation-modulation using genes that are subtly, but 
significantly regulated.
Detection of developmental toxicity using the differentiation track
Although developmental toxicants may cover a wide range of possible mechanisms of 
action, several studies have shown that many developmental toxicants tested shared 
the ability to modulate cardiomyocyte differentiation in the EST [19, 21, 22]. Therefore, 
to identify developmental toxicants, we focused on the compound-induced regula-
tion of differentiation-related genes in the EST. In our previous study, we showed that 
developmental toxicants could be identified using differential gene expression [177]. 
We employed the PCA-derived ‘differentiation track’ method to identify developmental 
toxicants using genes that were transcriptionally responsive to cardiomyocyte differen-
tiation of ESC. In that study, genes were used that were regulated during the first 96h of 
ESC differentiation, however additional analyses showed that the later time points were 
less informative for the identification of compound-induced differentiation modulation. 
Using the genes regulated during the first 48h of differentiation only improved the 
significance of deviation from the ‘differentiation track’ of the developmental toxicants 
studied. Therefore, in the current study gene expression during the first 48h of differen-
tiation only was investigated. Here, the 3579 ESC-differentiation-responsive genes were 
used to derive the PCA-defined differentiation track. Developmental-toxicant-exposed 
groups appeared to deviate significantly from the time-matched controls on this track, 
confirming the modulations of the differentiation process.
Selection of those genes that were both transcriptionally responsive in ESC differen-
tiation and to exposure to each of the developmental toxicants studied resulted in a 
set of only 26 genes. Importantly, these genes described a similar ‘differentiation track’ 
as compared to the 3579 genes during the 48-h period of ESC differentiation studied. 
Using the refined set of 26 genes, the significance of deviation from the time-matched 
controls on the differentiation-track appeared to be in line with the developmental-toxic 
properties of the tested compounds, and for all compounds tested the significance of 
deviation was increased as compared to the analysis based on all 3579 developmental 
genes. Further studies are needed to establish whether this descriptive gene set is 
indeed predictive for other developmental-toxic compounds.
Leave-One-Out cross validation
We applied the commonly used cross-validation according to the Leave-One-Out prin-
ciple to get a first impression of the predictivity of our gene expression approach. This 
validation showed that each compound, when its data was not included in refining the 
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gene set, deviated significantly from the time-matched controls on the differentiation 
track, indicating that it was correctly predicted as a developmental toxicant on the basis 
of the remainder of the data. As the single exception, the deviation of MBP-exposed 
cultures from its time-matched controls was borderline nonsignificant (p=0.066). This 
MBP analysis was performed using 220 genes, 194 genes more as compared to the 26 
genes of the refined gene list. The relatively mild effects of MBP on the additional genes 
caused the borderline non-significant deviation of this experimental group. In addition, 
the significance values of other compounds tested against these Leave-One-Out gene 
sets showed to be in line with their developmental-toxic properties, with only two ex-
ceptions. Altogether, the Leave-One-Out cross validation resulted in correct significance 
values for track deviations in 27 out of 30 cases, thereby demonstrating the robustness 
of the approach.
A significant improvement of the ‘differentiation track’ approach compared to the 
‘classical EST’ is that effects on genes of various differentiation-related processes 
are included in the analysis, while the ‘classical’ EST focuses exclusively on inhibi-
tion of cardiomyocyte differentiation. In our previous work we showed that MBP and 
6-aminonicotinamide, both mainly affecting structures of mesodermal origin, could be 
identified using the ‘differentiation track’ approach [177]. In the current study, we studied 
the wider applicability of this approach using compounds that do not only specifically 
affect mesodermal-derived tissues. RA and VPA mainly affect ectodermal-derived tissues 
[186, 187]. Furthermore, also compounds that induce developmental toxic effects via 
effects on cell survival and proliferation, 5-FU and MAA [97, 98, 184, 185], were included, 
as well as a negative control (PenG). The identification of differentiation modulation 
of these diverse developmental toxicants shows that the applicability domain of EST 
with our new approach is not limited to compounds specifically affecting mesodermal-
derived tissues.
This study as well as other studies show that gene expression changes are a function 
of compound concentration [51, 189]. In the present study developmental toxicants 
were tested at single concentrations inhibiting cardiomyocyte differentiation. Also in 
other studies single concentrations were selected that are known to induce effects on 
classical end points [190, 191]. Auerbach et al. [190] used two concentrations for assess-
ment of carcinogenic activity when evaluating chemicals with unknown carcinogenic 
potency, which improved the assessment of potential carcinogenicity. Concentration-
response analysis will be important in future studies to refine our model and to improve 
the identification of developmental toxicants.
In conclusion, these findings are promising in terms of the prospect of using gene 
expression profiling in combination with ESC differentiation models in order to predict 
developmental toxicity. The PCA-derived ‘differentiation track’ proved to be a suitable 
concept for use in the dynamic ESC differentiation system, as modulation of gene ex-
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pression correlating with ESC differentiation by developmental toxicants was robustly 
detected. Further development, standardization and validation of this model are needed 
via testing of gene-expression modulation of additional compounds in a concentration-
response design. Additional key genes could be identified in subsequent studies, which 
may further improve the prediction of developmental toxicity in the model. Enhancing 
predictivity, throughput and applicability domain are key aspects that may be improved 
through this approach, facilitating its incorporation as a test system for developmental 
toxicity in regulatory toxicology.
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CHAPTER 6
Evaluation of developmental 
toxicant identification using gene 
expression profiling in embryonic 
stem cell differentiation cultures
Dorien BW v12.indd   105 12-05-11   14:07
106 Chapter 6
Abstract
The murine Embryonic Stem cell Test (EST) is an alternative testing method designed 
to assess potential developmental toxicity of compounds. The implementation of tran-
scriptomic in the EST has been shown to reduce the culture duration and improve end 
point evaluation, and is expected to result in an enhanced predictability and definition 
of the applicability domain. We evaluated the identification of developmental toxicity 
in the EST using two gene sets (‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’), 
defined in our earlier studies. Non-exposed ESC differentiation cultures were sampled 
0, 24, and 48h after initiation of differentiation. Additionally, cultures exposed to twelve 
diverse well-characterized positive and negative developmental toxicants were isolated 
24h after the onset of exposure. Inhibition of ESC differentiation was evaluated in paral-
lel by morphological scoring on culture day 10. Transcriptomic analysis was conducted 
using the Affymetrix GeneChips platform. We applied Principal Component Analysis 
on the basis of the two predefined gene sets to define the ‘differentiation track’ that 
represents ESC differentiation. The significance of derivations in the gene expression 
based ‘differentiation track’ due to compound exposures were evaluated to determine 
developmental toxicity of tested compounds. We successfully predicted developmental 
toxicity using transcriptomics for 83% (10/12) and 67% (8/12) of the compounds, re-
spectively using the two predefined gene sets (‘Van_Dartel_heartdiff_24h’ and ‘EST bio-
marker genes’). Our study suggests that the application of transcriptomics may improve 
the applicability of the EST for the prediction of the developmental toxicity of chemicals.
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Introduction
Currently, regulatory hazard identification of chemicals is mainly based on animal stud-
ies. However, these studies require high numbers of experimental animals, significant 
amounts of test chemical and have a long duration, which all together make animal 
studies extremely costly. The need for new approaches has been advocated in a new 
testing paradigm in toxicology by the US National Research Council (NRC) [192]. Their 
vision is driven by the need for more efficient tests preferably based on human mod-
els, to predict chemical-induced pathway disturbance leading to human disease. The 
development of cell-line-based models is being encouraged, since such tests can be 
efficiently designed, which enables high-throughput screening.
One of the best studied cell-line-based tests within developmental toxicology is the 
Embryonic Stem cell Test (EST) [19], which is therefore of particular interest as model 
to predict potential developmental toxicity, in line with the view of the NRC. The EST 
uses murine embryonic stem cells (ESC) that can be induced to differentiate towards 
contracting cardiomyocytes. Inhibition of this differentiation process by compound 
exposure can be microscopically observed and is used to evaluate the toxicity of the 
tested compound. Currently this test is mainly used for prioritization of compounds for 
further testing in pharmaceutical industry, however, when optimized, the EST may also 
be used in regulatory settings to predict potential developmental toxicity. Transfer of 
the assay to a human cell line is a future option.
The aspects of the EST that will need improvement to allow implementation include 
characterization of the predictability, which is defined by the accuracy of the test model 
as determined by the percentage of false positives and false negatives. Secondly, the 
applicability domain of the EST, which pertains to its biological end points as well as 
the chemical categories for which the test is suitable in terms of prediction [23] has 
not yet been defined. Finally, also the subjective end point evaluation and the relatively 
long culture duration are weaknesses of the EST. Together, these aspects are expected to 
improve by implementation of molecular techniques into the EST.
The first studies that implemented molecular end points into the EST focused on single 
markers for the prediction of developmental toxicity [25, 30]. Subsequently, Chapin et al. 
illustrated the usefulness of studying compound-induced regulation of multiple genes 
and of pathway modulation to identify developmental toxicants [21, 193] as was also 
suggested by the NRC [192].
For the identification of developmental toxicity using ESC differentiation cultures, 
we confirmed that gene set-based analyses are highly valuable [111]. We identified 38 
genes that were up-regulated in unexposed 24h ESC differentiation cultures, which 
were combined in a gene set and named ‘Van_Dartel_heartdiff_24h’. This novel gene set 
was uniquely down-regulated in ESC differentiation cultures exposed to the develop-
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mental toxicant monobutyl phthalate, showing its potential in developmental toxicity 
evaluation. More recently, we developed an alternative tool for developmental toxicant 
identification in EST by using a continuous representation of ESC differentiation in time 
using principal component analysis (PCA), defined as the “differentiation track” [177]. A 
differentiation-track derived gene set was identified, consisting of 26 differentiation-re-
lated genes responsive to a group of tested developmental toxicants, which was named 
‘EST biomarker genes’ [194]. In that study, applying a differentiation-track algorithm 
using ESC differentiation-related gene sets, we successfully identified developmentally 
toxic compounds.
In the present investigation, we have studied the performance of our gene sets for the 
identification of developmental toxicity by testing the modulation of ESC differentiation 
by additional compounds using both the ‘Van_Dartel_heartdiff_24h’ and the ‘EST bio-
marker genes’ gene sets and applying the ‘differentiation track’ approach. Our analyses 
show that, with a new and independent data set of compounds tested at single concen-
trations, the in vitro developmentally toxicity prediction corresponded in 83% and 67% 
with the in vivo data for the ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ gene 
sets respectively. These findings suggest that our predictive gene signature approach 
may be useful in assessing potential developmental toxicity.
Materials and methods
Test compounds
Test compounds used in this study were monobutyl phthalate (MBP; CAS No. 131-70-4, 
TCI Europe, Zwijndrecht, Belgium), monomethyl phthalate (MMP; Cas No. 4376-18-5, TCI 
Europe), monoethylhexyl phthalate (MEHP; CAS No. 4376-20-9, TCI Europe), flusilazole 
(FLU; Cas No. 85509-19-9, Sigma-Aldrich, Zwijndrecht, The Netherlands), hexaconazole 
(HEX; CAS No. 79983-71-4, Sigma-Aldrich), triadimefon (TDI; CAS No. 43121-43-3, Sigma-
Aldrich), carbamazepine (CBZ; CAS No. 298-46-4, Sigma-Aldrich), methylmercury chlo-
ride (MeHg; CAS No. 115-09-3, Sigma-Aldrich), warfarin (WARF; CAS No. 81-81-2, Fluka, 
Buchs, Switzerland), nitrofen (NIF; CAS No. 1836-75-5, Fluka), methotrexate (MTX; CAS 
No. 133073-73-1, Sigma-Aldrich), which were dissolved in dimethyl sulfoxide (DMSO), 
and saccharine (SACC; CAS No. 82385-42-0, Sigma-Aldrich), which was dissolved in 
phosphate buffered saline (PBS).
A summary of in vivo developmental effects of the studied compounds is presented 
in Table 1.
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Resazurin cell viability assay
The effect of compound exposure on cell number was determined using resazurin 
dye reduction, which is a measure for the number of viable cells per well [178], as we 
described previously [150]. For each compound a minimum of five concentrations were 
tested in three independent experiments. Cultures were exposed to a maximum DMSO 
concentration of 0.2%, which did not affect cell viability. The resazurin reduction of 
exposed cells relative to control measurement was calculated and plotted against the 
test concentrations using PROAST software [103]. The cell survival at the concentrations 
tested in the transcriptomic experiment was calculated on the basis of the curve fit.
Table 1. In vivo developmental effects of selected compounds caused by prenatal exposure.
Compound LEL
Target 
Species
Developmental Toxicity Literature
Monobutyl 
phthalate
250 mg/kg bw Rats
Male reproductive tract malformations, 
cleft palate, cardiovascular, urogenital, 
skeletal malformations
[91, 92, 198]
Monomethyl 
phthalate
≥1000 mg/kg bw - - [121]
Monoethylhexyl 
phthalate
0.5 mg/kg bw Mice
Anterior neural tube defects, skeletal 
abnormalities
[199]
100 mg/kg bw Rats
Neural tube defects, vascular 
malformations
[200]
Flusilazole 0.4 mg/kg bw Rats Urogenital malformations [201]
Hexaconazole 2.5 mg/kg bw Rats Skeletal malformations [201]
Triadimefon 50 mg/kg bw Rats Axial skeletal malformations [201]
Carbamazepine ≥1000 mg/kg bw Mice - [202]
NR Human
Small head circumference, mild facial 
dysmorphia, developmental delay
[202, 203]
Methylmercury 
chloride
6 mg/kg bw Rats
Delayed vaginal opening, hydrocephalus, 
impaired behavioral response
[204, 205]
Warfarin 0.3 mg/ kg bw Human
Nasal hypoplasia, central nervous 
disorders
[18]
3 mg/ kg bw Rats Hemorrhage, hydrocephaly [206]
Nitrofen 0.15 mg/kg bw Rats
Diaphragmatic hernia, abnormal 
development of heart, kidney, lung
[207]
Methotrexate 0.3 mg/kg bw Rats
Embryolethal, cleft palate, skull defects, 
and severe fore and hindlimb dysplasias
[208]
Saccharine ≥1000 mg/kg bw - - [90]
LEL= Lowest Effect Level, NR=Not Reported
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Pluripotent embryonic stem cell culture and cardiomyocyte differentiation
Pluripotent murine D3 embryonic stem cells (ESC; ATCC, Rockville, MD) were cultured 
in a monolayer in Dulbecco’s Modified Eagle Medium (DMEM) based (Gibco BRL, Gaith-
ersburg, MD) medium supplemented with leukemia inhibitory factor (LIF; Chemicon, 
Temecula, CA), as described previously [7, 102]. In short, hanging drop cultures were set 
up to obtain embryoid bodies (EB) using single ESC suspensions in complete medium 
without LIF. [7, 102, 177]. These EB cultures were used as the primary step for differentia-
tion of ESC. Inhibition of cardiomyocyte differentiation was evaluated by calculating the 
mean scores of 24 differentiation cultures relative to the mean scores of control cultures. 
In total four classes of differentiation were defined: Strongly beating differentiation 
cultures (multiple contracting foci and >40% of the cells beating) received three points, 
moderately beating cultures (one or more contracting foci and 10-40% of the cells 
beating) was given a score of two, weakly beating differentiation cultures (one contract-
ing focus, <10% of the cells beating) received only one point. Differentiation cultures 
without presence of contracting cardiomyocyte foci were scored negative and received 
0 points.
Inhibition of cardiomyocyte differentiation by compound exposure
ESC differentiation cultures were exposed from the EB-stage at day three onwards to 
effective concentrations of the selected test compounds, that were calculated (on the 
basis of historic data) to inhibit ESC differentiation by 50% (ID50) using PROAST curve fit-
ting [103]. All cultures, including control non-exposed cultures, were exposed to noncy-
totoxic 0.2% DMSO concentrations for comparability reasons. Cultures were microscopi-
cally evaluated at day 10 of the culture (n=2) to assess the inhibition of cardiomyocyte 
differentiation, while parallel cultures were used for gene expression analysis at earlier 
time points as explained below.
RNA isolation and whole genome gene expression profiling
RNA of compound-exposed cultures was isolated 24h after the onset of exposure, which 
corresponds with culture day 4. DMSO-exposed control differentiation cultures were 
harvested after 0, 24 and 48h from the EB-stage at day 3, which corresponds with culture 
day 3, 4, and 5. Each experimental group consisted of 8 replicates of which the cells 
were directly collected in RNA protect (Qiagen, Venlo, The Netherlands) to stabilize RNA. 
Total RNA was purified using the RNeasy plus mini kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s instructions. The quantity of RNA in each sample was 
measured using a NanoDrop Spectrophotometer (NanoDrop technologies, Wilmington, 
DE) and RNA integrity was assessed on the 2100 Bioanalyzer (Agilent Technologies, 
Amstelveen, The Netherlands) using the RNA 6000 Nano Chip Kit (Agilent Technologies). 
Preparation of the RNA samples for gene expression analysis using the Mouse Genome 
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430 2.0 arrays (Affymetrix) was done as described previously [194]. Quality controls were 
performed according to the manufacturer’s instructions and were within acceptable 
limits for all arrays.
Data analysis and statistics
Robust Multichip Average (RMA) normalization of Affymetrix CEL files and probe to gene 
mapping were performed as we described previously [194]. Of the probe-set definitions 
included in the custom annotation, 16,331 probe sets defined by the Brainarray custom 
Chip Description File (CDF) version 11 (http://brainarray.mbni.med.umich.edu/Brainar-
ray/Database/CustomCDF) [182] and 4648 additional probe sets defined by Affymetrix 
chip annotation 26 were used in further analyses, giving a total of 20,979 probe sets. 
Probe sets for Affymetrix internal controls or probe sets that did not correspond to an 
Entrez Gene ID were not used in further analyses. Raw and normalized data are avail-
able from ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession number 
E-MTAB-300.
Statistical analyses were carried out using the R statistical software environment 
(http://www.r-project.org) using log-transformed values. Maximal fold ratios (FR) in 
individual gene expression between the experimental groups were determined by com-
paring the average normalized signal values per group and were calculated as the maxi-
mum/minimum ratio. Genes that were significantly differentially expressed between 
any of the non-exposed experimental groups were identified by a one-way ANOVA on 
the normalized data, using the cut-off criteria of a p<0.001 and FR>1.5. The percentage 
of commonly regulated genes was calculated relative to the limiting gene set.
Definition of the differentiation track
To visualize normal ESC differentiation, we defined the ‘differentiation track’ of these 
cultures as we described previously [177]. In short, PCA analysis was performed with R 
using defined gene lists that visualize the continuous differentiation of ESC on the basis 
of gene expression dynamics that represent the differentiation track. Coordinates along 
the first and second principal component were calculated for each sample and deviation 
of compound exposed cultures from the ‘differentiation track’ was analyzed by apply-
ing a Hotelling T-test to these coordinates compared to those of time-matched control 
cultures. Significant deviation from the ‘differentiation track’ (p<0.05) was considered 
characteristic for developmental toxicants.
To study the correlation between the degree of differentiation inhibition and the 
significance of ‘differentiation track’ deviation, Spearman’s rank correlation coefficient 
was calculated.
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Figure 1. Heatmap of the mean gene expression values of the unexposed control samples at 0, 24, 
and 48h of differentiation in our previous (_prev; van Dartel et al., 2010a) and present study using the 
differentiated-related genes identified in our previous study (3579 genes; A) and in the present study 
(3780 genes, B). PCA plots based on ESC differention-related genes in our previous study (C) and the 
present study (D). Unexposed ESC differentiation samples of the previous study (circles) and the current 
study (triangles) are presented. For color figure, see Color figures section.
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Results
ESC differentiation-related gene regulation
The gene expression profiles of the unexposed ESC differentiation samples at 0, 24 
and 48h were compared revealing 3780 genes that were transcriptionally responsive 
to ESC differentiation, using p<0.001 (corresponding false discovery rate = 0.0021) and 
FR>1.5. We compared these genes to the 3579 genes that we identified previously as 
ESC differentiation-related genes, using the same experimental design [177]. In total, a 
large number of genes (2700 genes, 75.4%) were identified to be commonly regulated 
in both studies and showed similar differentiation dynamics (Figure 1). Using p<0.001 
and FR>1.0 for the present study, this overlap between differentiation-regulated genes 
was 91.5%, indicating that most of the non-overlapping genes were still significantly 
regulated in the present study, but to a lesser extent (Table 2).
The unexposed experimental samples of this study and of our previous study were 
plotted using Principal Component Analysis (PCA) using the genes that were identified 
as differentiation-related genes in the previous study (3579 genes, Figure 1C) and in the 
present study (3780 genes, Figure 1D). Replicates within experimental groups clustered 
together, as well as experimental groups isolated after the same culture duration in 
the two different studies. Furthermore, the PCA-plot showed that experimental groups 
appeared in chronological order and continuous ESC differentiation could therefore 
be represented by the curve connecting these samples, which we named ‘the differ-
entiation track’. The position of the time-matched experimental groups of our present 
study (triangles) compared to our previous study (circles) showed some variation, which 
was most likely caused by slightly different temporal progression of ESC differentiation 
between experiments.
Compound-induced effect on ESC differentiation and cellular viability
ESC differentiation cultures were exposed to single test concentrations, selected on 
the basis of historic data. Effects of the test compounds on ESC differentiation and cell 
viability were scored in cultures parallel to those analyzed for gene expression in the 
present study, and results are presented in Figure 2. SACC and MMP did not affect ESC 
differentiation at high concentrations tested, which is in line with their absence of ef-
Table 2. Commonly regulated genes in ESC differentiation studies.
Present study FR>1.5 
(n=3780)
Present study FR>1 
(n=9774)
Previous studya FR>1.5 (n=3579) 2700 (71.4%) 3278 (91.5%)
Previous studya FR>1 (n=12409) 3658 (96.8%) 8613 (88.1%)
a van Dartel et al., 2010a
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fects on embryonic development. Only mild effects on cell viability were observed in 
SACC-exposed cultures (85% cell viability). No effects on cell viability and, remarkably, 
also no effects on ESC differentiation were observed in the cultures exposed to the de-
velopmentally toxic compound MBP. On the other hand, the in vivo more potent phthal-
ate MEHP, and also FLU, HEX, TDI and WARF affected ESC differentiation effectively in 
absence of cytotoxicity or proliferation inhibition (>90% cell viability). Cultures exposed 
to NIF, MeHg, MTX and CBZ also inhibited ESC differentiation, but these compounds 
also induced a moderate to strong reduction of cell number, ranging from 19% in CBZ-
exposed cultures to 54% in MeHg-exposed cultures.
Compound-induced deviation from the differentiation track
To study inhibition of ESC differentiation by compound exposure, we applied the ‘dif-
ferentiation track’ algorithm using the predefined differentiation-related gene sets 
‘Van_Dartel_Heartdiff_24h’ and ‘EST biomarker genes’. The majority of the genes within 
these sets were also differentially expressed among ESC differentiation cultures across 
time in the present study, namely 32/38 of the ‘Van_Dartel_heartdiff_24h’ and 22/26 
of the ‘EST biomarker genes’ gene set (Figure 3A and B). These predefined gene sets 
represent slightly different ESC differentiation dynamics as reflected by the differences 
in the projections of the differentiation tracks in the PCA plots. Both gene sets could 
successfully be used to describe the ‘differentiation track’ as shown in Figure 3C and D.
The modulation of ESC differentiation was analyzed by calculating the significance of 
deviation of exposed cultures from control ESC differentiation using the two predefined 
gene sets ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ (Table 3A). The non-
significant deviation of SACC using the ‘Van_Dartel_heartdiff_24h’ gene set and the 
SACC MMP MBP MEHP FLU HEX TDI WARF NIF MeHg MTX CBZ
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Figure 2. Average ESC differentiation (n=2, error bars indicate upper and lower values) and average cell 
viability (n=3, error bars indicate standard deviation) as observed in the compound-exposed cultures that 
were cultured in parallel to those tested for gene expression.
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Figure 3. Mean gene expression of the ‘Van_Dartel_heartdiff_24h’ (A) and ‘EST biomarker genes’ (B) gene 
sets at 0 h, 24 h, and 48h of control ESC differentiation cultures (CON). * Indicate significantly differentially 
expressed genes among the 0 h, 24 h, and 48h CON groups. Principal Component Analysis of the control 
ESC differentiation cultures (individual samples, circles) at 0 h, 24 h, and 48h of ESC differentiation using 
the ‘Van_Dartel_heartdiff_24h’ (C) and ‘EST biomarker genes’ (D). For color figure, see Color figures section.
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non-significant deviation of MMP with both gene sets were in line with the in vivo non-
developmentally toxic properties of these compounds. The majority of the ten positive 
developmental toxicants deviated significantly from the time-matched unexposed cul-
tures on the differentiation track, which was expected on the basis of their in vivo effects. 
MBP, HEX and MeHg were falsely predicted as being non-developmentally toxic in one 
out of two predictions, although these p-values were borderline non-significant for MBP 
(p=0.061) and HEX (p-value=0.053). The developmental toxicant NIF was consistently 
incorrectly predicted as a negative developmentally toxic compound using both gene 
sets. We also evaluated the performance of the ‘Van_Dartel_heartdiff_24h’ gene set 
Table 3. Significance of deviation of compound-exposed cultures of the present study (A) and our 
previous study (B; van Dartel et al., 2010a) from the defined ‘differentiation track’ (p-value) using selected 
gene sets. *Statistical significant deviation of compound-exposed from time-matched cultures on the 
‘differentiation track’ (p<0.05). Significance values that correspond with the in vivo developmental toxicity 
of the compound are in bold.
A
Compound-exposed 
experimental group
‘Van_Dartel_Heartdiff_24h’a 
(n=38 genes)
‘EST Biomarker genes’b (n=26 
genes)
SACC 0.059 2.1E-2*
MMP 0.159 0.072
MBP 3.7E-2* 0.061
MEHP 4.5E-3* 1.2E-3*
FLU 2.5E-3* 3.7E-2*
HEX 0.053 2.0E-2*
TDI 5.6E-3* 7.8E-3*
WARF 6.3E-09* 5.7E-3*
NIF 0.271 0.229
MeHg 4.8E-2* 0.18
MTX 1.2E-05* 2.3E-3*
CBZ 9.1 E-3* 1.1E-3*
B
Compound-exposed 
experimental group
‘Van_Dartel_Heartdiff_24h’a
 (n=38 genes)
Penicillin G 0.118
5-fluorouracil 1.0E-10*
methoxyacetic acid 2.1E-7*
monobutylphthalate 0.186
retinoic acid 4.1E-6*
valproic acid 4.0E-2*
a van Dartel et al., 2009a
b van Dartel et al., 2010a
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for the identification of developmental toxicity using data of our previous study [194] 
(Table 3B). Five out of the six compounds were correctly identified, using this gene set.
An overview of the predictions of the compounds tested in this study using the 
‘differentiation track’ approach with the gene sets ‘Van_Dartel_heartdiff_24h’ and 
‘EST biomarker genes’ is shown in Table 4A and 4B, respectively. The overall accuracy 
of the predictions using the ‘Van_Dartel_heartdiff_24h’ gene set was 83% (10/12). The 
two incorrect predicted compounds were positive developmental toxicants that 
were predicted to be negative (HEX and NIF, Table 3). The accuracy of the predictions 
using the ‘EST biomarker genes’ was 67%, since 8 out of 12 predictions were correctly 
predicted. The falsely predicted compounds included one negative compound (SACC) 
and three positive compounds (MBP, NIF, MeHg, Table 3). Evaluation of the ‘Van_Dar-
tel_heartdiff_24h’ gene set using data of our previous study [194] showed that 83% (5/6) 
of the compounds were correctly identified (Table 4C). MBP appeared to be the only 
misclassified compound, being falsely labeled as non-developmentally toxic.
Spearman correlation coefficients (R values) were calculated of the correlation 
between the significance of ‘differentiation track’ deviation and the degree of ESC 
differentiation inhibition based on available data from our studies. The R values, -0.71 
and -0.69, obtained for the ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ re-
spectively, revealed that the significance of deviation from the ‘differentiation track’ is 
Table 4. Classification results of the 12 compounds tested in the present study using the ‘Van_Dartel_
heartdiff_24h’ gene set (A) and ‘EST biomarker genes’ gene set (B), and of the six compounds tested in our 
previous study (van Dartel et al., 2010a) using the ‘Van_Dartel_heartdiff_24h’ gene set (C).
A
‘Van_Dartel_heartdiff_24h a In vivo embryotoxicity classification
Positive Negative
In vitro embryotoxicity prediction Positive 8 0
Negative 2 2
B
‘EST biomarker genes’b In vivo embryotoxicity classification
Positive Negative
In vitro embryotoxicity prediction Positive 7 1
Negative 3 1
C
‘Van_Dartel_heartdiff_24h’a In vivo embryotoxicity classification
Positive Negative
In vitro embryotoxicity prediction Positive 4 0
Negative 1 1
a van Dartel et al., 2009a
b van Dartel et al., 2010a
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partly dependent on the degree of ESC differentiation inhibition (Figure 4). Therefore, 
for correct prediction of developmental toxicity, the effect size of the concentration of 
the test compound used appears to be an important factor.
Discussion
Reproducible gene responses in ESC differentiation
The present study showed that gene expression signatures in ESC differentiation are 
highly reproducible between independently performed studies. As many as 91.5% of 
the previously identified differentiation-related genes [194] were identified as signifi-
cantly regulated in the present study.
We performed PCA analysis to visualize the continuous differentiation of ESC on the 
basis of gene expression dynamics that represent the differentiation track. PCA has been 
shown previously to be a valuable approach to describe embryonic development [153], 
neural cell lineage differentiation [195], and ESC differentiation [177]. In the present 
study, the differentiation tracks on the basis of the genes identified to be involved in ESC 
differentiation in both studies were very similar (Figure 1C versus 1D). Furthermore, the 
differentiation tracks showed that the samples of the present study differed only slightly 
from the time-matched samples of our previous study. The variation was observed along 
the track, and therefore this difference may be primarily explained by a slight variation 
in the timing of differentiation. In addition, also within experimental groups, variation of 
ESC differentiation was observed along the differentiation track, supporting the notion 
that the track represents continuous ESC differentiation.
The reproducibility of gene expression profiles of differentiating ESC facilitates the 
use of a predefined gene set for developmental toxicity prediction. Apparent variance 
in temporal progression of ESC differentiation between experiments is not expected 
to hamper the use of predefined gene sets, since the genes within the gene sets also 
showed temporal regulation and thus follow the dynamics of ESC differentiation.
Differentiation track-based evaluation of developmental toxicity
Studying gene expression signature in differentiation ESC allows the possibility to in-
vestigate compound-induced effects on multiple cellular processes. The present study 
shows that compounds that affected development either via proliferation or differentia-
tion were detected in the EST protocol. Although effects on the mesodermal-derived 
cardiomyocyte differentiation has been classically used as the end point for evaluation of 
differentiation inhibition, also compounds affecting structures derived from other germ 
layers can potentially be discriminated using the EST [19]. This is explained by the pres-
ence of cells from the ectodermal and endodermal germ layers within the differentiation 
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cultures [6, 87], which resembles the in vivo situation, in which the mesodermal germ 
layer develops by induction between the ectoderm and endoderm germ layers [113].
The predictive capacity of both gene sets appears promising in view of the accura-
cies that were calculated using data of a limited set of 12 test compounds tested at 
single concentrations. The accuracies obtained were 83% for the gene set ‘Van_Dar-
tel_heartdiff_24h’ and 67% for the gene set ‘EST biomarker genes’. Unfortunately, the 
negative control SACC was misclassified using the ‘EST biomarker genes’ gene set. This 
could be explained by the cell viability results, which showed that SACC caused some 
degree of cytotoxicity at the concentration tested in the transcriptomic study. Regard-
ing the false-negative compounds, two of which were observed using the ‘Van_Dar-
tel_heartdiff_24h’ set (HEX and NIF), and three using the ‘EST biomarker genes’ set (MBP, 
NIF, MeHg), two predictions appeared to be borderline non-significant (HEX and MBP) 
and one incorrect prediction may be caused by the observed large variation in ESC dif-
ferentiation inhibition (MeHg, Figure 2). Data analyses of our previous transcriptomic 
study showed that MBP was also incorrectly identified as being non-developmentally 
toxic using the ‘Van_Dartel_heartdiff_24h’ gene set. The significance values for ‘differen-
tiation track’ deviation correlated well with limited differentiation inhibition (Figure 4) 
and this may explain the misclassifications of MBP and MeHg.
Remarkably, although the strong developmental toxicant NIF inhibited ESC differen-
tiation as assessed on day 10 of the EST protocol, NIF was not identified as develop-
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Figure 4. Spearman correlation of significance of deviation from the ‘differentiation track’ using ‘EST 
biomarker genes’ and ‘Van_Dartel_heartdiff_24h’ with ESC differentiation inhibition.
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mental toxicant using the ‘differentiation track’ method. The regulation of 570 genes 
by NIF (not shown), included many genes that are known to play an important role in 
development, such as Hoxd9, Wnt8a, Tdgf1 and Shh. Regarding the significant number 
of NIF-regulated genes, it is not likely that the timing for studying gene expression was 
insufficient. Apparently, the effect of NIF was not reflected by the gene sets that were 
used for studying differentiation modulation. The gene sets used in the present study, 
Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’, will need further refinement to 
optimize identification of a wider array of developmental toxicants and to assess their 
relative validity.
Aspects for further optimization of developmental toxicant identification in the EST
Obviously, compound concentration is an important factor when assessing the toxicity 
of compounds, as has been shown also in the EST [150, 196, 197]. In the present study, 
the identification of developmentally toxic compounds was based on gene expression 
data of compounds tested at single concentrations only, which represents the most 
economic gene array study design. With this approach we were able to show that the 
degree of ESC differentiation inhibition correlated well with the significance of ‘differ-
entiation track’ deviation. Previous studies have shown that also the gene expression 
response is related to compound concentration [51, 189]. Therefore, the prediction of 
developmental toxicants is expected to improve by analyzing transcriptomic responses 
of test compounds in a concentration-response design, and although significantly more 
cost-intensive, this will be the subject of our future studies.
Additional improvements of our approach will include increasing the throughput 
of the assay using custom gene chips. In addition, future studies may be based on 
compound-induced gene signatures of human ESC (hESC). Implementation of these 
hESC is expected to improve the predictability of the assay [16]. Unfortunately, routine 
hESC culture as well as hESC differentiation protocols are still very labor-intensive and 
therefore the development of optimized culture protocols is essential for successful use 
of hESC in the EST.
Conclusions
In this transcriptomic study, we have demonstrated the application of gene expression 
analysis for the prediction of potential developmental toxicity, by testing compounds 
at single concentrations. To our knowledge this is the first study that evaluates this 
approach in the field of developmental toxicology. This approach may lead to improve-
ments of the predictability and the characterization of the applicability domain of the 
EST, which may ultimately facilitate its incorporation as a test system for developmental 
toxicity in regulatory strategies.
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Abstract
The murine Embryonic Stem cell Test (EST) is designed to evaluate developmental toxic-
ity based on compound-induced inhibition of embryonic stem cell (ESC) differentiation 
into cardiomyocytes. The addition of transcriptomic evaluation within the EST may result 
in enhanced predictability and improved characterization of the applicability domain, 
therefore improving usage of the EST for regulatory testing strategies. Transcriptomic 
analyses assessing factors critical for risk assessment (i.e. concentration) are needed to 
determine the value of transcriptomic evaluation in the EST. Here, using the developmen-
tally toxic compound, flusilazole, we investigated the effect of compound concentration 
on gene expression regulation and toxicity prediction in ESC differentiation cultures. 
Cultures were exposed for 24h to multiple concentrations of flusilazole (0.54-54µM) and 
RNA was isolated. In addition, we sampled control cultures 0, 24, and 48h to evaluate 
the transcriptomic status of the cultures across differentiation. Transcriptomic profiling 
identified a higher sensitivity of development-related processes as compared to cell 
division-related processes in flusilazole-exposed differentiation cultures. Furthermore, 
the sterol synthesis-related mode of action of flusilazole toxicity was detected. Principal 
Component Analysis using gene sets related to normal ESC differentiation was used to 
describe the dynamics of ESC differentiation, defined as the ‘differentiation track’. The 
concentration-dependent effects on development were reflected in the significance of 
deviation of flusilazole-exposed cultures from this transcriptomic-based differentiation 
track. Thus, the detection of developmental toxicity in EST using transcriptomics was 
shown to be compound concentration-dependent. This study provides further insight 
into the possible application of transcriptomics in the EST as an improved alternative 
model system for developmental toxicity testing.
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Introduction
The current regulatory guidelines for toxicological hazard identification require large 
numbers of experimental animals. As a consequence of the implementation of the new 
EU regulation for Registration, Evaluation and Authorization of Chemicals (REACH) in 
2007, the potential toxicity of thousands of chemicals needs to be assessed over the 
coming years. To reduce the number of experimental animals needed within REACH, al-
ternative methods for toxicity testing are required. Since more than 60% of experimental 
animals in REACH will be used for reproductive and developmental toxicity assessments 
[119], the demand for in vitro alternative test methods is particularly high for these areas 
of testing. Several alternative methods for the identification of developmental toxicity 
have been developed, varying from whole embryo cultures of rat or zebrafish, and organ 
cultures, to continuous cell-line based assays, such as the Embryonic Stem cell Test (EST) 
[19, 84-86]. None of these assays have achieved regulatory acceptance, due in part to 
their uncertain predictive capacity as well as their ill-defined applicability domain, i.e. 
the biological end points that are incorporated and the chemical categories for which 
developmental toxicity can correctly be predicted.
The EST is a cell-line based standardized in vitro assay that has been established to 
classify compounds with respect to their developmentally toxic potential [19]. The EST 
measures the inhibition of murine ESC differentiation into contracting cardiomyocytes 
upon exposure to compounds. The EST is considered a promising alternative assay for 
developmental toxicity prediction [170]. However, it still has several weaknesses that 
need improvement to allow successful regulatory acceptation. These aspects include 
the relatively long culture duration, subjective and laborious end point scoring and the 
limited characterization of its applicability domain and predictability [170].
Since the emergence of transcriptomics in the 1990s [209], many studies have shown 
that this technique provides a powerful tool to study toxicological mechanisms and 
toxicity profiles at the level of gene expression. The use of transcriptomics in predictive 
toxicology has been extensively studied for the prediction of carcinogenicity, using liver 
tissue of in vivo exposed experimental animals [33, 34, 36, 37, 210]. These data indicate 
that a gene expression-based predictive model can be an effective tool for identifying 
carcinogens. In addition, promising results have been published in other fields of toxi-
cology, including developmental toxicology [41].
The implementation of transcriptomics in the EST may validate this test as a suc-
cessful in vitro model for predicting developmental toxicity. We recently showed that 
compound-induced gene regulation could be observed shortly after the initiation of 
compound exposure, resulting in an abbreviated test protocol [111, 177]. Furthermore, 
gene expression changes pertain not to cardiac muscle cells only but to all cell types 
present in the culture. Therefore, gene expression end points may improve the predict-
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ability and applicability domain of the model. We have identified ESC differentiation-
related genes and showed that developmental toxicants could be identified by the 
differential expression of these genes [194].
So far, most transcriptomic studies have investigated the toxicity of a single test 
compound concentration. Only few studies have addressed concentration-dependent 
gene expression changes, often by testing only a low and a high dose [51, 211], but also 
more comprehensive concentration-response studies have been described [49, 212, 
213]. Mostly, the selection of these concentrations has been based on their observed 
phenotypic/morphological effects in the model system. Overall, compound concentra-
tion appeared to relate to both the magnitude of gene induction and the number of 
differentially expressed genes. Several studies have shown that dose-response assess-
ment of gene expression is of great importance for correct prediction of toxic properties 
[41, 49, 75, 190]. In a recent study, we showed the interdependence of morphological 
effect size and the extent of gene expression changes, suggesting that effect prediction 
through gene expression is modulated by compound concentration [214].
The present study was designed to investigate the effect of compound concentration 
on gene expression in ESC differentiation cultures. Six concentrations of flusilazole were 
tested, which makes this study one of the most extensive studies in concentration-
related gene expression responses to date. Flusilazole was selected due to its known 
developmental toxic properties, causing growth retardation and skeletal abnormalities 
in rodent models [215] and its relevance for human health risk in view of its global 
use as a fungicide in agricultural practice [216]. In the present study, gene expression 
profiling confirmed concentration-dependent transcriptomic changes in differentiating 
ESC exposed to flusilazole. Gene expression-linked developmental-related processes 
appeared to be most sensitive to flusilazole exposure. Genes related to cell division as 
well as processes related to sterol metabolism, the pharmacological mode of action of 
flusilazole, were found to be affected. Furthermore, we applied Principal Component 
Analysis (PCA) using gene sets related to ESC differentiation to describe the dynamics 
of differentiating ESC in the EST protocol, previously defined as the ‘differentiation track’ 
[177]. These analyses showed that the concentration-dependent effects on development 
were also evident by the extent of deviation of flusilazole-exposed cultures from the 
differentiation track. This study provides further insight into the use of transcriptomics 
in ESC differentiation as a model system for developmental toxicology.
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Materials and methods
Pluripotent embryonic stem cell culture and differentiation
Pluripotent murine D3 embryonic stem cells (ESC; ATCC, Rockville, MD) were cultured 
in monolayer in Dulbecco’s Modified Eagle Medium (DMEM) based (Gibco BRL, Gaith-
ersburg, MD) medium supplemented with leukemia inhibitory factor (LIF; Chemicon, 
Temecula, CA), as described previously [7]. Induction of cardiomyocyte differentiation 
was performed according to the INVITTOX protocol [7] with few adaptations [102, 177].
Resazurin cell viability assay
To facilitate interpretation of the gene expression data, we assessed the effect of flusi-
lazole (CAS No. 85509-19-9, Sigma-Aldrich, Zwijndrecht, The Netherlands) exposure on 
cell viability. We used resazurin dye reduction as a measure for the number of viable cells, 
as described previously [150]. Flusilazole was dissolved in dimethyl sulfoxide (DMSO) 
and ESC differentiation cultures were exposed to final DMSO concentrations of 0.2%, 
which did not affect cell viability. Control cultures were also exposed to 0.2% DMSO for 
comparability reasons. ESC differentiation cultures were exposed to flusilazole during 
the first 3 days of the EST protocol, since effects on cell viability are most pronounced 
during this early phase of the EST protocol [150]. Flusilazole was tested at concentra-
tions ranging from 0.1 to 300 µM in three independent runs. The resazurin reduction of 
exposed cultures relative to solvent control cultures was calculated and plotted against 
the flusilazole concentrations using PROAST software [103]. The cell survival at the con-
centrations tested in the transcriptomic experiment and the concentration at which cell 
viability is reduced by 50% (IC50) were calculated on the basis of the curve fit.
Inhibition of ESC differentiation by flusilazole exposure
Compound concentrations tested in the present transcriptomic study were selected on 
the basis of our concentration-range finding studies on ESC differentiation inhibition. 
We selected a flusilazole concentration range that was equally spaced on a logarithmic 
scale and that covered the complete concentration-response range. Six concentrations 
of flusilazole (0.54, 1.8, 5.4, 18, 27 and 54 µM) were selected and we exposed ESC dif-
ferentiation cultures from the embryoid body (EB)-stage at day three onwards. Cultures 
were microscopically evaluated at day 10 of the culture to assess the inhibition of cardio-
myocyte differentiation, while parallel cultures were used for gene expression analysis at 
earlier time points as explained below. In each experiment, ESC differentiation inhibition 
was evaluated by calculating the mean scores of 24 exposed cultures per compound 
concentration relative score to the mean scores of 24 control cultures [214]. The ESC 
differentiation at the concentrations tested in the transcriptomic experiment and the 
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concentration at which ESC differentiation is reduced by 50% (ID50) were calculated on 
the basis of the curve fit.
RNA isolation and whole genome gene expression profiling
RNA from flusilazole-exposed cultures was sampled 24h after the start of exposure (cul-
ture day 4, 8 replicates per group), and RNA from DMSO-exposed control differentiation 
cultures was sampled after 0, 24 and 48h from the EB-stage at day 3 (culture day 3, 4, 
and 5, 8 replicates per group). RNA isolation and preparation of the corresponding RNA 
samples for gene expression analysis using the Mouse Genome 430 2.0 arrays (Affyme-
trix) was done as described previously [194]. Quality controls, including scaling factors, 
average intensities, present calls, background intensities, noise, and raw Q values, were 
performed according to the manufacturer’s instructions and showed to be within ac-
ceptable limits for all chips.
Data analysis and statistics
Normalization of Affymetrix CEL files was performed using the Robust Multichip Average 
(RMA) algorithm [179] with RMAexpress [180]. Probe to gene mapping was done as de-
scribed previously [194]. Of the hybrid probe-set definitions included in the custom an-
notation, 16,331 probe sets defined by the Brainarray custom Chip Description File (CDF) 
version 11 (http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF) 
[182] and 4,648 additional probe sets defined by Affymetrix chip annotation 26 were 
used in further analyses, giving a total of 20,979 probe sets. Probe sets for Affymetrix 
internal controls or probe sets that did not correspond to an Entrez Gene ID were not 
used in further analyses. Raw and normalized data are available at ArrayExpress (http://
www.ebi.ac.uk/arrayexpress/) under accession number E-TABM-1027.
Statistical analyses were carried out using the R statistical software environment ver-
sion 2.9.1 (http://www.r-project.org) and the R-packages DNAMR and Limma using log-
transformed values. For each gene, maximal fold ratios (FR) in gene expression between 
the experimental groups were determined by comparing the average normalized signal 
values per group and were calculated as the maximum/minimum ratio. Genes that were 
significantly differentially expressed between any of the non-exposed experimental 
groups were identified by a one-way ANOVA, using the cut-off criteria of a p<0.001 
and FR>1.5. Six pairwise t-tests were performed to identify significantly transcription-
ally responsive genes between each treatment group and its time-matched unexposed 
control group using the cut-off criterion of p<0.001.
To identify the biological processed altered by flusilazole-exposure, we studied func-
tional annotation and enrichment for Gene Ontology (GO) biological processes using 
the tools on the DAVID website [183]. GO identifiers (GOID) were selected if the p-value 
was less than 0.001 in at least one of the experimental groups. Furthermore, the number 
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of genes changed within a certain GOID had to be either greater than 30 or less than 300 
to exclude GOIDs that are either too specific or too general. The absolute average fold 
change of the genes that caused enrichment in at least one of the experimental groups 
was calculated for a subset of the identified enriched GOIDs for each flusilazole-exposed 
experimental group. These subsets were generated based on the specificity of the GOID: 
child terms were selected above parent terms in cases where both parent and child 
terms were enriched [217]. For more detailed analyses of regulated GOIDs, we selected 
six GOID that reflected the flusilazole-induced response on the three identified themes, 
‘development’, ‘lipid metabolism’ and ‘cell division’. Within each theme, the most specific 
GOID was selected, i.e. comprising the lowest number of genes. Since the majority of the 
enriched GOIDs were related to development we selected four GOIDs that were related 
to this category, and one GOID that was related to the other two categories.
Definition of the differentiation track
To visualize the normal ESC differentiation, we defined the ‘differentiation track’ of these 
cultures as we described previously [177]. In short, PCA analysis was performed using 
the previously defined gene sets ‘Van_Dartel_heartdiff_24h’ [111] and ‘EST biomarker 
genes’ [194]. Thereafter, the chronological order of the control ESC differentiation 
groups in the PCA plot represented the ‘differentiation track’: a continuous representa-
tion of ESC differentiation based on the dynamics of gene expression. Coordinates along 
the first and second principal component were calculated for each sample. Deviation of 
flusilazole-exposed cultures from the time-matched controls on the ‘differentiation track’ 
was analyzed by applying a Hotelling t-test to these coordinates. Significant deviation 
from the ‘differentiation track’ (p<0.05) was considered characteristic for developmental 
toxicants. In addition, we created heatmaps of the genes corresponding to these ear-
lier defined gene sets ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ to visualize 
gene expression using GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium).
Validation gene expression using real-time PCR
Transcriptomic results were validated using real-time PCR (RT-PCR). RNA of all samples per 
experimental group was pooled and used to generate cDNA by using the high-capacity 
cDNA archive kit containing random hexamer primers (Applied Biosystems, Foster City, 
CA). mRNA presence was measured in duplo with Taqman gene expression assays (Ap-
plied Biosystems) on a 7500 Fast Real-Time PCR System, with a two-step PCR procedure 
according to the manufacturer’s protocol. The thermal cycling conditions were 95°C for 
20 s for the first cycle, followed by 40 cycles of 95°C for 3 s and 60°C for 30 s. The mRNA 
markers we used were Hoxa1 (Mm00439359_m1) and Mesp2 (Mm00655937_m1) both 
annotated to anterior posterior pattern formation, and Cyp51 (Mm00490968_m1) and 
Sc4mol (Mm00499386_m1) both annotated to sterol biosynthesis. Tbp was selected 
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as housekeeping gene for Hoxa1 and Sc4mol, Polr2a was selected as housekeeping 
gene for Mesp2 and Cyp51. The mRNA expression was normalized to the value of the 
housekeeping gene for each reaction according to the comparative Ct method and 
expressed relative to the expression level in unexposed cultures. Statistical gene expres-
sion regulation was calculated by performing a Student’s t-test. Results were considered 
statistically significant if p<0.05.
Results
Flusilazole-induced effects on cell viability and differentiation
Flusilazole caused a concentration-dependent decrease in cell viability, with <80% cell 
viability at the two highest flusilazole concentrations that were tested in the transcrip-
tomic study (Figure 1 and Table 1). The calculated ID50 and IC50 of flusilazole were 5.9 and 
55.9 µM respectively, showing that ESC differentiation is a more sensitive end point as 
compared to cell viability. Except for the lowest concentration tested, all tested flusilazole 
concentrations affected ESC differentiation in a concentration-dependent manner, up to 
100% inhibition at the highest test concentration tested (Figure 1 and Table 1).
Flusilazole-induced gene expression changes
Gene expression was compared between flusilazole-exposed ESC differentiation 
cultures and time-matched solvent control-exposed cultures to identify significantly 
differentially expressed genes (Table 1). At the lowest test concentration (0.54 µM), 
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Figure 1. Concentration-response curves of ESC differentiation (triangles; n=2) and cell viability (circles; 
n=3) after flusilazole exposure. Large symbols represent the mean of replicate measurements. The curves 
are fitted using the log-logistic model, showing the solvent control samples on the left of the curve.
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where no inhibition of ESC differentiation or cell viability was observed, 108 genes were 
significantly differentially expressed. The number of differentially regulated genes ap-
peared to increase in a monotonic fashion with increasing concentration of flusilazole 
exposure, with a total number of 2010 genes significantly differentially expressed at the 
highest test concentration (54 µM).
We identified 3780 genes (p < 0.001 and fold ratio (FR) >1.5) that were regulated with 
time in the unexposed experimental groups. An increasing percentage of flusilazole-
regulated genes overlapped with these ESC differentiation-related genes, reaching 
a plateau of approximately 50% of genes commonly expressed at 5.4 µM flusilazole-
exposed cultures (Table 1). These high percentages of genes that overlap with the genes 
identified in ESC differentiation indicate a specific differentiation-modulating response. 
Exposure to 54 µM flusilazole resulted in a similar number of genes that were shared 
with the ESC differentiation-regulated genes (n=871) as compared to the 27 µM expo-
sure group (n=870), showing no additional differentiation modulation at the highest 
test concentration.
To study the effects of flusilazole exposure at the level of biological processes, we 
studied GO enrichment of the regulated genes. These analyses revealed a total of 94 
enriched GOIDs in at least one of the flusilazole-exposed experimental groups (Supple-
mentary Table 1). The majority of genes modulated by flusilazole exposure function in 
developmental-related processes (66 GOIDs). In addition, over-represented GOIDs were 
related to other processes such as ‘lipid metabolism’ (9) and ‘cell division’ (9). The fold 
Table 1. Number of significantly differentially expressed genes (p<0.001) after 24h exposure to a 
concentration range of flusilazole. ESC differentiation (exposure days 0-10) and cell viability (exposure 
days 0-3) at the concentrations tested in this transcriptomic study were calculated using the curve fit of 
the data presented in Figure 1.
Concentration 
of flusilazole 
exposure
ESC 
differentiation 
(percent of 
control)
Viability 
(percent of 
control)
Differentially 
expressed genes after 
flusilazole exposure* 
(n)
Common genes 
differentially expressed 
both during ESC 
differentiation** 
and after flusilazole 
exposure*
(n (%))
0.54 µM 93.9% 94.9% 108 27 (25.0%)
1.8 µM 80.9% 94.6% 372 118 (31.7%)
5.4 µM 53.0% 93.2% 377 185 (49.1%)
18 µM 12.1% 84.8% 552 258 (46.7%)
27 µM 4.2% 77.4% 1706 871 (51.1%)
54 µM 0.2% 53.9% 2010 870 (43.3%)
* Genes differentially expressed in exposed versus unexposed 24h experimental groups (p<0.001 and FR 
>1)
** Genes differentially expressed among 0h, 24h and 48h unexposed experimental groups p<0.001 and 
FR >1.5 (n=3780 genes)
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change inductions show clear concentration-related effects at the level of GOIDs (Figure 
2A) as well as at the individual gene level as shown for a subset of enriched GOIDs (Figure 
3). Furthermore, the enrichment of the GOIDs also appeared to be concentration-related 
as observed by a higher relative gene count with increasing test concentrations (Figure 
2B).
GO analyses revealed three major themes of related GOIDs impacted by flusilazole: 
development, lipid metabolism, and cell division. Out of these three categories of genes, 
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Figure 2. (A) Concentration-related effect of flusilazole exposure in ESC differentiation cultures on absolute 
average fold change of a subset of enriched GOID. For comparability reasons the absolute average fold 
change was calculated using the significantly differentially expressed genes that contributed to the 
enrichment in at least one of the experimental groups. (B) Concentration-related effect of flusilazole 
exposure in ESC differentiation cultures on relative gene count associated with Gene Ontology Identifiers 
(GOID). GOID in red-yellow are related to development, in green to cell division and blue to lipid metabolism. 
‘Total’ refers to total number of genes annotated to that GOID, and ‘regulated’ refers to total number of 
statistically significant genes that contributed to the enrichment of that GOID in at least one experimental 
group. Asterisks indicate statistically significantly enriched GOID. For color figure, see Color figures section.
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GOIDs related to development appeared to be most sensitive to flusilazole exposure, 
showing over-representation already after exposure to 5.4 µM. Genes that contributed 
to the enrichment of the development-related GOIDs included both up- and down-
regulated genes (Figure 2A and 3A). The most significant enrichment and highest 
relative gene count was obtained for lipid metabolism-related GOIDs (Supplementary 
table 1 and Figure 2A). The lowest concentration of flusilazole at which this enrichment 
was observed was 18 µM. The genes that were responsible for enrichment of the lipid 
metabolism-related GOIDs were all up-regulated after flusilazole exposure (Figure 2A 
and 3B). The significantly enriched GOIDs related to cell division showed pronounced 
over-representation at the two highest test concentrations only as reflected by the 
relative gene count (Figure 2A). Figure 3C shows the differentially expressed genes that 
contributed to the enrichment of the GOID ‘nuclear division’. Most of the genes posi-
tively related to cell cycling were down-regulated by flusilazole exposure, whereas the 
majority of cell cycle genes up-regulated by flusilazole treatment appeared involved in 
cell cycle arrest (not shown).
RT-PCR analyses revealed that Hoxa1 and Mesp2, annotated to the developmental-
related process ‘anterior posterior pattern formation’, were significantly differentially 
expressed by flusilazole exposure from respectively 0.54 and 1.8 µM onwards (Supple-
mental Figure 1). In addition, the significant up-regulation of the expression level of 
both Cyp51 and Sc4mol, involved in sterol biosynthesis, was shown by RT-PCR from 
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Figure 3. Average fold change of individual genes that were significantly differentially expressed in at 
least one experimental group and contributed to the significant enrichment of ‘anterior posterior pattern 
formation’ (A), ‘sterol biosynthetic process’ (B) and ‘nuclear division’ (C).
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Figure 4. Mean gene expression of the ‘Van_Dartel_heartdiff_24h’ (A) and ‘EST biomarker genes’ (B) gene 
sets at 0 h, 24 h, and 48h of control ESC differentiation cultures (CON). * Indicate significantly differentially 
expressed genes among the 0 h, 24 h, and 48h CON groups. Principal Component Analysis of the control 
ESC differentiation cultures (individual samples, circles) at 0 h, 24 h, and 48h of ESC differentiation and 
flusilazole-exposed cultures (mean of n=8 samples, asterisks) using the ‘Van_Dartel_heartdiff_24h’ (C) and 
‘EST biomarker genes’ (D). C’ and D’ present the enlargement of the CON 24h samples and the flusilazole-
exposed cultures (FLU). For color figure, see Color figures section.
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respectively 5.4 and 18 µM onwards (Supplemental Figure 1). All evaluated genes follow 
a clear concentration-dependent gene expression regulation.
Concentration-related deviation of flusilazole-exposed cultures from differentiation track
The modulation of ESC differentiation was further studied by analyzing the concentra-
tion-related deviation from the ‘differentiation track’ defined by PCA. The gene sets used 
for defining the ‘differentiation track’ were defined previously, and represent slightly 
different stages of ESC differentiation. The ‘Van_Dartel_Heartdiff_24h’ genes were all 
up-regulated at 24h as compared to earlier time points, while the ‘EST biomarker genes’ 
gene set includes genes that were up- or down-regulated in ESC differentiation cultures 
sampled up to 48h of differentiation. Gene expression showed that the majority of the 
genes within these sets were also differentially expressed among ESC differentiation 
cultures sampled after 0, 24 and 48h in this study, namely 84% and 85% in the ‘Van_Dar-
tel_Heartdiff_24h’ and ‘EST biomarker genes’ gene set respectively (Figure 4A and B).
Table 2 presents the p-values for significance of deviation from the ‘differentiation 
track’ for flusilazole-exposed cultures. The coordinates of ESC differentiation cultures 
exposed to 0.54 and 1.8 µM flusilazole versus time-matched unexposed ESC differentia-
tion were not statistically significantly different in both PCA figures representing the dif-
ferentiation tracks (Table 2, Figure 4C and D). At concentrations of 5.4 µM flusilazole and 
higher, ESC differentiation cultures appeared to deviate significantly from both differ-
entiation tracks. In both PCA plots, the position of flusilazole-exposed cultures deviated 
concentration-dependently away from their time-matched unexposed cultures (CON 24 
h) and towards the CON 0h samples at the lower three concentrations, to subsequently 
turn towards the CON 48h samples at the next higher two concentrations. The position 
of the highest test concentration in the PCA fell outside this smooth deviation pattern.
Table 2. Significance of deviation of flusilazole-exposed cultures from the time-matched controls on the 
defined ‘differentiation track’ (p-value) using selected gene sets.
Concentration of flusilazole 
exposure
‘Van_Dartel_Heartdiff_24h’a (n=38 
genes)
‘EST Biomarker genes’b
(n=26 genes)
0.54 µM 0.346 0.298
1.8 µM 0.077 0.370
5.4 µM 2.5E-03* 3.7E-02*
18 µM 1.1E-02* 4.8E-04*
27 µM 3.0E-06* 5.5E-07*
54 µM 6.6E-07* 1.5E-04*
* Significant p-value for deviation from differentiation track
a van Dartel et al. (2009a)
b van Dartel et al. (2010b)
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Discussion
In recent years, toxicogenomic has proven a valuable tool in predictive toxicology [37, 
41]. Early initiatives to use in vitro alternatives combined with transcriptomics for the 
prediction of toxicity have shown promising results [45, 218]. Several studies have ad-
dressed molecular end points in the assessment of developmental toxicity in various 
models [25, 30, 49, 219-221]. We hypothesized that combining the EST with toxicoge-
nomics may lead to an improved model for in vitro developmental toxicity prediction 
by optimization of important aspects, including culture duration, end point evaluation, 
and definition of the predictability and applicability domain. In a previous paper [214], 
we presented evidence that the detection of developmental toxicity by transcriptomics 
in EST was influenced by the compound concentration tested. In the present study, we 
investigated the concentration-dependent transcriptomic responses to flusilazole in 
ESC differentiation cultures and their impact on the detection of developmental toxicity.
Concentration-dependent flusilazole-induced effects on ESC differentiation cultures
Flusilazole appeared to affect both ESC differentiation and cell viability, with effects on 
ESC differentiation occurring at roughly 10-fold lower concentrations indicating spe-
cific flusilazole-induced differentiation-modulating effects. In addition, gene expression 
analysis revealed that approximately 50% of the genes regulated after flusilazole expo-
sure also appeared to be regulated during ESC differentiation. This finding is in line with 
our previous study in which gene expression signatures of differentiation modulators 
showed a significant overlap with ESC differentiation-related genes [194]. In the present 
study, the effect of flusilazole on ESC differentiation was observed by transcriptomics 
at the lowest concentration tested, with developmental-related genes such as Tdfg1, 
Mesp2 and Otx1 [222-224] significantly differentially expressed (not shown).
Analyses based on enrichment of GOIDs were used to interpret the significant gene 
expression changes in ESC differentiation cultures exposed to flusilazole and to provide 
additional information about concentration-dependent ESC differentiation modula-
tion. Most of the enriched GO terms included developmental processes, the remaining 
enriched GOIDs were cell division- and lipid metabolism-related processes and leaving 
only a few terms unassigned. Increasing flusilazole concentrations resulted in a higher 
gene count of GOIDs, and in addition the fold change of these genes increased with the 
test concentration, an effect that has also been described previously in other models 
[189, 225]. Enrichment of developmental-related GOIDs increased concentration-
dependently and was already observed at the lowest tested concentration, indicating 
that developmental processes were the most sensitive process affected, which was 
confirmed by RT-PCR. Cell division-related processes were mainly enriched at the two 
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highest test concentrations, which anchors the phenotypically observed cytotoxicity of 
flusilazole.
Besides the flusilazole-induced effects on ESC differentiation and cell viability, flusi-
lazole exposure also resulted in a clear concentration-dependent perturbation of the 
sterol biosynthesis pathway, and other lipid metabolism-related processes, as observed 
by DAVID analyses. This relates to the specific antifungal mode of action of triazoles, 
including flusilazole, which is inhibition of lanosterol-14α-demethylase (Cyp51), an 
enzyme required for sterol biosynthesis in all eukaryotic systems [226, 227]. The affinity 
of the mammalian Cyp51 to flusilazole is 100 times lower than that of its fungal coun-
terpart, which explains its effective use as fungicide [228]. RT-PCR results confirmed the 
transcriptomic results by showing a clear concentration-dependent induction of Cyp51 
expression that was statistically significant from 5.4 µM onwards. The gene expression 
response caused by triazoles in rats revealed the differential expression of genes involved 
in lipid metabolism, including sterol biosynthesis [51, 229]. Five of the 10 genes targeted 
by the triazole triadimefon within the sterol biosynthesis pathway [51] were also affected 
in our ESC differentiation model after flusilazole exposure. This finding demonstrates 
that the compound’s mode of action was also detected using transcriptomics in the EST. 
This perturbed lipid metabolism could have played a role in the decreased cell viability 
observed at the highest test concentrations, as is also observed in fungi after exposure 
to triazoles [228].
Although studying gene expression response of complete GOID is very useful, the 
gene expression profile of individual genes within GOID may provide additional infor-
mation about the induced gene expression response [230]. Within the present study, we 
observed that the genes in the enriched functional classes related to development were 
all concentration dependently regulated, although some were up-, and others or down-
regulated with diverse magnitudes among the genes studied, which we showed for a 
subset of GOID in Figure 2A and 3A. This finding is reminiscent of the complexity of gene 
expression alterations which accompany embryonic cell differentiation. On the other 
hand, we observed consistent concentration-dependent up-regulated gene expression 
profiles for the lipid metabolism-related GO terms, reminiscent of the mode of action of 
triazoles (see above). Conversely, we observed cell division-related GO terms were es-
sentially down-regulated concentration-dependently. Within the GO term ‘nuclear divi-
sion’, only six genes showed an opposite expression profile as they were up-regulated by 
flusilazole treatment and these appeared involved in cell cycle arrest, while most of the 
genes that were down-regulated by flusilazole exposure function in cell cycling. These 
observations matched the cytotoxic response of flusilazole at 27 and 54 µM.
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Detection of developmental toxicity using the differentiation track
Flusilazole-induced differentiation modulation was further studied using the ‘differentia-
tion track’ approach. This approach takes advantage of the gene expression dynamics of 
differentiating ESC [177, 231], or embryonic development [232] which can be reflected 
in a PCA-based differentiation track. We have shown previously that developmentally 
toxic compounds could be identified by their deviation from the ‘differentiation track’ 
[177]. We used the ‘Van_Dartel_heartdiff_24h’ and the ‘EST biomarker genes’ gene sets 
to define differentiation tracks, which both clearly reflected the dynamics of ESC dif-
ferentiation as shown in the PCA figures. A vast majority of the genes within these gene 
sets were significantly regulated among the control experimental groups in the present 
study. Moreover, the pattern of regulation highly reflected the initial gene expression 
profile. The ‘Van_Dartel_heartdiff_24h’ gene set includes genes that were up-regulated 
at 24 h, whereas the ‘EST biomarker genes’ were identified by their dynamic gene expres-
sion during the first 48h of ESC differentiation. These differences in gene expression in 
time were reflected in the different projection of the experimental samples in both PCA 
plots. Nevertheless, the mutual distances among experimental samples in both PCA 
plots were comparable, demonstrating the robustness of the approach.
The use of this ‘differentiation track’ approach for the identification of the develop-
mental toxicity of compounds relies on their effect on the expression signature of the 
entire gene set (‘Van_Dartel_heartdiff_24h’ or ‘EST_biomarker genes’). We and others 
have shown previously that individual genes within a process need not necessarily be 
significantly regulated by exposure, while on the level of gene sets compound-induced 
effects can still be captured effectively [111, 233]. Within the present study we showed 
that the ‘differentiation track’ approach is useful for the identification of concentration-
related ESC differentiation modulation. The concentration-related increase in signifi-
cance of differentiationtrack deviation observed in flusilazole-exposed cultures was in 
agreement with our morphological scoring and GO analysis results.
Furthermore, besides the use of the significance of ‘differentiation track’ deviation, the 
direction of ‘differentiation track’ deviation of compound-exposed cultures may give ad-
ditional information on the nature of effects on ESC differentiation cultures. The projec-
tions of the lower three flusilazole concentrations (0.54, 1.8, 5.4 µM) appeared in almost 
the same directions relative to controls. However, the projections of the subsequent 
two flusilazole concentrations (18 and 27 µM) deviated from this pattern towards the 
CON 48h samples. This may be due to the pronounced induction of sterol biosynthesis-
related genes starting at 18 µM (Figure 2). The PCA projection of cultures exposed to 
the highest concentration of flusilazole (54 µM) discontinued again from the pattern of 
lower concentrations. This may be explained by the cytotoxic effects as evidenced both 
by gene expression (Figure 2) and morphological end points (Figure 1) that occurred 
uniquely at the concentration of 54 µM flusilazole in ESC differentiation cultures.
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In the present study, compound concentrations were selected on the basis of the 
morphological outcome of the ‘classical’ EST, an approach that has been used frequently 
[190, 191]. When testing a compound with unknown toxicity, test concentration selection 
could be based on cytotoxicity data. Our results suggest the need to include compound 
concentrations below the range of cytotoxicity, since this is important for acquiring in-
formation about the relative sensitivity of ESC differentiation modulation as compared to 
cytotoxicity. Additional studies testing (non-)developmental toxicants with different po-
tencies are needed to evaluate the usefulness of this approach of concentration selection.
Conclusions
We showed previously that the degree of compound-induced ESC differentiation inhibition 
correlated to the significance of deviation from the ‘differentiation track’ [214]. In the present 
study, we show concentration-dependent effects on multiple cellular processes in flusilazole-
exposed cultures, and identified the relative sensitivity of enriched processes. We observed 
a higher sensitivity of developmental-related processes as compared to cell division-related 
processes, and in addition confirmed the sterol synthesis pathway mediated mode of action 
of flusilazole toxicity by differential gene expression. Furthermore, gene expression regulation 
of the gene sets ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ using the ‘differentia-
tion track’ approach illustrated that the detection of the differentiation modulating proper-
ties of flusilazole in EST is concentration-dependent. In conclusion, studying gene expression 
modulation by compounds within the EST protocol allows a more detailed description of 
the effects of the test compound at the molecular level as compared to the ‘classical’ EST. In 
addition, the choice of test concentrations proved an essential aspect of study design in view 
of the predictability of the assay for the detection of developmental toxicants.
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Discriminating classes of developmental 
toxicants using gene expression profiling 
in the Embryonic Stem cell Test
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Abstract
The Embryonic Stem cell Test (EST) has been shown to be a promising in vitro method 
for the prediction of developmental toxicity. In our previous studies, we demonstrated 
that the implementation of gene expression analysis in the EST may further improve 
the identification of developmental toxicants. In the present study, we investigated if 
gene expression profiling could be used to discriminate compound classes with distinct 
modes of action (MoA) using the EST protocol. Gene expression data of our previous 
study were used and were analyzed of embryonic stem cell (ESC) differentiation cultures 
exposed to six compounds belonging to two classes with distinct MoA, namely phthal-
ates and triazoles. We used three approaches to study class-characteristic gene regula-
tion that may be useful for discrimination of compound classes. First, at the individual 
gene level, gene signatures characteristic for each class were identified that successfully 
discriminated both classes using Principal Component Analysis. Second, at the func-
tional level, enriched gene ontology (GO) biological processes showed their usefulness 
for class discrimination via hierarchical clustering. Third, two previously identified gene 
sets, which we designed to predict developmental toxicity, appeared successful in sepa-
rating phthalate from triazole compounds. In summary, we established the possibility to 
discriminate between compound classes in the EST system using three different specific 
transcriptomics-based approaches. Differential gene expression information specific 
for the class of compound under study may be employed to optimize prioritization of 
compounds within that class for further testing.
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Introduction
According to international legislation, current toxicity testing is primarily assessed using 
laboratory animals. In vivo studies are expensive, requiring a considerable number of ex-
perimental animals, and raise important ethical concerns. For these reasons, European 
policy is promoting alternative testing methods and assessment strategies to reduce the 
use of laboratory animals and whenever possible, replace animals employed for toxi-
cological studies [234]. Although none of the existing in vitro methods that have been 
identified is capable of replacing the existing classical in vivo approach, a select few have 
been recognized as potential alternative methods for the assessment of developmental 
toxicity [20].
One of the most studied in vitro alternatives for developmental toxicicity screening 
is the murine Embryonic Stem cell Test (EST). Our transcriptomic studies suggest that 
the implementation of toxicogenomics-based assessments into the EST may lead to 
improved prediction, by providing detailed information regarding modulation of em-
bryonic stem cell (ESC) differentiation in relation to concentration and time [177, 214, 
235] and furthermore, enabling the prediction of toxicity based on pre-determined 
gene lists related to ESC differentiation [214].
Diverse studies have shown that discrimination of compounds with similar modes of 
action is possible using biological activity profiling patterns. Compound discrimination 
has been used predominantly in drug discovery [236, 237], and this application has also 
been studied to assess its potential for toxicological screening [238, 239]. For example, 
Martin et al. demonstrated successful grouping of compounds with similar toxicological 
effects using signatures characteristic for specific toxic outcome (i.e. hepatomegaly and 
PXR activation). Application of compound discrimination analyses is of interest for rank-
ing of structurally related compounds with unknown toxicity for further testing. Many 
new compounds or compounds with insufficient toxicological data are structurally 
related to compounds of which a wealth of toxicological data is available. Before decid-
ing on generating a full toxicological profile of the new compound, it may be useful to 
compare the gene expression profile in an appropriate in vitro test of the new with the 
well-studied compound(s). If a comparable gene expression pattern is observed it may 
be possible to rely on the data of the tested compound as a surrogate for assessing 
the toxic properties of the new compound [240]. This approach has been supported by 
studies that were able to distinguish [241] or rank [242] similarly-structured compounds 
for their toxic potencies using gene expression profiling. Furthermore, discrimination of 
compounds based on specific signatures is of interest for prioritizing structurally-related 
compounds with unknown toxicity for further testing.
The objective of the present study was to evaluate the ability of the EST to categorize 
compounds with a similar mode of action by applying a toxicogenomic approach. In our 
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previous study, we evaluated the identification of developmental toxicants using gene 
expression analysis [194]. In this study, using this dataset, we assessed common and dif-
ferential gene expression regulation patterns of triazole and phthalate compounds, and 
evaluated whether these two classes are discriminated based on their gene expression 
response in the EST system. We selected these two classes of compounds on the basis of 
the availability of effect data in the EST, suggested different mechanisms of toxicity, and 
furthermore, the relevance of their effects on human health.
Triazoles are often used in agricultural settings as well as in pharmaceutical applica-
tions for their known antifungal effects. The fungicidal mode of action of triazoles is 
based on the inhibition of the enzyme lanosterol-14α-demetylase (Cyp51), which plays 
an essential role in sterol metabolism and is required for the synthesis and integrity of the 
fungal cell wall [227]. In addition, triazoles may affect also other Cyp-enzymes, which may 
result in developmental malformations when embryos are exposed prenatally [243, 244]. 
The observed effects include urogenital and skeletal malformations [201]. The triazole 
compounds that were selected for the present study were flusilazole (FLU), hexaconazole 
(HEX) and triadimefon (TDI) which all contain the 1,2,4-triazole moiety (Figure 1).
The second class of compounds included in the present study are phthalates, which 
are esters of phthalic acid (benzene-1,2-dicarboxylic acid) in ortho configuration. These 
compounds are widely used as plasticizers to increase the flexibility of a variety of PVC 
products like toys, vinyl floors and catheters. Developmental toxicity studies have shown 
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Figure 1. Chemical structures of triazoles and phthalates tested in the present study.
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that the monoester phthalates containing side-chain lengths of C4-C6 may induce 
teratogenic effects [121]. In the present study, we included two developmentally toxic 
phthalates, monobutyl phthalate (MBP; C4), and monoethylhexyl phthalate (MEHP; C6), 
as well as one non-developmentally toxic phthalate monomethyl phthalate (MMP; C1). 
Several modes of action have been suggested for the teratogenic properties of phthal-
ates, including intracellular acidification, altered cellular proliferation and induction of 
DNA damage [245, 246]. Malformations induced by the developmental toxic phthalates 
tested in the present study include external and skeletal malformations, cleft palate and 
hydrocephaly [92, 122, 199].
 In the present study, we evaluated the discriminatory ability of gene expression 
to classify triazoles and phthalates using multiple approaches based on 1) gene lists 
characteristic for each class identified in the present study 2) enriched Gene Ontology 
(GO) processes, and 3) gene lists derived from our earlier toxicogenomic studies that 
identify developmental toxicants in the EST. We could successfully segregate the tested 
compounds into two distinct classes using these approaches. It can be concluded that, 
as a proof-of-principle, our findings show the possibility of using gene expression data 
obtained from ESC differentiation inhibition for the discrimination of compound classes 
with different modes of action of developmental toxicity.
Materials and methods
Data of our previous study [214] were used for the analyses described here. The methods 
and data regarding culture conditions, compound exposures, assessment of differentia-
tion inhibition, and gene expression profiling have been described in full detail [214]. 
The data have been deposited in EBI’s ArrayExpress (http://www.ebi.ac.uk/arrayexpress) 
and are accessible through ArrayExpress accession number E-MTAB-300.
Test compounds
Previous studies showed that evaluating compounds at a concentration affecting dif-
ferentiation by 50% (ID50) resulted in successful identification of differentiation modulat-
ing, without inducing general toxic responses [111, 177, 194]. ID50 concentrations were 
calculated using historical concentration-response data from our lab.
ESC differentiation cultures were exposed to 1.4 mM monobutyl phthalate (MBP; 
CAS No. 131-70-4, TCI Europe, Zwijndrecht, Belgium), 1.4 mM monomethyl phthalate 
(MMP; Cas No. 4376-18-5, TCI Europe), 0.68 mM monoethylhexyl phthalate (MEHP; CAS 
No. 4376-20-9, TCI Europe), 5.4 µM flusilazole (FLU; Cas No. 85509-19-9, Sigma-Aldrich, 
Zwijndrecht, The Netherlands), 21 µM hexaconazole (HEX; CAS No. 79983-71-4, Sigma-
Aldrich), 160 µM triadimefon (TDI; CAS No. 43121-43-3, Sigma-Aldrich), or to solvent only 
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(CON; 0.2% dimethyl sulfoxide (DMSO)). Compound concentrations used in this study 
did not result in cytotoxic effects and inhibited ESC differentiation effectively, except for 
MMP- and MBP-exposed cultures that showed no inhibition of ESC differentiation [214].
Derivation of class characteristic gene signatures
Statistical analyses were carried out using the R statistical software environment (http://
www.r-project.org) using log-transformed values. Maximal fold ratios (FR) in gene ex-
pression were determined for each gene by comparing the normalized signal of the 
compound-exposed samples relative to the average normalized signal of the DMSO-
exposed samples. Significant gene expression responses were identified by performing 
pairwise t-tests between each treatment group and the unexposed control group using 
a p-value cut-off of <0.001. The selected p-value corresponded to a false discovery rate of 
0.03 over all compound comparisons in this study. The phthalate and triazole signatures 
were composed of the genes that were commonly differentially expressed with similar 
regulation by respectively the developmentally toxic phthalates MBP and MEHP, and by 
the three triazoles FLU, HEX and TDI.
The gene expression profile of the phthalate and triazole signature was visualized in 
a heatmap using GeneMaths XT (Applied Maths, Sint-Martens-Latem, Belgium). DAVID 
bioinformatics resources [183] was used to identify enrichment for Gene Ontology (GO) 
biological processes within the phthalate and triazole signatures. Functional annotation 
of genes was provided for parent terms that covered the identified enriched GO terms. 
In addition, we evaluated if genes within these signatures were among the previously 
identified genes that were regulated in early ESC differentiation [194].
Class discrimination - class signatures
The identified triazoles and phthalate signatures were used to study the discrimination 
of these compound classes, using Principal Component Analyses (PCA) with GeneMaths 
XT (Applied Maths, Sint-Martens-Latem, Belgium). In addition, control analyses were 
performed to study the robustness of our approach. First, we included available gene 
expression data of six other compounds (carbamazepine (160 µM), methotrexate (240 
nM), methylmercury (0.48 µM), nitrofen (100 µM), saccharine (5 mM), and warfarin (1.1 
mM)) tested in ESC differentiation cultures according to a similar incubation protocol 
[214] to study the discrimination of phthalates or triazoles from a more diverse set of 
compounds, using respectively the phthalate- or triazole- unique signature. Second, we 
included gene expression data of MBP that was tested previously in ESC differentiation 
cultures [194] to study if the gene response of that experimental group grouped with 
the response of the remaining developmentally toxic phthalates, using the phthalate 
and triazoles signature. Finally, we evaluated the use of class-specific genes for iden-
tification of compound classes, by performing a leave-one-out analysis on the triazole 
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gene expression data. Gene lists were identified that were regulated by a combination of 
two triazoles, FLU and HEX, FLU and TDI, or HEX and TDI, and were used to study triazole 
discrimination using PCA. For each experimental group deviation from the unexposed 
samples was analyzed by applying a Hotelling T -test to the coordinates.
Class discrimination - GO processes
GO identifiers (GOID) that were overrepresented in the phthalate or triazole signature, as 
evaluated using DAVID, were selected if the p-value was less than 0.05, and the number 
of genes annotated to a certain GOID had to be greater than 30 and less than 300 to ex-
clude GOID that are either too specific or too general. For each GOID that was enriched 
within the phthalate or triazole signature also the gene count, which is the number of 
genes annotated to that GOID that co-occurred in the phthalate or triazole signature, 
was presented. For further analyses, child terms were selected above parent terms in 
cases were both parent and child terms were enriched [217]. We selected additional 
genes annotated to the enriched GOID using AmiGO [247] and used the respective ex-
pression data to study if hierarchical clustering (Euclidean clustering, Ward linkage) 
could separate the phthalate-exposed from the triazole-exposed experimental groups 
using GeneMaths XT. The confidence value for each node in the observed clustering tree 
was obtained by bootstrapping the clustering 1000 times. Bootstrap values >70 were 
considered sufficient, and >85 were considered good.
Class discrimination - predefined gene sets
In addition, we studied the discriminative properties of previously identified gene sets 
that showed to be useful for identification of developmental toxicants. The expression 
data of the genes within these gene sets, ‘Van_Dartel_heartdiff_24h’ [111] and ‘EST bio-
marker genes’ [194] were used for hierarchical clustering of the experimental groups. As 
a negative control, the experimental groups were clustered using a gene set comprised 
of 200 genes not responsive to the test compounds.
Results
Compound-induced effects on gene expression in ESC differentiation cultures
On the gene expression level, the non-developmental toxicant MMP regulated only 
14 genes, while MBP (at the same molar concentration) and MEHP (at a two-fold lower 
molar concentration) altered the expression of 171 and 803 genes, respectively. We 
identified 68 genes that were commonly regulated by the two developmentally toxic 
phthalates MBP and MEHP (Figure 2A). In terms of directionality of response, MBP and 
MEHP similarly impacted 67/68 genes included in the phthalate signature and these 
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67 genes were used as the phthalate signature (Figure 3A). At equipotent concentra-
tions, the triazole compounds FLU, HEX and TDI regulated 377, 613 and 2206 genes, 
respectively. Sixty-eight genes were regulated by all three triazoles (Figure 2B). The 
expression profile of all genes included in the triazole signature was similarly affected 
in terms of directionality by the three triazoles (Figure 3B). These 68 genes were used as 
the triazoles signature. No genes overlapped between these two compound class gene 
signatures (Figure 2C). P-values corresponding to the regulation of genes within the two 
signatures are provided in Supplementary Table 1).
A large gene subset of both signatures, namely 46 genes (68%) and 26 (39%) for the 
phthalate and triazole signature respectively, was identified in the database of our 
earlier study [214] to be responsive in early ESC differentiation (Figure 3A and B). A large 
part of the genes included in the phthalate and/or triazole signature could be function-
ally related to the GOID ‘development’, ‘transcription’, ‘response to chemical stimulus’ 
(phthalate signature), or ‘steroid metabolic process’ (triazole signature).
DAVID GO Enrichment analysis revealed that the phthalate signature was enriched for 
‘negative regulation of cell differentiation’ (p-value 2.1E-4, gene count 6), and ‘response to 
inorganic substance’ (p-value 2.7E-3, gene count 4). GO terms related to the triazole signa-
ture were enriched for ‘anterior posterior pattern formation’ (p-value 2.9E-5, gene count 7) 
and ‘inner ear morphogenesis’ (p-value 2.3E-3, gene count 4). Furthermore, the GO term 
‘sterol biosynthetic process’ was significantly enriched (p-value 6.2E-3, gene count 3).
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Figure 2. Venn diagrams showing the number of significantly differentially expressed genes (p<0.001) 
per experimental group and the overlap of these regulated genes for phthalates (A) and triazoles (B). The 
number of genes that are regulated in common direction are presented between brackets. No genes were 
commonly regulated by both phthalates and triazoles (C).
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Class gene signatures based discrimination of phthalates and triazoles
We applied PCA using the defined phthalate and triazole signatures, respectively, to 
study discrimination of compound classes. Using the phthalate (Figure 4A) and triazole 
(Figure 4B) signatures respectively, phthalates (MBP and MEHP) appeared in distinctly 
separate groups from triazoles, indicating dissimilarity in gene expression profiles 
of these two particular gene sets between these two compound classes. In addition, 
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Figure 3. Heatmap of the identified phthalate signature (A) and triazole signature (B). Responsiveness 
of the genes to early ESC differentiation and annotation of the genes to parent terms covering enriched 
GOID are indicated on the right of each figure. For color figure, see Color figures section.
Dorien BW v12.indd   149 12-05-11   14:08
150 Chapter 8
Legend
   
    MMP
    MBP
    MEHP
    MBP_PREV
    FLU
    HEX
    TDI
    Additional compounds
    Unexposed control
-2
-1
0
1
2
Phthalate signature
PC1, 54%
PC
3,
 1
2%
Triazole signature_Leave-FLU-out
PC1, 54%
PC
3,
 1
5%
-4
-2
0
2
Triazole signature_Leave-HEX-out
PC1, 65%
PC
2,
 1
0%
-2
-1
0
1
Triazole signature_Leave-TDI-out
PC1, 64%
PC
2,
 9
%
-3 -2 -1 0
-1
0
1
2
Triazole signature
PC1, 68%
PC
2,
 8
%
PC1, 51%
-2
-1
0
1
2
Phthalate signature
PC
3,
 9
%
PC1, 51%
-2
-1
0
1
Triazole signature
PC
2,
15
%
-2
-1
0
1
2
Phthalate signature
PC1, 56%
PC
3,
 1
3%
-3 -2 -1 0
Triazole signature
PC1, 66%
PC
2,
 8
%
A B
C1 C2
D1 D2
E1 E2 E3
-1 0 1 2
-1 0 1 2
-2 -1 0 1 2
-2 -1 0 1 2 3
-2 -1 0 1 2
-1
0
1
2
-2 -1 0 1 2 3
-3
-2
-1
0
1
2
-2 0 2 4 6
Figure 4. Discrimination of phthalates from triazoles using principal component plots of monomethyl 
phthalate (MMP), monobutyl phthalate (MBP), monoethylhexyl phthalate (MEHP), flusilazole (FLU), 
hexaconazole (HEX) and triadimefon (TDI) on the basis of the identified phthalate signature (A) and the 
triazole signature (B). The principal component analysis-based discrimination was validated by studying 
the projection of additional compounds (C), by evaluating the position of MBP tested in our previous 
study (MBP_PREV, D), and by performing leave-one-out analyses (E). For color figure, see Color figures 
section.
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compounds within each class clustered together, indicating that the gene expression 
profiles within each class was similar. On the basis of the phthalate signature, cultures 
exposed to the non-developmental toxicant MMP were positioned closer to the nega-
tive controls than to the remaining phthalates (Figure 4A).
To validate the discriminating capacity of the phthalate- and triazole-signature for their 
respective class, we performed additional analyses. First, we evaluated the discrimination 
of the phthalate- or triazole-exposed cultures across a diverse set of compound-exposed 
cultures (including carbamazepine, methotrexate, methylmercury, nitrofen, saccharine, 
and warfarin) using PCA. Gene expression changes within the phthalate signature by 
triazole and phthalate compounds (Figure 4C1) indicated clear separation between MBP 
and MEHP on the one hand and the unexposed time-matched cultures on the other. 
The remaining exposed cultures were all positioned close to the control in comparison 
to the phthalate compounds, with the exception of one compound (carbamazepine), 
which overlapped with both MBP and MEHP exposed cultures and deviated from the 
control (corresponding p-values are provided in Supplementary Table 2). Evaluation of 
the triazole signature indicated strong differences in positioning between triazoles and 
unexposed time-matched cultures. The remaining compound-exposed cultures were all 
positioned near the control in comparison to the triazole compounds (Figure 4C2).
Second, we evaluated the position in the PCA of MBP as tested in an earlier study 
(MBP_PREV) [214] relative to phthalates and triazoles tested in the present study. 
MBP_PREV clustered together with the positive developmentally toxic phthalates MBP 
and MEHP, using both the phthalate and the triazole signature (Figure 4D). Finally, we 
used the leave-one-out approach to evaluate the usefulness of our method of gene 
set identification. To this end, we identified three new genes lists, each separate gene 
list consisted of all the genes that were commonly regulated in a combination of two 
triazole-exposed cultures, but not necessarily in the one that was left out. This resulted 
in 266, 177 and 97 genes that were commonly significantly differentially expressed 
in the same direction in cultures exposed to HEX and TDI, TDI and FLU, and HEX and 
FLU, respectively (Figure 2). Figure 4E shows that these gene lists clearly discriminated 
triazole-exposed cultures, and furthermore, the compound that was left out mapped 
closely to the other triazole-exposed samples.
Gene Ontology based discrimination of phthalates and triazoles
Figure 5A and 5B show the results of the hierarchical clustering of genes related to 
specific GOID that were enriched in either the phthalate- or triazole gene signature. 
Using genes associated with ‘negative regulation of cell differentiation’, ‘anterior pos-
terior pattern formation’, and ‘inner ear morphogenesis’ we were able to discriminate 
between phthalates and triazoles. The branching of the clustering tree was mostly 
good in discriminating triazoles from phthalates. However, the clustering based on the 
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genes associated with the GOID ‘response to inorganic substance’, grouped HEX and TDI 
together, whereas FLU was clustered with the phthalates. Clustering based on all genes 
annotated to the GOID ‘sterol biosynthetic process’ clustered the phthalate and triazole 
compounds separately, but TDI also appeared in a separate branch. The CON cultures 
clustered next to the negative developmental toxicant MMP in 4/5 of the GOID cluster-
ing analyses. Only in one clustering MBP was clustered next to the CON.
In addition, we studied overrepresentation of the class-enriched GOID in the sig-
nificantly regulated gene list of the individual experimental groups. It appeared that 
although the identified GOID were enriched within the triazole or phthalate signature, 
these GOID were not necessarily enriched in each individual compound-exposed group 
belonging to that class (Figure 5A and 5B). For example, genes annotated to the GOID 
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Figure 5. Hierarchical clustering of control (CON), monomethyl phthalate (MMP), monobutyl phthalate 
(MBP), monoethylhexyl phthalate (MEHP), flusilazole (FLU), hexaconazole (HEX) and triadimefon (TDI) 
using all genes annotated to gene ontology identifiers (GOID) enriched in the phthalate signature 
(A) or triazole signature (B), using predefined gene sets (C), and using a negative control gene set (D). 
Asterisks indicate significant GOID enrichment (p-value<0.05) within the significantly regulated genes 
(p-value<0.001) of that compound. The color of the nodes indicates the confidence value (bootstrap 
value) for each node in the clustering tree. For color figure, see Color figures section.
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‘anterior posterior pattern formation’ were overrepresented within the 68-genes contain-
ing triazole signature, whereas studying enrichment of this GOID using the compound-
specific gene lists revealed enrichment only in the FLU and TDI group, and not HEX. 
Furthermore, we identified that genes annotated to the GOID ‘anterior posterior pattern 
formation’ and ‘negative regulation of cell differentiation’ were overrepresented within 
experimental groups of both compound classes (Figure 5A and 5B).
Using predefined gene sets for discrimination of phthalates and triazoles
The discriminating properties of gene sets that we defined in our recent studies are 
presented in Figure 5C. The ‘Van_Dartel_heartdiff_24h’ gene set showed a clear separa-
tion between both classes, with reliable confidence for branching. The gene set ‘EST bio-
marker genes’ correctly clustered the developmental toxicants MBP and MEHP separate 
from the control, and the non-developmental toxicant MMP next to the control. Within 
the triazole class, both FLU and HEX clustered close to the control and TDI was separately 
branched.
The hierarchical clustering on the basis of the genes that were not responsive to the 
test compounds, the negative control gene set, did not discriminate the two compound 
classes correctly (Figure 5D).
Discussion
Identified class signatures show successful grouping of respective class
We performed the unsupervised clustering method PCA using the identified class 
signatures to study discrimination of phthalates and triazoles. PCA is often used in clas-
sification studies to discriminate samples based on their similarity in gene expression 
response that is reflected by the relative position of samples within the PCA [239, 248]. 
Although the position of the samples may differ according to data input and thereby 
influence discriminatory analyses, our PCA plots show robust positioning. For example, 
the position of the phthalate and triazole compounds in Figure 4A and B is very similar 
to those in Figure 4C1 and 4C2, respectively, whereas in the latter two plots 48 additional 
samples were included.
In this study, we observed that the triazole signature clearly discriminated triazole-
exposed samples from samples from all other chemical exposures. This observation 
was also evident using triazole signatures derived using a leave-one-out analysis, 
demonstrating that the discriminating property of the triazole signature was not biased 
by overfitting of the data. The high discriminating power of the triazole signature may in 
part be explained by the proposed mode of teratogenic action of triazole compounds. 
Triazoles are known to target Cyp enzymes involved in retinoic acid metabolism 
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(reviewed in [249]). Regulation of retinoic acid levels in the embryo is critical for de-
velopmental patterning [187, 188, 250]. Interestingly, our data are in line with retinoic 
acid metabolism-mediated disruption of pattern formation by triazoles. First, the GOID 
‘anterior posterior pattern formation’ was enriched in the triazole signature and in the 
individual gene lists of FLU and TDI. In addition, members of the retinol metabolism 
pathway (Crebp1, Rbp4, Rdh10) were identified within the individual gene lists of the 
triazole compounds (not shown).
The projection of MMP-samples in the PCA analyses towards the control samples 
confirms that, although MMP is similar in structure as MBP and MEHP, its effect on ESC 
differentiation cultures was dissimilar from that of the developmentally toxic phthal-
ates. This finding shows that toxicity ranking of compounds within a structural class is 
possible and suggests that this system could be used for prioritizing compounds within 
a class for further testing. Furthermore, we observed that the phthalate signature did 
not clearly discriminate the developmentally toxic phthalates from the carbamazepine-
exposed samples. This could perhaps be explained by a potentially similar teratogenic 
mode of action of phthalate esters and carbamazepine. It has been suggested that 
embryonic acidification caused by accumulation of weakly acidic compounds in the 
basic milieu of the early mammalian embryo may mediate teratogenesis [246]. Both 
carbamazepine and phthalates are weakly acidic, thus such a common mode of action 
may play a role. However, the gene expression signature characterizing this mode of 
action remains unknown at the present time.
GO processes group phthalate and triazole compounds
The assembly of the two class signatures was based on the significant expression of 
individual genes within the present data set. In addition, the discrimination between 
phthalates and triazoles was also studied on the functional level using the overrepre-
sented GOID and predefined gene sets for class discrimination.
We showed that a significant subset of genes within the identified class signatures 
(up to 7/68) corresponded to GOID, which were consequently identified as enriched 
GOID. Besides the 3-7 genes that contributed to the enrichment of the identified GOID, 
expression data of all genes annotated to these enriched GOID were included for the 
hierarchical clustering, which in some cases resulted in addition of expression data of 
>150 genes. These hierarchical clustering analyses convincingly discriminated phthal-
ates from triazoles with corresponding confident bootstrap values.
Although the GOID were identified to be enriched within the triazole or phthalate sig-
nature, the GOID were not per se enriched in each compound-exposed group belonging 
to that class. This indicates that a GOID does not necessarily need to be overrepresented 
for successful grouping of compounds. Interestingly, we observed that the genes be-
longing to the GOID ‘anterior posterior pattern formation’ and ‘negative regulation of 
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cell differentiation’ were also overrepresented within experimental groups of the other 
compound class. This finding indicates that significant enrichment of a GOID in experi-
mental groups does not inevitably mean that these groups will cluster together, since 
the enrichment may be caused by dissimilar regulation of genes within the GOID or 
regulation of other genes present within that GOID [230].
Predefined gene sets discriminate phthalate and triazole compounds
We also performed clustering analyses using the previously identified gene sets, ‘Van_
Dartel_heartdiff_24h’ [111] and ‘EST_biomarker_genes’ [194] that have been shown in 
a recent validation study to be useful in the identification of developmental toxicants 
[214]. As we discussed in these previous publications, these gene sets are based on 
genes involved in the early stage of ESC differentiation and are consequently strongly 
enriched for a multitude of development-related processes.
The gene set ‘Van_Dartel_heartdiff_24h’ includes genes that were up-regulated in 24h 
ESC differentiation cultures as compared to 6 and 12h ESC differentiation culture. This 
gene set showed its usefulness for categorizing phthalate compounds for their develop-
mental toxic potency and for discrimination between developmental toxic phthalates 
and triazoles exposure groups. Also the gene set ‘EST biomarker genes’ showed to be 
useful for categorization of compounds, albeit only within the phthalate class. This 
limitation is likely related to the approach of identification of the ‘EST biomarker genes’ 
gene set; in this gene set, all genes were included of which the expression was altered 
across normal ESC differentiation and which in addition were responsive to exposure of 
the developmental toxicants under study, including MBP [194]. Thus, the finding that 
this gene set correctly discriminates developmentally toxic phthalates, whereas the 
response to developmentally toxic triazoles appeared relatively modest, indicates that 
this gene set may be specified towards the differentiation-related responses observed 
by the compounds evaluated in that study.
Further improvement of compound discrimination is dependent on study design and analysis
The comparisons with gene expression data from our earlier studies were limited by 
the fact that most compounds were tested at single concentrations. To allow optimal 
comparison between compound-exposed experimental groups, we aimed at testing 
the compounds at equally effective concentrations, i.e. inhibiting ESC differentiation 
by approximately 50% as evaluated by morphological scoring. Unfortunately, MBP was 
less effective in terms of ESC differentiation inhibition in the present study, although 
nevertheless this exposure resulted in a gene expression response with significant 
commonalities to that of MEHP. This demonstrates that gene expression changes by de-
velopmental toxicants could already be identified at concentrations that did not affect 
ESC differentiation as evaluated by morphological scoring. This finding illustrates the 
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relatively high sensitivity of gene expression changes as compared to morphological 
scoring in EST. However, testing MBP at a 50% morphological effect concentration may 
have further enhanced the specificity of the phthalate signature.
The importance of compound concentration for the gene expression response was 
also evident from additional cluster analyses using gene expression data of FLU tested 
in a concentration series that was available from a previous study [235]. Whereas the 
cluster analysis based on GOID and the initial data (FLU tested at 5.4 µM) resulted in 
a misclassification of FLU for the GOID ‘response to inorganic substance’, using gene 
expression data of FLU tested at 18 µM resulted in a perfect discrimination of phthal-
ates from triazoles (Supplementary Figure 1). Moreover, also the clustering of the ‘sterol 
biosynthetic process’ resulted in an improved discrimination of the two studied classes. 
We and others have shown that compound concentration has significant effects on 
the gene expression response [49, 225, 251], and therefore we suggested studying 
compounds in a concentration-response design to optimize both the identification of 
potential developmental toxic properties and the discrimination between compound 
classes.
Even with the limited compound set evaluated in this study, it is apparent that each 
compound produced its own unique expression profile and that similarities in profiles 
between compounds can indicate similarities in toxic mechanisms. However, our study 
does not provide decision rules for compound classification, since this requires super-
vised models, such as support vector machines and logistic regression, based on a large 
data set. Studies have been described that use a large dataset to predict toxicological 
outcome and delineate mechanisms of action in a supervised manner [239, 252]. Ad-
ditionally some studies make use of reference toxicogenomic databases to allow these 
gene signature comparisons and improve the predictability of their study [238]. So far, 
the ToxRefDB has been the most advanced database in reproductive and developmental 
toxicology that covers both in vivo and in vitro data of 474 chemicals [253]. Unfortu-
nately, a toxicogenomic database that includes a substantial number of developmental 
toxicants is not (yet) available. Nevertheless, the discriminative gene sets identified in 
the present study can be used as starting points for more advanced classification studies 
using ESC differentiation.
In conclusion, we have demonstrated the ability to distinguish between two structural 
classes of compounds with distinct modes of action in the EST using toxicogenomic data. 
Transcriptomic responses proved to be more sensitive than classical morphological end 
point evaluation Studies examining concentration and time response will be critical in 
optimizing the discrimination of classes of compounds using toxicogenomics. The pres-
ent study serves as an example for the use of compound clustering using gene expres-
sion data of exposed differentiating ESC that may be useful for prioritizing compounds 
for further testing and for tailoring toxicological screening strategies.
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CHAPTER 9
Gene set assembly for quantitative 
prediction of developmental toxicity 
in the Embryonic Stem cell Test
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Abstract
The Embryonic Stem cell Test (EST) is an in vitro method for predicting developmental 
toxicity based on compound-induced inhibition of embryonic stem cell (ESC) differen-
tiation. We previously described how gene expression analysis in the EST can be used to 
describe normal ESC differentiation as well as identify compound developmental toxic-
ity, by means of our ‘differentiation track’ algorithm. In this study, we combined raw data 
from our three previous studies in a new integrated analysis, to identify a gene set that 
allows for improved prediction. By evaluating predictions of 100,000 randomly selected 
gene sets, we identified which genes contribute significantly to the prediction reliability. 
By additional cross-validation, we identified a set of 52 genes that allows for improved 
prediction of toxicity. The correlation between the predictions using this gene set and 
the magnitude of the EST end point was 0.85, and the gene set predicted developmental 
toxicity with 83% accuracy (area under the curve 89%). If compounds with ineffective 
data because of a too low tested concentration or too much variation between samples 
were excluded, even 100% accuracy could be reached based on 15 compounds. This 
novel gene set consists mainly of genes involved in the stem cell differentiation or other 
developmental processes. We expect that this set can be of use in future studies aimed 
at improving the EST for risk assessment, thus making a next step towards regulatory 
implementation of this method.
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Introduction
Current regulatory guidelines for toxicological hazard identification require large num-
bers of experimental animals. Animal use is especially high in the area of reproductive 
and developmental toxicity testing [119]. For this reason, numerous efforts are invest-
ing into developing alternative testing methods to achieve reduction, refinement and 
replacement of animal testing to predict reproductive and developmental toxicity. As a 
result, many alternatives testing methods have been developed in recent decades [254], 
although none have yet obtained regulatory acceptance. The ECVAM validation study of 
three alternatives has been the largest effort in this area so far [20], but still regulatory 
implementation has lagged behind, which is due to remaining uncertainties regarding 
applicability domains and predictive capacities of the tests involved [23, 170]. Improve-
ments in these areas are clearly necessary to increase acceptance and implementation 
of these tests in regulatory toxicology.
Of the three ECVAM validated alternatives for developmental toxicity, the Embryonic 
Stem cell Test (EST) is the only one which is completely animal-free [19]. The EST uses 
a continuous murine embryonic stem cell (ESC) line, which can be induced to differ-
entiate into contracting cardiomyocytes, via the formation of embryoid bodies (EB). 
After ten days of culture, the extent of differentiation is evaluated microscopically, and 
compounds inhibiting this differentiation process are considered as potential develop-
mental toxicants.
Despite its promise as an alternative assay [170], several disadvantages of the current 
EST protocol exist, including the long duration of culture and subjective scoring for the 
presence of contracting cardiomyocytes. Recent studies suggest that molecular biologi-
cal approaches, such as transcriptomics, may help to improve the prediction accuracy 
of this test system [111, 255, 256]. Furthermore, these studies provide more detailed 
information regarding mechanisms of action in relation to concentration [235] and time 
[177], thus allowing further optimization of this testing method both in terms of ap-
plicability domain as well as for developmental toxicity prediction.
As part of the analysis of transcriptomic data, Principal Component Analysis (PCA) 
has been applied to describe gene expression changes during embryonic development 
[153, 232] and stem cell development [177, 231]. These studies found that phases in the 
developmental process appear in a PCA visualization as a chronological differentiation 
track. In previous studies from our laboratory, we described that exposure of ESC to 
developmentally toxic compounds during early cardiomyocyte differentiation (day 3-5 
of culture), results in a deviation from the ESC ‘differentiation track’ (van Dartel et al., 
2010d). In other studies, we described two gene sets that can be used to define this ‘dif-
ferentiation track’ and can also be used to identify deviation form this track by exposure 
to developmental toxicants [111, 194]. The ‘Van_Dartel_Heartdiff_24h’ gene set includes 
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38 genes that were all up-regulated at 24h ESC differentiation compared to earlier time 
points. This gene set was observed to be down-regulated by the compound monobutyl 
phthalate, thereby showing its value in developmental toxicity identification. The 
‘EST_biomarker_genes’ gene set includes 26 genes that were up- or down-regulated 
during normal ESC differentiation (0-48 h) and also responsive to various developmen-
tal toxicant exposures. An evaluation study [214] showed that a ‘differentiation track’ 
algorithm using these gene sets can lead to up to 83% prediction accuracy in a group 
of 18 compounds. In addition, we found that the significance of ‘differentiation track’ 
deviation not only depends on the compound, but also on the concentration that was 
being tested [235]. Because this also applies to the EST end point of cardiomyocyte 
differentiation inhibition, it can be deduced that a more significant track deviation is 
predictive for a higher magnitude of the inhibition at the cardiomyocyte differentiation 
end point. Each of these initial studies individually provided information on the pos-
sible use of PCA in defining normal and altered differentiation and the application of 
gene sets in predicting toxicity. In the present study, the cumulative microarray data 
and toxicological information from these earlier studies have been combined in a new 
integrated analysis yielding a novel gene set that is investigated for its predictive ability 
on the tested compounds in the EST. The aim was to assemble a gene set that would 
allow for more accurate developmental toxicity prediction in terms of classification 
accuracy and/or more quantitative agreement between ‘differentiation track’ deviation 
and the morphological differentiation inhibition end point. Especially this latter aspect 
would be welcomed to demonstrate the applicability of the EST for quantitative data in 
human risk assessment.
In this study, we present an approach based on random sampling and testing of gene 
sets to evaluate which genes give good performance for toxicity prediction in the EST 
with the ‘differentiation track’ algorithm across multiple datasets. Using this approach, 
combined with cross-validation, we derive a gene set that gives better prediction per-
formance in both aspects mentioned.
Methods
In three previous publications from our group [194, 214, 235], methods and data regard-
ing culture conditions, compound exposures, assessment of differentiation inhibition, 
and gene expression profiling have been described in full detail. Microarray data ob-
tained in those studies are available at ArrayExpress (http://www.ebi.ac.uk/arrayexpress) 
under accession numbers E-TABM-903, E-MTAB-300, and E-TABM-1027.
Unless mentioned otherwise, R was used for all calculations described in this study. 
The algorithm for calculating deviation from the ‘differentiation track’ has been de-
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scribed previously [177, 194]. Briefly, starting from whole-genome normalized data, 
gene expression data for a selected subset of genes are log-transformed, and data for 
unexposed samples at 0 h, 24 h, and 48 h, together with compound treatment samples 
at 24 h, are used in a PCA. Coordinates along the first and second principal component 
are calculated for each sample. Deviation of compound-exposed samples from the 
‘differentiation track’ is analyzed by applying a Hotelling T-test to these coordinates 
compared to those of the time-matched control cultures.
To determine which genes make reliable indicators for ‘differentiation track’ devia-
tion, we used a five-step approach. First, the data set was restricted to those genes that 
showed significant differences in expression between the controls at 0 h, 24 h, and 48h 
(p<0.001, Fold Ratio (FR)>1.25). This reduced the number of genes in the data set from 
20979 (all annotated genes on the microarray) to 5601. In the second step, 100,000 
randomly selected sets of 30 genes each were taken from the data set (so that each gene 
was sampled on average 536 times). The amount of 30 genes per set was chosen to be 
in accordance with the approximate size of the two previously identified gene sets [111, 
194]. For each gene set, we calculated the p-value for ‘differentiation track’ deviation 
for each 24 h-exposed experimental group using the data of this group plus data of 
the three unexposed experimental groups, sampled at 0, 24, 48h of ESC differentiation, 
derived from the same study. Unexposed samples were used in the analysis as a refer-
ence group with (by definition) no differentiation inhibition. For each set, the calculated 
p-values for the various compound exposures were compared to the corresponding ESC 
differentiation inhibition by calculating the Spearman (rank-based) correlation. A low 
p-value for ‘differentiation track’ deviation is expected to correspond to a high degree of 
ESC differentiation inhibition, therefore genes of a gene set that have a low correlation 
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Figure 1. Vertical lines below the distribution curve indicate significance status of individual genes. Grey, 
not significant; dark grey, significant (FDR 5%) but not cross-validated; black, significant and cross-validated.
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are expected to be most predictive. The genes in the gene set were scored as a hit if the 
correlation for a gene set was less than -0.7571, which corresponds to the 10th percentile, 
based on a pilot run with 10,000 samplings. After the computations for 100,000 gene sets 
were finished, it was determined how many times each gene was sampled and how many 
times it had scored a hit (i.e. exceeded the threshold). This latter value was compared to 
the expected number of hits (i.e. 10% of the number of samplings). Because for most of 
the genes this scoring ratio (actual hits / predicted hits) followed a Gaussian distribution 
(Figure 1), this distribution was used to determine which genes had a significantly higher 
ratio, at a False Discovery Rate (FDR) of 5%. All identified genes were combined in a set 
(Pennings_Diff_Correlation) and track deviation p-values were calculated and compared 
to those calculated with the two previously described gene sets.
Fourth, a leave-one-out cross-validation (LOOCV) was carried out. This comprised of 
repeating the above procedure with each time one of the treatment groups left out, and 
determining which genes are found significant at an FDR of 5%. These cross-validation 
gene sets were used to calculate the p-value for the left out group. Finally, those genes 
in the Pennings_Diff_Correlation set that were confirmed by all cross-validations were 
combined in a restricted gene set (Pennings_Diff_Crossval).
Gene sets were evaluated for toxicity identification by means of the ‘differentiation 
track’ algorithm, using 18 compound-exposed cultures used in the biomarker discovery 
and validation study [194, 214]. Compounds were considered developmentally toxic if 
they showed significant deviation from the ‘differentiation track’ (p<0.05) and as non-
toxicants otherwise. For additional evaluation, Receiver Operating Characteristic (ROC) 
curves and their underlying Area Under the Curve (AUC) were obtained in R. Visualiza-
tion and hierarchical clustering of gene expression data was carried out using Gene-
Maths XT (Applied Maths, St-Martens-Latem, Belgium). Enrichment for Gene Ontology 
and other functional terms was determined using the DAVID Bioinformatics Resource 
website (http://david.abcc.ncifcrf.gov) [257]. Additionally, enrichment for other custom 
functional gene sets such as e.g. described in [258] was determined via an in-house 
developed R application.
To determine how genes or proteins in the Pennings_Diff_Correlation set act together 
in ESC differentiation, we collected a list of mutual gene or protein interactions via a 
query at STRING [259] (http://string.embl.de). Interactions were included in the list if 
they had high confidence scores (> 0.7) in mouse, high confidence scores in human, 
or medium confidence scores (> 0.4) in both. This list was further supplemented with 
curated interactions that were found through building a gene interactions network in 
MetaCore (www.genego.com). After redundancies in the list were removed, the interac-
tions were visualized in Cytoscape [127].
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Results
Assembly of a novel predictive gene set
With the methods described, we identified 132 genes that are significantly enriched 
among gene sets that show a strong correlation between ‘differentiation track’ deviation 
and ESC differentiation inhibition. These genes were combined to form a novel gene 
set that was named ‘Pennings_Diff_Correlation’ (Supplementary Table 1). Using the 
‘Pennings_Diff_Correlation’ gene set, we observed strong negative correlation (-0.904) 
between ‘differentiation track’ deviation of compound-exposed experimental groups 
and ESC differentiation inhibition (Table 1). As could be expected, weaker correlations 
were observed with the previously established gene lists EST_biomarker_genes set 
(-0.620) and Van_Dartel_Heartdiff_24h set (-0.714), respectively, that were based on 
more limited datasets.
We also determined the classification performance for the 18 previously described 
exposures by comparing the obtained p-values in a ROC curve (Figure 2). The resulting 
AUC is 0.956 for the Pennings_Diff_Correlation set, compared to 0.778 for the EST_bio-
marker_genes set or 0.867 for the Van_Dartel_Heartdiff_24h set. Again as expected, the 
Pennings_Diff_Correlation set showed in improved developmental toxicity prediction 
as compared to previously obtained gene sets. When the previously used p-value of 
0.05 was used as a cutoff between toxicants and non-toxicants, the overall number 
of misclassifications for the 18 exposures tested in the biomarker discovery [194] and 
validation study [214] was 3 with the Pennings_Diff_Correlation set, 3 with the Van_Dar-
tel_Heartdiff_24h set, and 4 for the EST_biomarker_genes set. Thus, using this p-value, 
A
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Figure 2. ROC curves are given for the magnitude of the cardiomyocyte inhibition (“inhibition”) and 
predictions made using the differentiation track algorithm. A, previously reported gene sets. B, gene sets 
reported in this study.
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the improvement in classification AUC is not reflected in a higher number of correct 
predictions compared to the Van_Dartel_Heartdiff_24h set.
Biological characterization
Hierarchical clustering on gene expression data across normal ESC differentiation (un-
exposed groups) for the 132 genes in the Pennings_Diff_Correlation set revealed four 
clusters with different expression timing patterns (Figure3 (inset)). Clusters A-D peaked 
at different culture time points, namely at 0h (labeled A), 24h (B), 24-48h (C), and 48h (D) 
(Supplementary Table 1). Thus, the set consists of genes of which the expression peaks 
cover the entire time period studied.
A considerable number of the 132 genes were found to function in development re-
lated processes. According to GO annotation, there are 62 genes annotated as involved 
in development (p-value = 3.7 E-20), including 34 involved in embryonic development 
(p-value 1.9 E-19). Most notable in this respect is the finding that the set contains nine 
Hox genes and seven other genes with homeobox domains (Alx3, Cdx2, Gbx2, Lhx1, Otx1, 
Otx2, Pou3f1). The highest ranking gene, Myl7, represents an example of more specifically 
cardiac-associated genes. The functional relevance of the 132 genes was further cor-
roborated by the presence of 45 genes which are also included in the ESC-differentiation 
co-regulation network which we recently constructed based on a collection of relevant 
literature [258]. Finally, via STRING and MetaCore databases queries, we identified 65 
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Figure 3. Gene or protein interactions found in the STRING and MetaCore databases are indicated as 
a connection between gene nodes. Gene node colors indicate the expression cluster to which a gene 
belongs (cluster A-D, see inset).
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gene or protein interactions among 50 of the 132 genes in the Pennings_Diff_Correla-
tion set (Figure 3).
When gene expression and interaction data are shown together (Figure 3) it can 
be seen that many of the interactions are between genes that share a similar time 
expression trend. More precisely, there are 30 interactions within time clusters (1.24% 
of all possible within-cluster interactions) versus 35 interactions between time clusters 
(0.56% of all possible between-cluster interactions). Thus, within-cluster interactions are 
relatively nearly 2.5 times more frequent, which is in agreement with the premise that 
cooperating genes should be similarly expressed. Also, the number of within-cluster 
interactions is highest in the genes which are expressed at later timepoints, consistent 
with a cellular system that becomes more specialized to a specific function. Within the 
network, the genes with most interactions (e.g. Dll1, Fgf3, Lefty2, Ncam1, Tgfb2, Wnt3) are 
all known as developmental genes.
Cross-validation
To test the robustness of our results, both with regard to the gene set obtained as well 
as the predicted p-values per compound exposure, we cross-validated the analysis us-
ing a LOOCV. When p-values were calculated for the exposure that was left out of the 
cross-validation, the values obtained were generally comparable with those for the Pen-
nings_Diff_Correlation gene set (Table1), with only the p-value for retinoic acid differing 
by more than an order of magnitude. The overall correlation for the LOOCV predicted 
values with the magnitude of EST differentiation inhibition was -0.824.
Of the 132 genes in the initial gene set, 87 were confirmed in the majority, and 52 in 
all of the cross-validations. We named the latter set of genes ‘Pennings_Diff_Crossval’ 
(Table2). Generally speaking, these are mainly the genes with higher scoring ratios, 
and correspondingly lower FDRs in the Pennings_Diff_Correlation set (Supplementary 
Table1, Figure 1). Using this set, p-values for compound-induced ‘differentiation track’ 
deviation were calculated, and the correlation between these significance values and 
ESC differentiation inhibition was -0.846. In addition, the AUC based on 18 previously 
tested exposures was 0.889 (Table 1). Classification on the 18 previously tested expo-
sures resulted in 3 misclassifications (MBP1, MBP2, VPA) (Table 1), which were the same 
as for the Pennings_Diff_Correlation set.
The Pennings_Diff_Crossval set also showed functional enrichment for developmen-
tal (28) and embryonic development (16) genes, as well as for 22 genes in the ESC-
differentiation co-regulation network. Also, 21 of the 50 genes with mutual interactions 
(Figure 3) are also included in the Pennings_Diff_Crossval set. As a relative percentage, 
these figures are between 2 and 9 % higher than for the Pennings_Diff_Correlation set.
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Table 2. Genes in the Pennings_Diff_Crossval set.
Gene symbol GeneID Scoring ratio Cluster
1700013H16Rik 75514 2.504 A
Bcl11a 14025 2.003 A
Lefty2 320202 4.806 A
LOC100045988 100045988 2.239 A
Pmaip1 58801 2.269 A
Tdgf1 21667 3.801 A
Zic2 22772 2.035 A
3110040M04Rik 73176 3.842 B
Adam19 11492 2.458 B
Adamts9 101401 1.992 B
Cbln1 12404 3.429 B
Chst7 60322 2.591 B
Dclk1 13175 2.267 B
Dlc1 50768 2.394 B
Dll1 13388 2.350 B
Dll3 13389 4.210 B
Egln3 112407 3.360 B
Gas1 14451 2.447 B
Gbx2 14472 2.247 B
Gm239 237558 2.183 B
Grrp1 72690 5.127 B
Itga8 241226 4.444 B
Mesp2 17293 2.862 B
S1pr5 94226 2.389 B
Tasp1 75812 2.139 B
Tbx6 21389 2.022 B
Anxa2 12306 3.113 C
Aplnr 23796 3.966 C
Asb4 65255 3.704 C
Cxcr4 12767 2.660 C
Fgf3 14174 2.560 C
Foxc1 17300 3.814 C
Frzb 20378 5.162 C
Hoxb1 15407 2.171 C
Lhfp 108927 3.461 C
Lhx1 16869 4.495 C
Mesp1 17292 5.244 C
Myl7 17898 8.865 C
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Gene symbol GeneID Scoring ratio Cluster
Rasgrp3 240168 2.767 C
Rbm24 666794 3.036 C
Arg1 11846 2.964 D
AU015836 385493 2.809 D
Cpm 70574 2.336 D
H19 14955 2.057 D
Hoxa1 15394 2.261 D
Hoxd1 15429 2.472 D
Id2 15902 2.620 D
Plac1 56096 1.906 D
Runx1t1 12395 3.013 D
Scara3 219151 2.660 D
Tgfb2 21808 3.489 D
Zfp503 218820 4.409 D
Toxicological response
A comparison of gene expression responses due to the various exposures (Figure 4) 
shows that most genes in the Pennings_Diff_Crossval set did not respond by a dose-
response consistent up- or down-regulation upon compound exposure. Instead, many 
genes showed either up- or down-regulation depending on the compound, indicating 
that toxicological effects are mediated through various mechanisms. In spite of this, 
some similarities could be found in a subset of the genes for some of the compounds. 
A similar gene expression profile could for example be seen for the triazoles (hexacon-
azole, triadimefon, flusilazole), which was especially characterized by induction of sev-
eral Hox-genes. This characteristic profile was not found among the other compounds, 
with exception of retinoic acid. Additionally, similarities can be seen between warfarin, 
methotrexate, and methyl mercury in a number of genes in cluster C, such as Myl7.
Discussion
In a series of previous papers, our laboratory described the use of a ‘differentiation track’ 
algorithm to study responses to compound exposure within a continuously chang-
ing biological system of ESC differentiating in vitro. This approach was built upon the 
knowledge that although developmental toxicants may cover a wide range of possible 
mechanisms of action, many of them share the ability to modulate ESC differentiation 
in the EST protocol by causing aberrant gene expression during critical developmental 
stages. Therefore, rather than looking for specific up-or down-regulation within a limited 
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number of biomarker genes, the ‘differentiation track’ algorithm determines the degree 
of deviation from the normal ‘differentiation track’ as a multivariate measure (i.e. dis-
tance) based on a larger number of genes. This is done by means of a PCA that includes 
control groups at 0, 24, and 48h plus a compound-exposed group at 24 h, so that the 
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Figure 4. Expression response to compound exposure for genes in the Pennings_Diff_Crossval set.
Samples are ordered based on compound class or profile similarities.
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PCA shows changes in time due to normal ESC differentiation as well as compound-
induced changes to this differentiation.
Based upon a proof-of-principle and a validation study [194, 214], the use of our ‘dif-
ferentiation track’ algorithm in hazard identification is sufficiently reliable to investigate 
if it can be further improved with regard to other aspects of the EST. One such aspect 
is to improve the correlation between the p-value for ‘differentiation track’ deviation 
and the quantitative EST phenotypical end point, i.e. the magnitude of cardiomyocyte 
differentiation inhibition. This will probably lead to a better prediction performance, but 
moreover it will allow using the data in a more quantitative manner, which will certainly 
help accept its use in human risk assessment [192, 240, 260].
The desire for a better correlation to a quantitative end point led us to assemble a 
novel gene set aimed at meeting these requirements. The algorithm used was written 
specifically for this study, but uses several elements (e.g. random sampling of genes, 
scoring them according to their performance, cross-validation) which are also used in 
more generally applicable methods for classification and biomarker selection, especially 
RandomForest [261]. As anticipated, the analysis resulted in a gene set with improved 
correlation with the EST end point, as well as the in vivo end point, compared to earlier 
gene sets. In addition, the classification based on data from 18 compounds previously 
tested (at concentrations that were calculated on the basis of historic data to inhibit 
cardiomyocyte differentiation with 50% compared with control cultures), also becomes 
better, with AUC values being 0.956 and 0.889 for the Pennings_Diff_Correlation and the 
Pennings_Diff_Crossval sets, respectively.
When a cutoff p-value of 0.05 is used, both of the new sets led to 3 misclassifications, 
equal to the number for the Van_Dartel_heartdiff_24h set, and one less that that for the 
EST_biomarker_genes set. More specifically, the two Pennings_Diff sets differed from 
the other two sets in that nitrofen (62.2% inhibition) was correctly classified, whereas 
the reverse was true for valproic acid (26.5% inhibition). Although this implies that 
one correct compound (mis)classification is exchanged for another, the finding that 
the compound with more inhibition now became classified correctly is in agreement 
with our aim of a better overall quantitative prediction performance. Moreover, the 
valproic acid-exposed samples show large variation (Figure 5) which is over an order 
of magnitude outside the range of the sample variations found for all other exposures 
(Figure 5), which has caused this compound to be not significantly different from the 
controls. Regarding the other two misclassifications, it is remarkable that they both 
occurred for monobutyl phthalate. This compound gives malformations at relatively 
high concentrations and is therefore considered a weak developmental toxicant [91, 
92, 122]. Moreover, monobutyl phthalate only affected ESC differentiation in one out 
of two studies, and data from these two studies did not lead to consistent predictions 
using the Van_Dartel_Heartdiff_24h and EST_biomarker_genes set (Table 1), which is 
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probably caused by the very limited induction of gene expression changes by MBP as 
observed in our previous studies as well as in the present study (Figure 4). This suggests 
that if MBP had been dosed at a higher concentration that led to more differentiation 
inhibition as well as gene expression changes, it might have been predicted correctly as 
developmentally toxic
Taken together, if variability among samples could be reduced and test compound 
concentration would be optimized, predictability of the Pennings_Diff_Crossval gene 
set could rise to 100% for the compounds tested. These aspects are reminiscent of gen-
eral issues in statistical analysis, with effect size and variability determining statistical 
significance. It may be worthwhile to consider testing several concentrations of a test 
compound rather than a single one in order to optimize analysis, which would addition-
ally reveal aspects of concentration-response and of potency of the compound tested 
concentration [235].
We applied the commonly used LOOCV method to determine the robustness of our 
gene set as well its prediction. This validation showed that most exposures, when their 
data were not included in assembling the gene set, got comparable p-values based on 
the data of the remaining exposures. This indicates that the predictions were sufficiently 
robust against overfitting on compound-specific effects. Because not all genes met 
the 5% FDR threshold in all of the exposures, we were able to reduce the 132 genes 
in the Pennings_Diff_Correlation set to a smaller set of 52 genes. This latter set (Pen-
nings_Diff_Crossval) also showed improved agreement with differentiation inhibition 
(R = -0.846) as well as compound class (AUC = 0.889) compared to previously described 
sets. Although its R and AUC values were not as high as the Pennings_Diff_Correlation 
set, it needs to be emphasized that larger set was obtained using the complete data 
set and therefore, on statistical grounds, some degree of overfitting can be expected. 
Therefore, because of the higher confidence restrictions applied, it is to be expected 
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Figure 5. Examples of differentiation tracks, with different kinds of variation among toxicant-exposed 
samples (black circles). 
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that the cross-validated gene set will probably give more realistic classification accura-
cies for applications in future studies.
In the comparisons of the classifications with the in vivo end point shown in Figure 
2, it becomes clear that both Pennings_Diff sets perform at a comparable level as the 
standard EST end point, which has an AUC of 0.911. Although the EST end point of mi-
croscopically scoring of contracting cardiomyocyte foci is a useful and convenient end 
point, it has two main disadvantages. Not only is optical scoring somewhat subjective 
but, additionally, the EST works as a ‘black box’ that does not give any information on the 
mode of action of a compound. Transcriptomics and other molecular approaches [177, 
256, 262] can help to improve these aspects of the EST, in providing more quantitatively 
reliable data that can also be analyzed to determine which processes are affected by 
toxicant exposures. Such data can help construct a better informed picture of its ap-
plicability domain.
Our cross-validated set, as well as the initial set, contains a large number of genes 
involved in development or stem cell-related processes. Moreover, these genes show 
expression peaks occurring across the time range studied, and nearly half of the genes 
have some kind of mutual interaction. This finding illustrates the biological robustness 
of our set(s) and gives confidence on its application in future studies. Remarkably, in 
spite of the biological relevance of our set, it shows little overlap with previously pub-
lished gene sets, with three genes (Frzb, Gas1, Mesp1) being included in the Van_Dar-
tel_Heartdiff_24h set and none in the EST_biomarker_genes set. Partially, this can be 
attributed to the fact that these other gene sets were based on other (smaller) data sets, 
but moreover, these sets were both obtained as an answer to slightly different kinds 
of research questions. The Van_Dartel_Heartdiff_24h set was determined as genes up-
regulated at 24h during normal ESC differentiation, whereas the EST_biomarker_genes 
set contains genes up- or down-regulated during 0 - 48h of normal ESC differentiation 
and also (up- or down-) regulated by five developmentally toxic compounds.
The varying toxicological responses found in the data indicate that several different 
mechanisms are involved for the compounds examined and that a method based on 
multiple genes covering multiple aspects of development – such as the developmental 
track – will allow optimal prediction of developmental toxicity. Interestingly, there are a 
number of genes for which some of the compounds examined gave comparable gene 
expression responses (Figure 4). Most notable here are the similar responses for the three 
triazoles studied (i.e. hexaconazole, triadimefon, flusilazole). Interestingly, these profiles 
are similar to that of retinoic acid, which lend further support to the hypothesis that 
their teratogenic mechanism lies in inhibiting common enzymes involved in retinoic 
acid metabolism, causing disrupted retinoic acid homeostasis [249]. Characteristic for 
these exposures were not only several homeobox containing genes, but also Arg1, Id2, 
and zinc finger protein 503 (Zfp503). This latter gene was previously identified as a puta-
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tive novel gene important for cardiac development [258], which is corroborated by its 
inclusion in the Pennings_Diff_Correlation set. Also, Chang et al. [263] described induc-
tion of this gene in embryonal carcinoma cells upon retinoic acid exposure, indicating 
a role in retinoic acid-induced developmental toxicity. A second example of a similar 
compound response is that of warfarin, methotrexate, and methyl mercury. In this case, 
the genes most affected include the known heart muscle protein Myl7 as well as Rbm24, 
and Cxcr4. These other two genes have more recently been found also to be involved in 
muscle development [264, 265]. These findings indicate that besides more accurate or 
more quantitative developmental toxicity classification, our gene set (and therefore the 
‘differentiation track’ method) can also serve to deduce mechanistic information from 
the data and possibly predict compound mode of actions using this method. Before 
such an approach can be effective, more compound and mechanistic data needs to be 
collected in a database suitable for compound comparison [238, 266]. Such additional 
compound data will in turn also allow for further improvement of gene sets as well as 
classification criteria for the ‘differentiation track’ algorithm.
In conclusion: by integrating the currently available data, we have identified a novel 
set of biologically relevant genes that allows for improved prediction of developmental 
toxicity. Using cross-validation, we confirmed that predictions using this set correlate 
better with the EST quantitative end point. Our data suggest that when combined with 
improvement of sample variability and effect size, predictions of close to 100% accuracy 
might be reached. We expect that our gene set can be of use in future studies aimed 
at improving the EST for risk assessment, thus making a next step towards regulatory 
implementation.
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Identification by gene co-regulation 
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embryonic stem cell differentiation
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Abstract
A combined analysis of data from a series of literature studies can lead to more reliable 
results than that based on a single study. A common problem in performing combined 
analyses of literature microarray gene expression data is that the original raw data are 
not always available and not always easy to combine in one analysis. We propose an ap-
proach that does not require analyzing original raw data, but instead takes literature gene 
sets derived from (supplementary) tables as input and uses gene co-occurrence in these 
sets for mapping a co-regulation network. An algorithm for this method was applied to 
a collection of literature derived gene sets related to embryonic stem cell differentiation. 
In the resulting network, genes involved in similar biological processes or expressed 
at similar time points during differentiation were found to cluster together. Using this 
information, we identified 43 genes not previously associated with cardiac embryonic 
stem cell differentiation for which we were able to assign a putative novel biological 
function. For six of these genes (Apobec2, Cth, Ptges, Rrad, Zfp57, and 2410146L05Rik), 
literature data on mouse knockout phenotypes supports their putative function. Three 
other genes (Rcor2, Zfp503, and Hspb3) are part of major pathways within the network 
and therefore likely mechanistically relevant candidate genes. We anticipate that these 
43 genes can help to improve the understanding of the molecular events underlying 
embryonic stem cell differentiation. Moreover, the approach introduced here can be 
more widely applied to identify possible novel gene functions in biological processes.
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Introduction
Combined analysis of microarray gene expression data from multiple studies offers 
the possibility to derive more reliable results than can be obtained from a single study. 
Although such combined analyses of microarray data are still comparatively rare, they 
have been successfully applied in well-studied research areas like cancer [267-269], host 
response to pathogens [270, 271], and aging [272]. However, for many microarray stud-
ies published in the literature, their inclusion in a combined analysis is hampered by the 
fact that their full (raw or normalized) gene expression data are not publicly accessible. 
Even if this is the case, differences in study designs or experimental procedures between 
studies can provide a practical barrier for inclusion. Furthermore, processing large 
amounts of data can be time-consuming and troublesome, strengthening the need for 
a convenient alternative.
We propose to use published microarray data in a different way, omitting normaliza-
tion and statistical issues between different studies. We do this by looking for jointly reg-
ulated genes based on co-occurrence in individual experimental gene sets. A gene set is 
here defined as a list of genes that are described as meeting the same regulation criteria 
in a given literature study, such as being significantly up-regulated, down-regulated, 
or being clustered together based on having similar expression patterns. In fact, most 
microarray study publications provide (supplementary) tables with gene lists that meet 
criteria suitable for the underlying study. In many cases, a gene set will correspond di-
rectly to such a table, sometimes to table subsections that have different headers. If two 
genes occur together in a gene set in one publication, there is a reasonable chance that 
they are relevant to the process and also that they are to a certain extent co-regulated. 
If this is reported in multiple studies, both these chances become increasingly likely. 
Therefore, by analyzing a sufficiently large number of gene sets, it becomes possible to 
determine with high confidence which genes are commonly regulated and additionally 
share co-regulation. The latter information can be used to construct a co-regulation 
network, which can provide additional insights into the regulatory processes involved 
[273, 274]. More specifically, if a gene with a hitherto unknown function is co-regulated 
with several genes that all are known to be involved in the same biological process, this 
gene then can be assumed to play a role in that process [275-277]. Furthermore, the 
number of connections (edges) that a gene has in a network can serve as an indicator 
for its importance in the network process [278].
In this study, we will show the applicability of our method using three different gene 
set collections. One of these collections, containing gene sets derived from studies on 
embryonic stem cell (ESC) differentiation, will be analyzed in more detail with a view to 
cardiomyocyte differentiation and its application in toxicity testing.
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During embryonic development, the heart is one of the first tissues to be formed 
and to acquire functionality. The cellular and molecular events involved in early cardiac 
development are highly conserved between different species (see review in [279, 280]). 
Cardiac progenitor cells originate in the mesodermal germ layer and ultimately dif-
ferentiate to cardiomyocytes via a cascade of development steps. Although molecular 
analysis of cardiac development has already identified several genes involved in (part 
of ) this complex differentiation process, much is still unknown. Embryonic stem cell 
models are often used as a practical model system to study in vitro cardiomyocyte differ-
entiation (reviewed in [281]). Several gene expression studies using this model system 
have been published, which allows for data from several related studies to be analyzed 
in combination.
We applied our method to construct and analyze a co-regulation network of ESC dif-
ferentiation, and used this network to derive groups of co-regulated and functionally 
related genes. Using this approach, we identified several novel genes involved in the 
cardiac cell differentiation process.
Methods
Libraries
The first gene set collection used is the c2.cgp collection, which was downloaded from 
the MSigDB website (www.broadinstitute.org/gsea/msigdb/). This collection contains 
1186 expert curated gene sets and a total number of 15891 unique gene identifiers 
(UGIs) derived from microarray experiments using chemical and genetic perturbations 
[82] and is to our knowledge the largest gene set collection publicly available. The sec-
ond gene set collection is the lung-inflammation collection, derived from 12 microarray 
studies used in a meta-analysis on acute lung inflammation models from 45 exposures 
to air pollutants; bacterial, viral, and parasitic infections; and allergic asthma models 
[271]. This collection contains 90 gene sets and 2680 UGIs.
We previously described the third gene set collection, which is the ESC-diff collection 
[111, 177] (and references sited therein). This collection contains gene sets derived from 
42 microarray studies describing gene expression changes during the differentiation of 
ESC to several types of tissue, with a certain emphasis on cardiomyocytes. During the col-
lecting process, gene sets were included if the underlying study was considered relevant 
based on mutual agreement by a developmental toxicologist and bioinformatician. To 
avoid redundancy, gene sets obtained using the Anni textmining tool were excluded for 
the present study as textmining is implicitly using literature data. The resulting gene set 
collection used contained 167 gene sets and a total number of 15196 UGIs.
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Co-regulation mapping
Gene co-regulation mapping was determined using an algorithm written in the statisti-
cal software environment R (www.r-project.org). Starting from a gene set collection in 
tab-delimited file format, UGIs were converted to uppercase (for computational con-
venience) and subsequently non-meaningful UGIs like “0” or “–” were removed. For the 
resulting gene symbols, the number of occurrences in the collection was calculated. For 
each combination of two (non-identical) symbols, co-regulation was determined using 
two criteria. First, the absolute number of sets in which both genes co-occurred had to 
be at least a certain (user-definable) threshold, to select for often co-regulated genes and 
ensure biological relevance. Second, relative co-regulation strength, calculated as the 
cosine correlation of gene set co-occurrences, had to be at least 50%. This is calculated as 
Na,b/√(Na*Nb), where Na,b is the number of sets in which geneA and geneB occur together, 
and Na and Nb are the number of occurrences of respectively geneA and geneB in all 
sets. If both these criteria were met, the two gene symbols were connected in a network 
description file for visualization with Cytoscape [127]. The criteria for choosing the user-
definable threshold were tested and optimized using the c2.cgp and lung-inflammation 
collection. For further analyses on these and the ESC-diff collection, a default stringency 
was defined so that the threshold for each data set led to approximately 5% of the total 
number of UGIs becoming mapped in the network description file.
The resulting co-regulation network was further visualized using Gene Ontology func-
tional annotations, or gene expression data from earlier studies [177, 271]. The presence 
of significantly densely connected clusters within the total network was determined 
using the Cytoscape plugin MCODE [282] using default settings.
Identification of novel genes involved in embryonic stem cell cardiac differentiation
For the genes in the ESC-diff co-regulation network mapping, Gene Ontology functional 
annotation and enrichment was determined using the Cytoscape plugin BiNGO [283] in 
combination with the DAVID web application (david.abcc.ncifcrf.gov) [183]. Genes were 
considered already associated with ESC differentiation if they were assigned to one of 
the following Gene Ontology terms: development processes (including stem cell, organ, 
heart, or muscle development), cell differentiation, cell proliferation, extracellular matrix 
(including collagen), contractile fiber, muscle system process (including muscle contrac-
tion), and heart contraction. Furthermore, genes for which the textmining tool Anni 
[138] found concept weights>10-5 for the above mentioned terms or the concepts “stem 
cells”, “gastrulation” or “ectoderm/endoderm/mesoderm formation” were considered not 
novel for stem cell differentiation. The concept weight is a measure Anni uses to indicate 
the degree of literature association of one term with another. We found that when 
distributions for a larger number of concept weights are combined, the distribution 
approaches its background level at concept weights around 10-5, and therefore concept 
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weights below this value are considered as not indicative for literature association. For 
the genes not functionally annotated by Gene Ontology or Anni, those that were part of 
an MCODE cluster enriched for one of the above functions were considered candidates 
for such a function.
Results
Method development
To show the applicability of our approach and to optimize the criteria used, we applied 
our algorithm to two gene set collections that are different in nature. The first of these 
is the MSigDB c2.cgp collection [82], which contains 1186 gene sets related to a wide 
range of chemical and genetic perturbations. Second, the lung-inflammation collection, 
with 90 gene sets, which is smaller and more focused on acute lung inflammation mod-
els. For both gene set collections we found that biologically meaningful co-regulation 
networks could be obtained (Fig 1A, 1B). For the c2.cgp collection, various co-regulation 
networks of varying sizes were found. Several of these consisted of genes with a com-
mon related functionality such as cell division or immunological response (Fig 1A). For 
the lung-inflammation collection, besides some smaller networks, a large and dense 
network of commonly inflammation-induced genes containing 120 genes was found 
(Fig 1B). This network includes 66 immune response genes, 61 of which overlap with the 
100 immune response genes found previously as part of a full-scale meta-analysis [5]. 
Moreover, this network contains all of the 23 ‘core inflammation response’ genes found 
in the previous meta-analysis.
Embryonic stem cell differentiation mapping
When the algorithm was applied to the ESC-diff gene set collection a large and densely 
interconnected network with 927 genes and 7402 edges was obtained (Fig 1C). The 
network appeared to have two major sub-networks, at the left and right hand side, 
respectively. This finding was found to be robust for various stringency settings, as was 
the observation that both major sub-networks comprised two minor sub-networks, The 
overall network was significantly enriched for several GO terms related to development, 
differentiation and muscle function. In addition, enrichment for several other functional 
categories was found, especially transcription factors, cell proliferation, small heat shock 
proteins, and several types of metabolite transport. However, we found that known car-
diomyocyte marker genes were located exclusively in the lower right hand side of the 
network, whereas stem cell pluripotency markers were located only in the top left. This 
suggests that these two areas correspond to different processes or phases in stem cell 
differentiation. Both the functional and timing aspects were examined further.
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By using the MCODE plugin, we identified 21 clusters within the overall network that 
are significantly densely connected. The size of these clusters varied from 4 to 39 genes, 
with an overall total of 304 genes. Several of these clusters were enriched for specific 
GO-terms. Clusters with such similar GO-term enrichments appeared together in the 
network graph and (by making small adjustments to the MCODE cluster size threshold 
parameter) it was found that they were mutually strongly connected. Taken together, 
three clusters groups could be distinguished (Fig 2A, Table 1,2,3, supplementary Table 
1). The first group contained five clusters (87 genes, upper left side of Fig 2A) that were 
mainly enriched for early developmental GO-terms such as stem cell development, 
embryonic development, and regulation of cell proliferation. The second group, con-
taining three clusters (25 genes, upper right side of Fig 2A), was enriched for terms such 
as organ development and embryonic development and GO-terms involved in later 
development stages. The third group (55 genes, lower right side of Fig 2A) contained 
three clusters and was enriched for specific heart- and muscle-related GO-terms such as 
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Figure 1. Network visualizations for three gene set collections. A, network for c2.cgp collection (591 
genes, 1243 edges); B, network for lung-inflammation collection (133 genes, 930 edges); C, network for 
ESC-diff (embryonic stem cell differentiation) collection (927 genes, 7402 edges) with transitions between 
sub-networks indicated as dashed lines. For color figure, see Color figures section.
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muscle development, muscle contraction, and heart development. In addition to devel-
opment- and muscle-related processes, the first two groups were enriched for transcrip-
tion factors, and the third group for small heat shock proteins. Next to the clusters in 
the three mentioned groups, five clusters (61 genes) were enriched for other biological 
processes related to transport and/or metabolism, and five other clusters (76 genes) did 
not show functional enrichment. The three groups mentioned above are each found 
in a distinct minor sub-network. The fourth minor sub-network in the lower left side of 
Figure 2A contains several genes that can be associated with early development, prolif-
eration, pluripotency, as well as several metabolic processes. However, the two clusters 
in this sub-network do not reach statistically significant functional enrichment.
A
B
Novel
Early (day 3)
Stem cell development  
Organ development
Genes in/outside
other clusters
Middle (day 4-5)
Late (day 6-7)
Early and late
No data
Figure 2. Embryonic stem cell cardiomyocyte differentiation co-regulation network. A, biological process 
enrichment in network clusters containing novel functional candidates; B, peak gene expression for genes 
in a stem cell differentiation time series. For color figure, see Color figures section.
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Table 1. Identified genes in cluster group 1 (associated with stem cell development, embryonic 
development, regulation of cell proliferation).
Gene symbol Gene description Novel
MCODE 
cluster
Edges
1700019D03RIK RIKEN cDNA 1700019D03 gene yes 2 74
2310003C23RIK RIKEN cDNA 2310003C23 gene yes 2 49
AVPI1 arginine vasopressin-induced 1 yes 2 36
LRRC2 leucine rich repeat containing 2 yes 2 69
PIPOX pipecolic acid oxidase yes 2 48
RCOR2 rest corepressor 2 yes 2 59
SLC25A36 solute carrier family 25, member 36 yes 2 31
STOML1 stomatin-like 1 yes 2 28
TMEM8
transmembrane protein 8 (five membrane-spanning 
domains)
yes 2 42
UPP1 uridine phosphorylase 1 yes 2 51
ZFP57 zinc finger protein 57 yes 2 51
COBL cordon-bleu no 2 52
ETV5 ets variant gene 5 no 2 85
JARID2 jumonji, AT rich interactive domain 2 no 2 83
KLF9 Kruppel-like factor 9 no 2 41
LEFTY1 left right determination factor 1 no 2 67
MYCN N-myc proto-oncogene no 2 68
NR0B1 nuclear receptor subfamily 0, group B, member 1 no 2 69
NTN1 netrin 1 no 2 47
PHC1 polyhomeotic-like 1 (Drosophila) no 2 62
REST RE1-silencing transcription factor no 2 40
RIF1 Rap1 interacting factor 1 homolog (yeast) no 2 88
SPRY2 sprouty homolog 2 (Drosophila) no 2 65
SPRY4 sprouty homolog 4 (Drosophila) no 2 79
TCFCP2L1 transcription factor CP2-like 1 no 2 67
ZIC5 zinc finger protein of the cerebellum 5 no 2 52
2200001I15RIK RIKEN cDNA 2200001I15 gene yes 6 30
IFITM2 interferon induced transmembrane protein 2 yes 6 43
JAM2 junction adhesion molecule 2 yes 6 75
MANBA mannosidase, beta a, lysosomal yes 6 61
MKRN1 makorin, ring finger protein, 1 yes 6 59
PDCL2 phosducin-like 2 yes 6 25
TDH L-threonine dehydrogenase yes 6 69
CTNNAL1 catenin (cadherin associated protein), alpha-like 1 no 6 23
DPPA3 developmental pluripotency-associated 3 no 6 65
ENAH enabled homolog (Drosophila) no 6 50
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Gene symbol Gene description Novel
MCODE 
cluster
Edges
GBX2 gastrulation brain homeobox 2 no 6 43
GPA33 glycoprotein A33 (transmembrane) no 6 35
GRSF1 G-rich RNA sequence binding factor 1 no 6 23
IFITM1 interferon induced transmembrane protein 1 no 6 29
KLF2 Kruppel-like factor 2 (lung) no 6 40
LEFTY2 left-right determination factor 2 no 6 33
MORC1 microrchidia 1 no 6 50
NANOG Nanog homeobox no 6 29
OTX2 orthodenticle homeobox 2 no 6 60
PCAF p300/CBP-associated factor no 6 33
SALL1 sal-like 1 (Drosophila) no 6 50
SERTAD2 SERTA domain containing 2 no 6 50
TGIF TGFB-induced factor homeobox no 6 28
TLE4
transducin-like enhancer of split 4, homolog of Drosophila 
E(spl)
no 6 51
ZFP64 zinc finger protein 64 no 6 24
ZIC3 zinc finger protein of the cerebellum 3 no 6 35
2410146L05RIK RIKEN cDNA 2410146L05 gene yes 17 29
ACP6 lysophosphatidic acid phosphatase yes 17 35
CDYL2 chromodomain protein, Y chromosome-like 2 yes 17 16
EPB4.1L4A erythrocyte protein band 4.1-like 4a yes 17 17
PTGES prostaglandin E synthase yes 17 24
FGF4 fibroblast growth factor 4 no 17 35
HCK hemopoietic cell kinase no 17 21
HK2 hexokinase 2 no 17 20
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 no 17 36
MRAS muscle and microspikes RAS no 17 19
NCL nucleolin no 17 18
NPHS1 nephrosis 1 homolog, nephrin (human) no 17 19
RARG retinoic acid receptor, gamma no 17 29
SGK serum/glucocorticoid regulated kinase no 17 45
TCFAP2C transcription factor AP-2, gamma no 17 34
CTH cystathionase (cystathionine gamma-lyase) yes 18 47
D14ERTD436E DNA segment, chr 14, erato doi 436, expressed yes 18 19
NFATC2IP
NFAT, cytoplasmic, calcineurin-dependent 2 interacting 
protein
yes 18 33
RANBP17 RAN binding protein 17 yes 18 17
SNX10 sorting nexin 10 yes 18 25
FOXD3 forkhead box D3 no 18 49
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To visualize the differentiation process in an alternative manner, we used data from a 
recent study in which we described gene expression changes during embryonic stem 
cell cardiac muscle cell differentiation [177]. This study was not included in the ESC-diff 
gene set collection and therefore provided independent data. For the genes for which 
differential expression was found, we used different colors to indicate at which differen-
tiation phase these genes had their highest expression. This visualization indicated that 
the left and right side of the network can be associated with early (undifferentiated stem 
cells) and late (more differentiated) time points, respectively (Fig 2B). This is in agree-
ment with the different functionalities based on GO-term enrichment. Genes expressed 
during intermediate time points did not group together, but appeared in either of the 
two network sides.
When these two visualization approaches were combined again, we found that out of 
the 167 genes in the three cluster groups (Figure 2A, Table 1,2,3), independent data from 
the van Dartel [177] study showed differential expression for 49 of these genes (29%, 
compared to 6% for the whole-genome data). Of these, 18 early expressed genes were 
all found in the stem cell development group (group 1). Of the 4 mid-phase expressed 
genes, 2 were found in the stem cell development group and 2 in the organ develop-
ment group (group 2). Of the 26 late expressed genes, 2 were found in the stem cell 
differentiation group, 4 in the organ development group, and 20 in the muscle/heart 
function group (group 3). Finally, one gene with both early and late high expression was 
found in the stem cell development group.
Gene symbol Gene description Novel
MCODE 
cluster
Edges
POU5F1 POU domain, class 5, transcription factor 1 no 18 32
SIX4 sine oculis-related homeobox 4 homolog (Drosophila) no 18 17
SOCS2 suppressor of cytokine signaling 2 no 18 43
SUZ12 suppressor of zeste 12 homolog (Drosophila) no 18 14
TDGF1 teratocarcinoma-derived growth factor 1 no 18 41
ZFP36L1 zinc finger protein 36, C3H type-like 1 no 18 46
AGTRAP angiotensin II, type I receptor-associated protein yes 19 22
ASS1 argininosuccinate synthetase 1 yes 19 11
DPPA5 developmental pluripotency associated 5 no 19 33
ESRRB estrogen related receptor, beta no 19 42
KLF4 Kruppel-like factor 4 (gut) no 19 32
MYBL2 myeloblastosis oncogene-like 2 no 19 46
TCL1 T-cell lymphoma breakpoint 1 no 19 29
TRP53 transformation related protein 53 no 19 15
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Novel embryonic stem cell cardiac differentiation genes
Using Gene Ontology for functional annotation of the genes in the embryonic stem cell 
development network, we found that of the 927 genes, 521 could be associated with 
GO processes relevant for ESC differentiation, and 418 with related Anni textmining 
concepts. Leaving out these genes left 327 genes not yet described to be involved in 
ESC differentiation, 165 and 162 of which were located at the left and right hand side 
of the network, respectively. Of these novel genes, 43 were also part of a significantly 
dense MCODE cluster with a functional enrichment for a GO-term related to ESC or 
cardiac differentiation, making them candidate genes for having a corresponding func-
tion assigned to them. These 43 genes are listed in Table 4 and indicated (in dark red, 
dark green or dark blue) in Figure 2. Concerning the overlap with other pathways found 
Table 2. Identified genes in cluster group 2 (associated with organ development, embryonic 
development).
Gene symbol Gene description Novel
MCODE 
cluster
Edges
COLEC12 collectin sub-family member 12 yes 9 8
ZFP503 zinc finger protein 503 yes 9 14
FOXC2 forkhead box C2 no 9 10
GATA5 GATA binding protein 5 no 9 7
HEY1 hairy/enhancer-of-split related with YRPW motif 1 no 9 33
HOXA3 homeo box A3 no 9 17
HOXB2 homeo box B2 no 9 42
HOXB4 homeo box B4 no 9 15
PDGFRA platelet derived growth factor receptor, alpha polypeptide no 9 29
RYR2 ryanodine receptor 2, cardiac no 9 10
SPON1 spondin 1, (f-spondin) extracellular matrix protein no 9 60
TBX2 T-box 2 no 9 28
ZFPM2 zinc finger protein, multitype 2 no 9 37
COL2A1 collagen, type II, alpha 1 no 12 20
FLRT2 fibronectin leucine rich transmembrane protein 2 no 12 21
ISL1 ISL1 transcription factor, LIM/homeodomain no 12 25
MEIS1 Meis homeobox 1 no 12 21
MRG1 Meis1-related gene 1 no 12 13
GAS6 growth arrest specific 6 no 14 18
HDAC7A histone deacetylase 7A no 14 14
ITGB1 integrin beta 1 (fibronectin receptor beta) no 14 18
MMP14 matrix metallopeptidase 14 (membrane-inserted) no 14 15
PEG3 paternally expressed 3 no 14 18
TIMP2 tissue inhibitor of metalloproteinase 2 no 14 17
VCL vinculin no 14 14
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Table 3. Identified genes in cluster group 3 (associated with muscle development, muscle contraction, 
heart development).
Gene symbol Gene description Novel
MCODE 
cluster
Edges
APOBEC2 apolipoprotein B editing complex 2 yes 1 57
G0S2 G0/G1 switch gene 2 yes 1 40
HSPB3 heat shock protein 3 yes 1 39
PPP1R14C
protein phosphatase 1, regulatory (inhibitor) subunit 
14C
yes 1 46
RRAD ras-related associated with diabetes yes 1 67
SYNPO2L synaptopodin 2-like yes 1 72
ACTN2 actinin alpha 2 no 1 77
ASB2 ankyrin repeat and SOCS box-containing 2 no 1 51
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow twitch 
2
no 1 43
CKM creatine kinase, muscle no 1 57
CSRP3 cysteine and glycine-rich protein 3 no 1 74
ENO3 enolase 3, beta muscle no 1 55
HSPB2 heat shock protein 2 no 1 69
HSPB7 heat shock protein family, member 7 (cardiovascular) no 1 62
ITGB1BP2 integrin beta 1 binding protein 2 no 1 50
LAMA4 laminin, alpha 4 no 1 48
LDB3 LIM domain binding 3 no 1 58
MB myoglobin no 1 44
MYBPC3 myosin binding protein C, cardiac no 1 39
MYH6 myosin, heavy polypeptide 6, cardiac muscle, alpha no 1 78
MYL3 myosin, light polypeptide 3 no 1 60
MYL4 myosin, light polypeptide 4 no 1 55
MYL7 myosin, light polypeptide 7, regulatory no 1 52
MYOM1 myomesin 1 no 1 34
MYOZ2 myozenin 2 no 1 70
NPPA natriuretic peptide precursor type A no 1 55
PGAM2 phosphoglycerate mutase 2 no 1 45
PLN phospholamban no 1 71
POPDC2 popeye domain containing 2 no 1 48
PPP1R12B
protein phosphatase 1, regulatory (inhibitor) subunit 
12B
no 1 33
SH3BGR SH3-binding domain glutamic acid-rich protein no 1 58
SMPX small muscle protein, X-linked no 1 66
TCAP titin-cap no 1 48
TNNC1 troponin C, cardiac/slow skeletal no 1 60
TNNI1 troponin I, skeletal, slow 1 no 1 52
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previously, among these novel genes there were no genes involved in cell proliferation, 
there were three transcription factors (Rcor2, Zfp57, Zfp503), and one heat shock protein 
(Hspb3).
Discussion
Since its introduction, microarray technology has grown to become used in over 6000 
PubMed-publications per year. The growth in the number of studies published has been 
followed by the development and application of various methods for combined or 
meta-analysis (reviewed in [284]). However, there are several practical issues related to 
such analyses of gene expression data, and one major hurdle is the limited public avail-
ability of the complete raw or normalized data sets used in literature studies. Several ap-
proaches to combined or meta-analyses have been published in the last few years and 
although this field is still developing, it becomes apparent that no single best method 
exists as the suitability of an approach will depend on the nature and quality of available 
data. In this study we propose an approach which is not based on the actual re-analysis 
Gene symbol Gene description Novel
MCODE 
cluster
Edges
TNNI3 troponin I, cardiac 3 no 1 59
TNNT2 troponin T2, cardiac no 1 63
TRIM63 tripartite motif-containing 63 no 1 32
TTN titin no 1 55
2310046A06RIK RIKEN cDNA 2310046A06 gene yes 7 36
TM4SF1 transmembrane 4 superfamily member 1 yes 7 45
ACTA1 actin, alpha 1, skeletal muscle no 7 37
CRYAB crystallin, alpha B no 7 42
DES desmin no 7 45
DKK3 dickkopf homolog 3 (Xenopus laevis) no 7 29
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 no 7 24
IL6 interleukin 6 no 7 31
NPPB natriuretic peptide precursor type B no 7 37
PTX3 pentraxin 3 no 7 38
ALPK2 alpha-kinase 2 yes 11 26
NEBL nebulette yes 11 27
RCSD1 RCSD domain containing 1 yes 11 31
MYL2 myosin, light polypeptide 2, regulatory, cardiac, slow no 11 29
MYOCD myocardin no 11 26
SMYD1 SET and MYND domain containing 1 no 11 21
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Table 4. Identified novel genes with functional evidence for a role in embryonic stem cell differentiation.
Gene symbol Gene description
MCODE 
cluster
Figure location
1700019D03RIK RIKEN cDNA 1700019D03 gene 2 Upper left
2310003C23RIK RIKEN cDNA 2310003C23 gene 2 Upper left
AVPI1 arginine vasopressin-induced 1 2 Upper left
LRRC2 leucine rich repeat containing 2 2 Upper left
PIPOX pipecolic acid oxidase 2 Upper left
RCOR2 rest corepressor 2 2 Upper left
SLC25A36 solute carrier family 25, member 36 2 Upper left
STOML1 stomatin-like 1 2 Upper left
TMEM8
transmembrane protein 8 (five membrane-spanning 
domains)
2 Upper left
UPP1 uridine phosphorylase 1 2 Upper left
ZFP57 zinc finger protein 57 2 Upper left
2200001I15RIK RIKEN cDNA 2200001I15 gene 6 Upper left
IFITM2 interferon induced transmembrane protein 2 6 Upper left
JAM2 junction adhesion molecule 2 6 Upper left
MANBA mannosidase, beta a, lysosomal 6 Upper left
MKRN1 makorin, ring finger protein, 1 6 Upper left
PDCL2 phosducin-like 2 6 Upper left
TDH L-threonine dehydrogenase 6 Upper left
2410146L05RIK RIKEN cDNA 2410146L05 gene 17 Upper left
ACP6 lysophosphatidic acid phosphatase 17 Upper left
CDYL2 chromodomain protein, Y chromosome-like 2 17 Upper left
EPB4.1L4A erythrocyte protein band 4.1-like 4a 17 Upper left
PTGES prostaglandin E synthase 17 Upper left
CTH cystathionase (cystathionine gamma-lyase) 18 Upper left
D14ERTD436E DNA segment, chr 14, erato doi 436, expressed 18 Upper left
NFATC2IP
NFAT, cytoplasmic, calcineurin-dependent 2 interacting 
protein
18 Upper left
RANBP17 RAN binding protein 17 18 Upper left
SNX10 sorting nexin 10 18 Upper left
AGTRAP angiotensin II, type I receptor-associated protein 19 Upper left
ASS1 argininosuccinate synthetase 1 19 Upper left
COLEC12 collectin sub-family member 12 9 Upper right
ZFP503 zinc finger protein 503 9 Upper right
APOBEC2 apolipoprotein B editing complex 2 1 Lower right
G0S2 G0/G1 switch gene 2 1 Lower right
HSPB3 heat shock protein 3 1 Lower right
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of original data, but on the co-occurrence of genes based on processing of gene sets 
derived from these data. One of the rationales behind our approach is the need for a 
combined analysis that allows inclusion of large numbers of literature microarray study 
results, even if the full original data are not (or not easily) available. Our algorithm for 
network construction allows the inclusion of almost any published study and further-
more does not require elaborate data processing or new software implementations; R 
and Cytoscape are freely available and already familiar to most bioinformaticians. The 
algorithm used by us is available as supplementary data.
The three underlying concepts for our approach have each already been described on 
their own. Firstly, co-expression or co-regulation networks [274] have become a com-
monly applied method to infer novel gene functionality [273, 275-277]. Secondly, algo-
rithms for determining gene co-occurrence in literature publications have been applied 
in textmining applications [285-288]. However, whereas textmining is mostly based on 
literature abstracts or database description fields, our approach specifically searches in 
(supplementary) tables, allowing the use of information that would otherwise have been 
overlooked. Thirdly, employing gene sets rather than full microarray data on the one 
hand or literature abstracts on the other has been described in several applications [126, 
289-291]. These approaches, however, look for statistically significant overlap between 
lists, or to an experimental gene set supplied by the user. Therefore, the combination 
of these methods provides a novel integrated type of approach that should be able to 
incorporate some of the advantages of each of the underlying methods. A potential 
weakness of our approach is that the quality of the gene set collection taken as the start-
ing point for this method will depend on the quality and relevance of the input data. 
We had to rely on the analyses done by the authors of the underlying studies, including 
the assessment of the reviewers and editors responsible for the process of peer review.
As part of the algorithm development, our approach was tested on two gene set 
collections, which were selected to be different in nature. Based on the multi-purpose 
c2.cgp collection, a large number of small networks were identified, including cell divi-
Gene symbol Gene description
MCODE 
cluster
Figure location
PPP1R14C
protein phosphatase 1, regulatory (inhibitor) subunit 
14C
1 Lower right
RRAD ras-related associated with diabetes 1 Lower right
SYNPO2L synaptopodin 2-like 1 Lower right
2310046A06RIK RIKEN cDNA 2310046A06 gene 7 Lower right
TM4SF1 transmembrane 4 superfamily member 1 7 Lower right
ALPK2 alpha-kinase 2 11 Lower right
NEBL nebulette 11 Lower right
RCSD1 RCSD domain containing 1 11 Lower right
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sion and immunological response networks (Fig 1A). The co-regulation network for the 
lung-inflammation gene set collection found a large network, of mainly immunological 
genes (Fig 1B), which comprises the majority of the immunological genes that were 
found regulated by a previous full meta-analysis [271]. Moreover, it contains all of the 23 
“core inflammation response” genes found previously [271]. These findings illustrate the 
usefulness of our approach.
For these two gene set collections, the examples given were obtained using stringency 
settings for which the number of genes in the network description file is around 5% of 
the number of unique gene identifiers in the collection, and these settings were chosen 
as the default stringency settings. However, comparable results were obtained when 
this fraction was between 1% and 10% (data not shown). This indicates that the results 
are robust against small changes in stringency. This was also found for the ESC-diff co-
regulation network mapping. Moreover, to ensure that the method does not lead to 
false positive results, the c2.cgp and lung-inflammation were scrambled; i.e. the genes 
were randomly relocated across the gene sets. Applying the algorithm to these sets did 
not result in a network even for the lowest stringency level (data not shown), confirming 
that the method is robust against random false positive findings.
Applying our algorithm to the ESC-diff gene set collection with 15196 UGIs results in a 
network with 927 genes mostly located within two major sub-networks that correspond 
to early and late differentiation processes stages, respectively. Combining GO-term func-
tional enrichment to MCODE clusters within the network reveals that genes involved in 
similar biological processes are significantly densely connected, which is in agreement 
with the premise that such genes are co-regulated. Moreover, this analysis shows that 
early differentiation events, such as loss of pluripotency, are concentrated in a cluster 
group at the left side of the network, whereas the right side of the network contains two 
cluster groups involved in later differentiation phases, one of which is specifically related 
to muscle and heart function (Fig 2A). The early-late division is supported by overlaying 
gene expression data from an independent study on ESC cardiomyocyte differentiation 
time series [177] (Fig 2B). Genes expressed during intermediate time points in that 
study did not form a separate sub-network, but instead appeared within either of the 
major sub-networks. This can partially be ascribed to the focus of most literature stud-
ies on the differences between undifferentiated and fully differentiated cells, leaving 
intermediate time point genes underrepresented in the combined gene set collection. 
Furthermore, whereas pluripotent stem cells or differentiated cardiomyocytes are both 
stable situations regarding gene expression, the intermediate phase can be described as 
consecutive waves of gene expression corresponding to sequential transient activation 
of differentiation programs [28, 29, 177]. Due to their transient expression, such genes 
are more difficult to identify than those involved in the initial and final phase of the 
differentiation process and they may therefore have been described in smaller numbers 
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[29, 177]. Both these factors will lead to a relatively smaller number of co-regulation 
edges among intermediate phase genes, which influences the Cytoscape visualization 
as its mapping algorithm is developed for grouping together connected genes rather 
than visualizing data as a time series. Nevertheless, the additional use of the MCODE 
plugin results in three functional cluster groups that are visually separated and each 
correspond to a particular differentiation phase.
At the lower left side of Figure 2A, there is a small sub-network containing a number 
of genes involved in development, proliferation and pluripotency. These genes could 
have been expected to occur in the larger sub-network in the upper left side of this 
figure. The presence of a separate sub-network might indicate a possible common 
factor influencing the (co-) expression of these genes. However, as the main associated 
processes are still comparable to that of its larger neighbor except that the functional 
annotation enrichment of this smaller sub-network is not significant, the relevance of 
this sub-network should not be overinterpreted. The same can be said for the six groups 
of two or three genes each in the very lower right of the network visualization. Their 
occurrence as separate groups is not robust to small changes in the algorithm settings 
used, and they can be considered as falling just short of being connected to the main 
network.
The three functional groups in the network contain over 60 genes with a GO annota-
tion organ development as an umbrella term, or more specific terms regarding develop-
ment of a specific organ or tissue. Apart from those involved in heart or muscle, there 
was also functional enrichment for the following terms: blood vessel development, ear 
development, eye development, gland development, immune system development, 
lung development, nervous system development, skeletal development, as well as 
some of their daughter terms. Although several genes are annotated to the develop-
ment of more than one type of organ, muscle and heart (-specific) development-related 
genes are significantly found in the third group (Table 3), and the second group (Table 2) 
significantly contains genes (specifically) involved in the development of other organs. 
Because genes expressed during the intermediate and late time points in the van Dartel 
[177] study are found in the sub-networks around the second as well as the third group, 
this indicates that during culture conditions favoring cardiomyocyte differentiation, also 
other types of tissues are formed.
Other functional analyses showed that the overall network not only contains various 
development- and heart/muscle-associated genes, but in addition genes involved in 
cellular proliferation, transcription and also several members of the alpha crystallin/
small heat shock protein family. The first of these processes can easily be understood as 
the starting point of stem cell differentiation in a culture of proliferating cells. Likewise, 
transcription factors are necessary to trigger and regulate the developmental changes 
that occur between proliferating stem cells and fully differentiated cells, which can 
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explain why these genes are mainly found in the development-related first and second 
group, but hardly in the muscle function-related third group. In contrast, this third 
group contains a number of small heat shock proteins and the structurally related alpha 
crystallin B. Several members of this chaperonin family have already been associated 
with muscle contraction or development, and as Hspb3 has not been associated with 
such a role yet, this might indicate a novel function for this protein. However, although 
a common relevance of chaperonins in heart function is conceivable, extending this as-
sociation to Hspb3 would require additional study and verification, as there is evidence 
that in heart Cryab and Hspb2 act through different and distinct mechanisms within 
cardiomyocytes [292].
Of the 927 genes in the network, 327 (35%) have been described in multiple gene 
lists, but have not yet been linked to a related developmental process in Gene Ontology 
or by literature association. Although in most of the studies the genes are only part of 
a bulk of differentially expressed genes, this combined study shows that there is good 
evidence to describe them as novel genes involved in ESC differentiation. Furthermore, 
based on their position in the network, it can already be assumed whether they are 
mainly expressed at early or late differentiation stages. For 43 of these novel genes, there 
is even more specific evidence, namely that they are part of densely connected cluster 
groups within the overall network that are enriched for a relevant biological function.
To determine the in vivo relevance of these 43 genes, we searched the literature as 
well as the Mouse Genome Informatics (http://www.informatics.jax.org) and the In-
ternational Knockout Mouse Consortium (http://www.knockoutmouse.org) databases 
for mouse knockout phenotype data. For twelve genes phenotype data have been de-
scribed. In the case of four genes, these data are supportive of the putative function 
in heart or muscle development inferred from the network. The Apobec2 knockout 
phenotype revealed a role in maintenance of slow/fast muscle fiber-type ratios [293]; 
Cth deletion results in overproliferation of smooth muscle cells [294]; deletion of the 
Ptges gene leads to adverse ventricular remodeling after myocardial infarction [295]; 
and Rrad knockout mice display cardiac hypertrophy [296]. In the case of Rrad, this is 
further supported by additional human data [296]. For an additional two genes, mouse 
knockout data are consistent with an early developmental function. Mice homozygous 
for a 2410146L05Rik (Ooep) null allele exhibit female infertility associated with a failure 
of embryos to progress beyond the 2 cell stage [297]; for Zfp57, loss of its the zygotic 
function causes partial neonatal lethality, whereas eliminating both the maternal and 
zygotic functions of Zfp57 results in a highly penetrant embryonic lethality due to ef-
fects on genomic imprinting [298]. Taken together, in vivo knockout data corroborate 
the putative function for half the genes for which such data are available.
This indicates that the other genes in Table4 also provide interesting candidates for 
further studies regarding embryonic stem cell cardiac differentiation. Among these, 
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Hspb3 and two transcription factors (Rcor2 and Zfp503) are part of pathways enriched 
within the network, which makes them the mechanistically most conceivable starting 
points. We compared expression data for these genes across multiple tissues and cell 
types by means of the BioGPS website (http://biogps.gnf.org) [299, 300]; Hspb3 showed 
high expression in heart and skeletal muscle, Rcor2 in mouse embryonic stem cell lines, 
and Zfp503 in multiple tissues. This is in agreement with their proposed biological role, 
although further study will be required to corroborate their mechanistic and functional 
importance.
In addition to mechanistic studies of stem cell differentiation, we expect the newly 
found genes to be potentially useful in applied test systems using ESC differentiation as 
a model to identify developmental-toxic properties of compounds, such as the Embry-
onic Stem cell Test (EST) [19]. The implementation of molecular biological approaches 
in such models may help to improve the prediction accuracy of the model [111, 177]. 
Furthermore, it may help in understanding the biology of the model, which is useful for 
the definition of its applicability domain. Thus, a further knowledge of genes involved 
in cardiomyocyte differentiation as well as their regulation can help to further optimize 
such test models for developmental toxicity.
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Summary of main findings
The EST is an in vitro testing model that has been developed for the prediction of devel-
opmental toxicity. Although the EST has shown promising results, the test has not yet 
been accepted as valid alternative assay for the evaluation of developmental toxicity. As 
outlined in chapter 1, we anticipated that the implementation of transcriptomics may 
improve the EST regarding culture duration, end point evaluation, applicability domain 
definition and predictive capacity. Within this thesis, multiple studies are described that 
contributed to optimization of the EST. The main findings of these investigations are 
summarized in Figure 1 and described below.
The experiments described in chapter 2 aimed at unraveling the intertwined rela-
tion of proliferation and differentiation in the EST protocol. Experiments showed that 
end points characteristic for cell viability and proliferation, including EB size, protein 
concentration and cell cycle distribution, were affected in cultures exposed during the 
first 3 days of the protocol to non-specific developmental toxicants (5-fluorouracil and 
5-bromo-2’-deoxyuridine), whereas the specific developmental toxicants (monobutyl 
phthalate (MBP) and 6-aminonicotinamide (6-AN)) did not affect these parameters. Fur-
thermore, it was shown that the earliest markers for development are detected around 
day 3. Together, these findings suggested that for improved assessment of compound-
induced effects on embryonic stem cells (ESC) differentiation as a measure for develop-
mental toxicity, compound exposure should begin following day 3 of culture.
In chapter 3, we further characterized the ESC differentiation process in the EST 
model via transcriptomic analysis of ESC differentiation cultures. The cultures were 
sampled 6, 12 and 24h after the onset of differentiation at day 3 and showed a clear 
induction of well-known developmental markers as a response of ESC differentiation. All 
genes identified to be induced in ESC differentiation in that study were combined in a 
gene set (‘Van_Dartel_heartdiff_24h’). For detection of subtle gene expression changes, 
additional analyses based on enrichment of gene sets were performed using gene set 
collections derived from databases and literature as well as the novel derived gene 
set ‘Van_Dartel_heartdiff_24h’. These analyses confirmed ESC differentiation by down-
regulation of pluripotency-related gene sets and concomitant up-regulation of devel-
opment-related gene sets. Furthermore, the novel gene set ‘Van_Dartel_heartdiff_24h’ 
showed significant overlap with other developmental-related gene sets, indicating 
that this set describes early ESC differentiation-related responses. In addition, gene 
expression regulation upon exposure to the developmental toxicant MBP was studied. 
Although the concentration of MBP effectively inhibited ESC differentiation as assessed 
via morphological evaluation, no individual genes were regulated by the treatment. 
However, gene set enrichment analysis showed that our novel gene set (‘Van_Dartel_
heartdiff_24h’) was significantly down-regulated, thereby showing direct evidence that 
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Figure 1. Summary of main findings.
Dorien BW v12.indd   204 12-05-11   14:08
Summary and general discussion 205
MBP modulated ESC differentiation. This finding was supported by increased expression 
of pluripotency-, proliferation-, and non-mesodermal differentiation-related gene sets.
In chapter 4, we studied the temporal gene expression regulation in ESC differen-
tiation cultures up to 96h after initiation of differentiation. Our analyses revealed both 
early, midterm and late responses during ESC differentiation that confirmed the behav-
ior of important processes known to be related to development. Down-regulation of 
genes related to pluripotency and proliferation were identified as early response, and 
up-regulation genes annotated to differentiation-related processes as late response. In 
addition, two transiently expressed genes clusters at 24 and 48h were identified. Only a 
few genes of these clusters have been annotated to developmental-related processes, 
but it was anticipated that these genes are associated to development. We showed that 
Principal Component Analysis (PCA), using the identified genes regulated during ESC 
differentiation, could be used to describe the route of ESC differentiation, named the 
‘differentiation track’. Furthermore, the ‘differentiation track’ showed to be a successful 
approach for identification of developmental toxicants in the EST protocol. The develop-
mental toxicants MBP and 6-AN deviated significantly from the time-matched controls 
on the defined differentiation track, which was in line with the developmental-toxic 
properties of the compounds.
The study described in chapter 5 confirmed the possibility to identify developmental 
toxicants via the ‘differentiation track’ approach. Using the obtained gene expression 
data, a minimum subset of genes was identified to define the differentiation track, 
which included 26 genes regulated both in ESC differentiation and by exposure to each 
of the developmental toxicants, named ‘EST biomarker genes’. The ‘differentiation track’ 
defined by the gene set ‘EST biomarker genes’ correctly identified the compounds that 
were under study. Moreover, leave-one-out cross-validation showed a favorable perfor-
mance of developmental toxicant identification using our gene set approach.
Identification of developmental toxicity using the EST and the gene sets identified 
in chapter 3 and 5, respectively ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’, 
was evaluated in chapter 6 by testing 12 additional compounds. The obtained accura-
cies were 83% (10/12) for the gene set ‘Van_Dartel_heartdiff_24h’ and 67% (8/12) for 
the gene set ‘EST biomarker genes’. Furthermore, it was shown that ESC differentiation 
inhibition, which is related to compound concentration, correlated with the significance 
‘differentiation track’ deviation. Based upon this finding, it was concluded that for correct 
prediction of developmental toxicity compound concentration appears an important 
factor.
The effect of compound concentration on gene expression regulation in ESC differ-
entiation cultures was subject of the study described in chapter 7. The developmental 
toxicant flusilazole was selected as test compound. This study confirmed that the 
significance of deviation of compound-exposed cultures of from the defined ‘differen-
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tiation track’ is concentration-dependent. Furthermore, gene expression profiling in 
flusilazole-exposed cultures showed alterations in developmentally related processes 
at all concentrations and preceded ESC differentiation inhibition. Effects of flusilazole 
exposure on cell-division-related processes were only detected at the highest concen-
tration. In addition, flusilazole’s pharmacological mode of action could be identified by 
the regulation of sterol-synthesis-related processes. Overall, gene expression regulation 
was identified with increasing magnitude and significance of response at increasing 
concentrations.
Furthermore, it was studied if gene expression profiling could be used to discriminate 
compound classes with distinct modes of action. In chapter 8, gene expression data of 
ESC differentiation cultures exposed to six compounds belonging to two classes, namely 
phthalates and triazoles, was evaluated. As a proof of principle, three different data 
analysis approaches demonstrated class-characteristic gene regulation that was useful 
for discrimination of phthalates and triazoles. Moreover, within the phthalate class, the 
gene expression profile of the non-developmentally toxic phthalate was dissimilar from 
that of the developmentally toxic phthalates, which indicates that toxicity ranking of 
compounds within a structural class may be possible.
Using available transcriptomic data of chapter 5, 6 and 7, a de novo analysis was per-
formed that identified a gene set that resulted in improved prediction of developmental 
toxicity as described in chapter 9. A large number of the genes within the novel gene 
set are involved in development and stem-cell-related processes, which illustrated the 
biological robustness of the set. Using cross-validation, it was confirmed that develop-
mental toxicity prediction using this gene set and the ‘differentiation track’ approach 
correlated better with the EST quantitative end point.
In chapter 10, a co-regulation network of ESC differentiation was constructed. To cre-
ate this network, jointly regulated genes were identified based on their co-occurrence in 
individual experimental gene sets previously described in literature. This co-regulation 
network showed two major sub-networks that correspond to early and late differentia-
tion processes stages, respectively. The early–late division was supported by overlaying 
gene expression data from our independent study on ESC differentiation time series 
described in chapter 4. Using the co-regulation network several genes not previously 
associated with the ESC differentiation process were revealed for which a putative novel 
biological function was assigned.
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General discussion
Studying differentiation modulation within the EST
A more detailed description of processes active during ESC differentiation contributes to 
improved definition of the relevance of the EST. In this regard, the intertwined relation 
of proliferation and differentiation in ESC differentiation has been extensively studied in 
chapter 2 to allow a more specific identification of compound-induced effects on ESC 
differentiation. This investigation showed that during ESC differentiation proliferation 
gradually decreases and concomitantly differentiation increases from day 3 onwards, 
thereby confirming previous findings [88, 89, 301]. Consequently, it has been suggested 
that when specific effects on differentiation are of interest, such as in the identification 
of potential developmental toxicants, compound exposure should perhaps more spe-
cifically be limited to the differentiation phase of the protocol. This study suggested that 
to optimally research specific effects of compounds on differentiation modulation, com-
pound exposure should begin following day 3 of culture. These findings are in contrast 
to the suggestion of the ECVAM/ReProTect report of Marx-stoelting et al that a simple 
ESC cytotoxicity test may be used to predict developmental toxicity, which was based 
upon an identified strong correlation between cytotoxicity and effects on ESC differ-
entiation [170]. Within that evaluation, assessment of specific developmental effects of 
compounds was based on data that applied the classical study design of the EST. Thus, 
ESC differentiation cultures were exposed throughout the complete ten days of the 
assay that includes the phase dominated by proliferation. Identification of compound 
induced effects on functional processes during ESC differentiation has been considered 
to provide more relevant information for reliable toxicity prediction than cytotoxicity 
data alone. Consequently, investigations that contribute to elucidation of functional 
processes within the EST are greatly welcomed. Modern genomic technologies meet 
this demand of providing a more detailed description of the biology of the model via 
the possibility to study responses on the whole genome level. Studies applying genomic 
technologies within the EST may contribute to successful implementation of the EST as 
an alternative testing method in regulatory toxicity testing.
Implementation of transcriptomics into the EST
First initiatives on the implementation of molecular techniques in the EST
The first studies that evaluated gene expression regulation as a consequence of com-
pound exposure in the EST were based on a selection of well-known developmental 
markers. The first study on compound-induced gene expression regulation in the EST fo-
cused on the cardiac markers Myh6 and Myh7 and showed that end point objectivation 
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of the EST could be obtained by performing gene expression analysis [30]. Later, Pellizer 
et al. focused on gene regulation of four selected markers that are involved in different 
stages of cardiomyocyte differentiation, Pou5f1, T, Nkx2-5, and Myh6 [31]. Exposure of 
the EST cultures to the test compounds lithium and retinoic acid resulted in dissimilar 
modulation of the dynamic gene expression of the selected genes, indicating the differ-
ential mechanism of developmental toxicity of these two compounds. These promising 
results have stimulated more research that aimed at predicting developmental toxicity 
in the EST using gene expression analysis.
Characterization of ESC differentiation using a transcriptomic approach Building upon 
these initial molecular-based studies examining a collection of markers representative 
of ESC differentiation, recent transcriptomic studies have provided a robust assessment 
of the dynamics of ESC differentiation. A part of these studies compared gene expression 
profiles of relatively late stages of differentiated cell cultures with pluripotent ESC [26, 
80, 144, 145, 302-304]. These studies confirmed that the expression pattern in the spe-
cialized cell types derived from ESC reflects the functional processes present in fetal cell 
types. However, the molecular pathways that govern early phase of ESC differentiation 
are incompletely understood, although recent studies, including our study described in 
chapter 4, have started to address this issue on the global molecular level [27, 177, 305-
307]. Together, these studies have shown that early ESC differentiation is characterized 
by a cascade of time-dependent early, midterm and late gene expression responses. The 
behavior of important processes known to be related to development have been identi-
fied in ESC differentiation cultures, such as down-regulation of pluripotency (including 
Nanog, Pou5f1 and Sox2) and proliferation (including Ccnb2, Ccnd1, Ccne1, Ccnh, Cdk2) 
as an early response, and up-regulation of differentiation (including Shh, Gata6, Sox17, 
Nestin) as a late response [177, 305, 306]. These and other genes were also present in 
multiple literature-derived gene sets that were used to describe ESC differentiation 
[111, 177], thereby suggesting their functioning in ESC differentiation. In addition, the 
co-occurrence of genes within these differentiation-related gene sets was used to create 
a co-regulation network in chapter 10 that included well-known pluripotency and dif-
ferentiation markers. This co-regulation network showed three sub-networks associated 
with either early or late responses in ESC differentiation, namely stem cell development, 
organ development and heart development. Furthermore, the transcriptomic stud-
ies that evaluated the gene expression responses in ESC differentiation also revealed 
transient midterm gene expression responses that included genes that were not yet 
annotated to developmental-related processes, but were co-expressed with well-known 
developmental markers [27, 28, 177, 307]. A similar observation has been described in 
chapter 3 in which a novel gene set was identified named ‘Van_Dartel_heartdiff_24h’ 
that comprises genes co-expressed with the well-known developmental markers T and 
Mesp1, but also included genes not previously associated with development. Other 
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studies have shown that genes co-expressed with known developmental markers may 
function in embryonic development since in situ hybridization studies detected expres-
sion of many of these transcripts in embryos [27, 135, 143]. These studies suggest that 
in vitro ESC differentiation monitoring by transcriptomics may effectively mimic gene 
expression in embryonic development and may be a useful model for studying devel-
opmental toxicity.
Identification of developmental toxicants via gene expression alterations in the EST
Our study described in chapter 3 as well as other studies have shown that gene expres-
sion responses in models of embryonic development upon toxicant exposure may be 
limited [111, 146, 177]. For that reason, array analysis tools that use data from multiple 
genes, such as pathway or gene set based analyses, have been applied for the identifica-
tion of developmental toxicant-induced effects in our subsequent analyses. Such meth-
ods have been shown to be more powerful than those based on effects of individual 
genes [111, 177, 308]. However, the interpretation of regulated gene sets is complex, 
especially when multiple transiently expressed gene sets are evaluated, such as in ESC 
differentiation modulation, because individual gene sets only describe a part of the 
process. To overcome this limitation, a method that allows for a continuous description 
of ESC differentiation should be applied.
In chapter 4, it was shown that the continuous developmental changes occurring 
in routine ESC differentiation can be reflected in a ‘differentiation track’ using principal 
component analysis (PCA). In a recent transcriptomic study of Sharov et al., a similar 
approach was used to describe embryonic development [153]. The expression profiles 
of almost 3000 genes of mouse stem cells and early embryos were used in a PCA and 
resulted in the identification of developmental timing of the samples. Later, Fang et al. 
showed that this concept is also successful in describing the development of human 
embryos during the first third of organogenesis [232]. Besides the use of this approach 
to visualize and quantify the differentiation status and developmental potency status 
of cells, this concept is also valuable to identify differentiation modulation by develop-
mental toxicants, using the significance of ‘differentiation track’ deviation as a measure 
for developmental toxicity [111, 214].
Initially, in chapter 4, the ‘differentiation track’ in the EST was described using a large 
set of genes that were regulated in ESC differentiation, which showed the possibility 
for identification of developmental toxicants. However, to allow for future robust in-
expensive assay development, a further reduction of the number of genes needed to 
describe the ‘differentiation track’ was desirable. Besides the identification of the gene 
set ‘Van_Dartel_heartdiff_24h’ in chapter 3 that includes 38 genes regulated in early 
ESC differentiation, the gene set ‘EST biomarker genes’ was identified in chapter 5 that 
includes 26 genes responsive to ESC differentiation which, in addition, were regulated 
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by developmental toxicant exposure. We showed in chapter 5 and chapter 6 that both 
gene sets could successfully be applied to define the differentiation track.
The duration of compound exposure at sampling appeared to be an important factor 
for successful identification of developmental toxicants as shown in chapter 4. Increased 
variation at later stages of differentiation together with a less dynamic gene expression 
profile hampers identification of developmental toxicants at later differentiation stages. 
On the other hand, the identification of differentiation modulation at relatively early 
stages of differentiation may be hindered due to limited differentiation progression in 
the samples isolated early as was observed in chapter 3. Overall, our studies showed 
that sampling 24h after initiation of compound exposure was a good starting point for 
studying differentiation modulation in the EST.
Within chapter 3 and chapter 5 it was shown that initial evaluation of develop-
mental toxicity identification showed promising results for both gene sets. However, 
to ensure confident decision-making, any new predictive test needs to be validated by 
testing the performance of toxicant identification using a set of additional compounds. 
Chapter 6 described the validation of the EST in combination with the ‘differentiation 
track’ using the ‘Van_Dartel_heartdiff_24h’ and ‘EST biomarker genes’ gene set. This 
validation was performed using gene expression data of 12 and 18 test compounds, 
respectively, tested at single concentrations. The accuracy values obtained were 83% for 
the ‘Van_Dartel_heartdiff_24h’ gene set and 68% for the ‘EST biomarker genes’. Later, by 
integrating available EST-transcriptomic data as described in chapter 9, a new analysis 
identified a gene set that successfully described ESC differentiation and allowed for 
further improvement of developmental toxicity prediction. Evaluating the performance 
of this gene set in combination with the ‘differentiation track’ approach showed that the 
developmental toxic properties of all 15 compounds that met the inclusion criteria were 
correctly predicted, which resulted in an overall accuracy of 100% for these compounds. 
In perspective of the 78% accuracy of the validated EST in which compounds were 
tested in concentration-response design [19], these results are very promising. However, 
evaluation of additional developmentally toxic compounds, and especially also negative 
controls, is of importance to confirm the successful performance of the differentiation 
track-based EST using the novel identified gene set.
Gene expression regulation associates with compound concentration
Several studies have shown that compound concentration dependent assessment of 
gene expression is of great importance for the identification of toxic properties [75, 190]. 
In a series of transcriptomic studies of Naciff et al., gene expression changes on indi-
vidual genes showed clear concentration-related induction of fold change and number 
of regulated genes [49, 50, 212]. This finding was confirmed by the studies of Robinson 
et al. who evaluated gene responses in embryos exposed to metals [213, 251]. Addition-
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ally, in chapter 6 the interdependence of morphological effect size and the extent of 
gene expression changes was shown within the EST. In chapter 7, we described a com-
prehensive study that evaluated the concentration-related gene expression regulation 
of the teratogen flusilazole within the EST confirmed that gene expression regulation 
was identified with increasing magnitude and significance of response at increasing 
concentrations [235]. Using the ‘differentiation track’ approach, the flusilazole-exposed 
samples showed a concentration-related pattern of deviation from the differentiation 
track. Furthermore, within this study, functional analyses revealed three major themes 
affected by flusilazole exposure, namely development, lipid metabolism and cell divi-
sion. The enrichment of the functional processes related to lipid metabolism and cell 
division confirmed flusilazole’s mode of action and cytotoxic effects, respectively. How-
ever, developmental-related processes appeared most sensitive to flusilazole exposure 
and were identified in the absence of ESC differentiation inhibition as determined by 
morphological evaluation. Together, these findings indicate that a compound-induced 
gene expression response is concentration-related in terms of fold change, significance 
and affected functional processes. In addition, gene expression responses may be more 
sensitive than and precede morphological effects. Thus for prediction of potential devel-
opmental toxicity using the EST, compound concentrations should be carefully selected. 
We suggest that compounds should be tested below the range of cytotoxicity, because 
this allows comparison of the relative sensitivity of ESC differentiation modulation as 
compared to cytotoxicity. For example, a concentration that results in 80% cell viability 
can be selected as highest concentration and subsequent concentrations being a fixed 
fraction of the highest concentration.
The possibility to identify compound induced responses with greater sensitivity us-
ing gene expression profiling asks for a definition when to consider gene expression 
responses as adaptive or adverse. Identification of regulation of a functional process 
does not necessarily represent an adverse biological response. Consequently, it is not 
easy to establish adversity of a compound-induced response. In a recent review by 
Kienhuis et al. on the application of toxicogenomics for risk assessment, it was stated 
that at present changes in traditional toxicology parameters are leading when decid-
ing whether a cellular response reflect adaptive or adverse effects [309]. An important 
challenge in the use of toxicogenomics for hazard characterization will be the develop-
ment of concentration-response modeling tools to determine adversity of the observed 
compound-induced effect [192].
Furthermore, concentration-response modeling may be used for relative potency 
ranking of developmental toxicants within the EST, which may ultimately replace the 
commonly used stratified prediction of developmental toxicity in many in vitro models. 
The use of relative potency ranking has been described previously for evaluation of 
relative toxic properties of dioxin-like compounds [310]. An initial study of Peters et 
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al. showed promising results of the application of potency ranking of developmental 
toxicants using the EST [311]. Later, de Jong et al showed that relative potency of a 
series of homologous compounds, glycol ether alkoxy acid metabolites and valproic 
acid analogues, tested within the EST, matched in vivo ranking [196, 312]. In addition, 
developmental toxicity potency ranking may be applied using toxicogenomic data. 
For example, within the EST, the significance of ‘differentiation track’ modulation may 
allow ranking for developmental toxic properties of compounds. However, evaluation of 
concentration-related gene expression responses of additional compounds with vary-
ing developmental toxic potency needs to be studied to confirm the application of the 
‘differentiation track’ for this ranking approach.
Interspecies- and in vitro to in vivo extrapolation
At present the EST is based on a mouse ESC line. It has been demonstrated that interspe-
cies variation may be a problem for assessing developmental toxicity in vivo [313]. The 
use of hESC [314] in an equivalent of the murine EST would give added value to the 
safety assessment of compounds, since the data obtained would be more directly ap-
plicable to human hazard assessment. Until now, significant limitations that have been 
associated with hESC cultures regarding maintenance of pluripotency, differentiation 
ability and handling time hindered the use of hESC. Fortunately, recent studies have 
obtained promising advancements regarding these aspects that will facilitate the use of 
hESC in the EST [315]. First steps in establishing a developmental toxicity test method 
based on hESC have already been taken [16, 17] and will eventually make interspecies 
extrapolation redundant.
Extrapolating in vitro concentrations to the in vivo situation will always be a crucial 
aspect for all alternative testing models [316]. Within pharmaceutical industry, the use 
of in vitro to in vivo extrapolation modeling has been widely employed to assess the 
kinetics of drug candidates [317]. Also within alternative models for assessment of 
developmental toxicity physiologically based kinetics models have been developed. 
Recent studies indicate that these kinetic considerations may improve the extrapolation 
of in vitro results to the in vivo situation and increase the predictive value of in vitro tests 
[118, 318]. These evaluations are indispensible for the application of in vitro toxicity data 
for risk characterization.
Application of computational approaches to further improve the EST
Prediction of developmental toxicity may be further improved by using in silico 
computational approaches both from the biological and the chemical perspective. 
Computational models, such as bioinformatics, data-mining, text-mining and modeling 
endeavors, may cope with the increasing quantity and quality of biologic information 
of genomic studies [271, 273, 319, 320]. Computational approaches are particularly 
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useful for systems biology in understanding biological networks under normal condi-
tions, which can subsequently be useful to study the behavior of networks within such 
models after compound exposure. In addition, computational models can be used for 
detailed characterization of chemical properties, which may provide insight into factors 
such as placental transfer and identification of compounds with similar biologic activ-
ity. These advantages contribute to the shift of in vivo to cell-based models to study 
toxicant-induced responses on the pathway level. Therefore, the application of compu-
tational approaches in predictive toxicology is among the objectives of the U.S. National 
Research Council (NRC) report on toxicity testing in the 21st century [192]. In addition, 
the US Environmental Protection Agency (EPA) ToxCast program promotes the use of 
computational approaches to develop models that use data of 467 in vitro assays for 
prediction of compound-induced toxicity in humans.
Meta-analysis in bioinformatics has contributed to identification of putative novel 
biological function of genes in diverse research areas [267, 271, 273]. In chapter 10, 
a meta-analysis using published gene lists derived from 42 transcriptomic studies was 
performed that described gene expression regulation in ESC or embryonic develop-
ment. This analysis revealed 43 genes that were not previously associated with ESC 
differentiation but that were co-regulated with established ESC differentiation markers 
in a network based on individual experimental gene sets. Such integrative analyses 
reveal putative novel gene function that might not have been discovered without bio-
informatics resources. This information may lead to improved gene function annotation 
that may allow enhanced data interpretation [177, 233] and may aid in description of 
functional pathways, ultimately leading to improved prediction of developmental toxic-
ity. This example clearly indicates the added value of integrated data set analyses of 
comprehensive large scale collections of both biological and chemical data to support 
concept-based modeling and statistical computations.
Due to the fact that developmental toxicants are structurally diverse and may have 
widely distinct activity features [321], the use of one single gene set trained on a fraction 
of well-documented developmental toxicants may not be capable of identifying devel-
opmental toxicants of previously untested compound classes. It has been suggested 
that a category approach would overcome this difficulty [254, 322]. This approach is 
supported by the recent finding that toxicogenomic responses of four teratogens in 
the whole embryo culture model had limited overlap [55]. The overlap of regulated 
genes by compounds within a category may be more pronounced and these genes may 
subsequently result in improved predictive power for additional compounds within the 
category, albeit that this represents a relatively narrow chemical domain of applicabil-
ity. Furthermore, class-specific gene sets may allow toxicity ranking within compound 
classes as well as discrimination between compounds with diverse modes of action. As 
an example, in chapter 8, the categorization of phthalates and triazoles has been shown 
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within the EST, using gene sets characteristic for the class-specific differentiation modu-
lation. Using three different informatics approaches the distinct gene expression regula-
tion between compounds of the two different classes was evident. Moreover, within the 
phthalate class, the gene expression of the non-developmentally toxic phthalate was 
dissimilar from that of the developmentally toxic phthalates, which shows that toxicity 
ranking of compounds within a structural class may be possible.
The successful use of computational toxicology has been shown in a study of Green et al. 
that delineated a biological regulatory network regulated in mouse embryonic headfold 
by ethanol exposure [323]. Another promising example of integration of bioinformatics 
approaches to understand embryonic development at the systems level and prediction 
of developmental toxicity is the virtual embryo model that is under development at the 
US EPA [324]. The first goals of this virtual embryo project are to create a knowledge 
base and simulation engine that enable in silico reconstruction of key developmental 
landmarks. Next, critical effects of compound exposure on these networks are simulated 
and used for developmental toxicity prediction [325]. Such innovative developments in 
the field of computational toxicology will provide a wealth of additional information that 
will optimize the application of in vitro methods in developmental toxicity assessment.
When successful biomarker signatures are identified, gene expression evaluation can 
eventually be performed using customized gene chips, which will reduce experimental 
costs. In addition, quick experimental designs, such as the 96-well format EST [326], 
will contribute to enabling faster screening of series of compounds using the EST. Fur-
thermore, wet-lab procedures can be automated, such as RNA isolation, amplification, 
labeling and hybridization and efficient (semi-) automated data analysis can be used to 
analyze data and flag potential developmental toxicants [327]. Altogether, these techni-
cal advances together with the application of transcriptomic in the EST may move the 
EST forward to a predictive model with high-throughput.
Regulatory implementation of the EST
After the introduction in 1997 of the EST as an alternative model for assessing devel-
opmental toxicity, over 65 studies have been published that aimed at characterizing 
or improving the predictive capacity of the EST. Despite these efforts, the EST has still 
not reached regulatory acceptance at present. Part of this situation may be explained 
by unrealistically high expectations about the assay [328]. It should be realized that no 
single in vitro method, even if combined with other tests in a battery approach, will com-
pletely correctly predict the developmental toxicity of compounds, simply because each 
of these methods represents reductionistic models of the complete pregnant human in 
all its stages of pregnancy [254], and the entire reproductive cycle is more than a sum of 
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individual mechanisms represented in in vitro tests. For this reason, a full replacement 
of in vivo testing strategies by in vitro alternatives is not possible. On the other hand, if 
crucial mechanisms and end points could be mimicked in well-established in vitro as-
says and batteries, their use could preclude in vivo testing of compounds emerging as 
developmental toxicants in vitro, and overall substantially reduce animal testing.
Several critical factors have hampered EST implementation in regulatory toxicology, 
including kinetics and interspecies extrapolation, as discussed in the previous section. 
However, the major issues with respect to implementation of the EST are related to the 
establishment of its applicability domain and predictive capacity.
Applicability domain
The applicability domain of an alternative test has been defined by Hartung et al. [23] 
as consisting of two essential components. First, the biological mechanism(s) and end 
point(s) incorporated in the test need to be defined to assess what types of effects it can 
detect. Compounds that only affect mechanisms and end points outside the applicability 
domain will be scored as false negatives in the test. The EST has been advocated to detect 
developmental toxicants in general [19]. This is an optimistically wide definition given 
that the test is restricted to scoring effects on the number of spontaneously contracting 
cardiomyocyte foci that have differentiated from embryonic stem cells in culture. A more 
limited definition of applicability domain would probably be realistic, which may range 
from relatively simple embryonic stem cell proliferation inhibition via cardiomyocyte 
differentiation inhibition to a wider spectrum of embryonic cell differentiation. The lat-
ter is based on the notion that cardiomyocytes derive from the mesodermal germ layer 
that is formed by induction between ectoderm and endoderm. Since derivatives of each 
of the germ layers have been detected in EST cultures [329] it is clear that cardiomyocyte 
foci counts give only a limited end point of the complexity of differentiation present in 
EST. With the introduction of omic techniques, developmental toxicology has gained a 
wealth of innovative tools that allow a more detailed description of the biological end 
points of the EST as described in this thesis. We have shown that transcriptomic studies 
have already contributed to improved knowledge about the biological processes active 
during ESC differentiation. In addition, first initiatives using proteomics have shown 
the proof of principle that developmental toxicants can be detected via altered protein 
profiles [219, 256]. Furthermore, comparison of developmental stage-specific functional 
processes between embryogenesis in vivo and the EST protocol will characterize the de-
velopmental window of EST both in terms of timing as well as developmental pathways 
covered by this model [330]. The second component of applicability domain as defined 
by Hartung et al. [23] refers to the chemical domain for which the test can be employed. 
In the past, validation studies designed to define performance of EST using a group of 
diverse chemicals in terms of molecular structure and biological mechanism have given 
Dorien BW v12.indd   215 12-05-11   14:08
216 Chapter 11
false hopes as to the general performance of the test for the universe of chemicals [21, 
22]. Category approaches may constitute a more promising approach for defining the 
chemical applicability domain of EST. This class-specific toxicity evaluation has shown 
successful results for retinoids in the limb bud micromass [331] and for glycol ether 
alkoxy acid metabolites and valproic acid analogues in the EST [196, 312]. Moreover, 
these studies showed that the potency ranking of compounds within a class could suc-
cessfully be extrapolated between EST and the in vivo situation, in some cases aided by 
kinetic extrapolation methods. This approach could provide more accurate predictions 
regarding developmental toxicity in vivo and may be particularly useful for prioritization 
by prescreening of compounds within classes under development in industry.
Predictability
The predictability of an assay is generally defined as the performance of the assay de-
termined by the percentages of correct positive and negative outcomes within a series 
of compounds tested [332]. The ECVAM interlaboratory validation study of the EST 
showed that 78% of 160 experiments, corresponding to 20 compounds, resulted in cor-
rect predictions in predefined classes of non, weak and strong developmental toxicants 
[19]. Furthermore, these compounds had widely diverse physicochemical properties, 
which suggested that the observed predictability would hold with testing additional 
compounds. Paquette et al. subsequently evaluated the accuracy of the EST for in-house 
and marketed pharmaceuticals, and showed that, although compounds with receptor-
mediated mechanisms were excluded from the validation set, the overall accuracy for 
marketed pharmaceuticals was 85% [22]. However, for in-house compounds, the overall 
accuracy was only 53%, mainly due to bad separation of non from weak developmentally 
toxic pharmaceuticals. An additional validation study of 14 compounds showed a very 
low (4/13) predictability [170]. Thus, these validation studies left considerable remaining 
uncertainty as to the general predictability of EST. The above efforts in defining predict-
ability as reviewed here have suffered from both the absence of a prior definition of the 
biological domain of EST, as well as from the variety of chemical domains to which the 
validation test chemicals belonged. In addition, validation was done based on a math-
ematical prediction model that placed each compound in one of three categories (non, 
weak, strong developmental toxicants) [197]. The prediction model was derived from 
the results of a limited set of six compounds, and did not take account of the biological 
domain of the test. Furthermore, categorical designations of toxicities as used in that 
study are subjective given that toxic potency is a continuum and thresholds between 
categories are therefore artificial. We believe that with an appropriate description of 
applicability domain in terms of its biological and chemical boundaries as discussed 
above, validation studies such as those done in the past may become superfluous. As an 
example, an estrogen binding assay has a well described biological domain, and testing 
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a limited set of estrogens and non-estrogens suffices for showing that the test is robust 
[333, 334]. Therefore, predictability depends largely on the definition of the applicability 
domain. Transcriptomic studies have already shown promising results in determining 
the predictive capacity of the EST [214, 335]. These studies used gene sets within the 
biological domain of the differentiation processes present in the assay [214, 335]. Fur-
ther studies will need to expand this line of research in order to improve predictability 
on the basis of a well-defined applicability domain.
Current and future application of the EST
For successful regulatory acceptance of the EST, mechanistic validation of the assay is 
of prime importance. For this, the domain of applicability in terms of developmental 
pathways needs further elucidation. A detailed definition of active processes within 
the culture system will allow definition of the biological pathways and stage of embry-
onic development covered by the model and subsequently may result in reliable iden-
tification of developmental toxicants affecting that component of development. Other 
models, such as those based on differentiation of ESC into other lineages [15, 336], can 
further complement to the domain of applicability of the EST.
One further way forward in the prediction of developmental toxicity using alterna-
tive testing methods is the battery approach [3]. A battery of alternative models, each 
covering a specific aspect of reproduction or development, in combination may cover 
large parts of the reproductive cycle, and may improve the detection of reproductive 
toxicants. In a recent study performed within the 6th European Framework Program 
Project ReProTect, a ring trial was conducted in which the adverse effects on reproduc-
tion and development of ten blinded reproductive toxicants were correctly predicted 
using a test battery of 14 in vitro assays [337]. This study showed a proof of principle 
that a battery approach can be successful in predicting effects on fertility and embry-
onic development. However, it must be noted that the compounds tested were specific 
strong developmental toxicants and therefore not a realistic reflection of the universe 
of chemicals.
In future, the battery approach may be used in a test strategy to predict developmen-
tal toxicity of unknown compounds, so that compounds with clear adverse effects on 
one of the end points do not need further in vivo testing. In addition, more adequate 
testing strategies based on in vitro assays combined with computational modeling may 
provide detailed information of compound toxicity and may provide mechanistic in-
sights into the compound’s mode of action. This information can subsequently be used 
for prioritization for more in-depth testing, thereby contributing to reduction of experi-
mental animal use. Genomic technologies have the advantages that toxic responses can 
be studied on the biological pathway level and for this reason may provide a useful 
approach in modern toxicity prediction.
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Within this review, the progress that has been made in implementing transcriptomics 
in the EST have been summarized and additional aspects that need improvement to 
allow a successful use of the EST for hazard identification in regulatory settings are dis-
cussed. At present, the EST has its application primarily in in-house hazard identification. 
To reach regulatory implementation, definition of biological and chemical applicability 
domain are essential. Additional mechanistic studies such as those utilizing genomic 
tools are needed that allow further characterization of developmental pathways in the 
EST protocol. In addition, a comprehensive comparison of the developmental processes 
active in ESC differentiation with in vivo embryogenesis will allow more precise defini-
tion of the developmental pathways and developmental timing covered by the EST. 
Finally, a detailed definition of the applicability domain of the EST is expected to result 
in reliable predictability of the EST for the developmental phase covered.
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Inleiding
In de toxicologie, de leer van giftige stoffen, worden erg veel proefdieren gebruikt om 
de schadelijkheid van stoffen te voorspellen. Voornamelijk binnen de reproductie- en 
ontwikkelingstoxicologie worden grote aantallen proefdieren gebruikt, omdat voor 
deze studies vaak meerdere generaties nodig zijn. Er is grote behoefte aan alternatieve 
methoden voor het voorspellen van toxiciteit, omdat de huidige manier van onderzoek 
met behulp van proefdieren ethisch ongewenst is. Bovendien biedt de huidige methode 
voor toxiciteit voorspelling niet de capaciteit om de toxiciteit van de vele duizenden 
stoffen met onvolledig toxiciteitsprofiel te evalueren.
Een veelbelovende alternatieve testmethode voor het voorspellen van schadelijkheid 
van een stof voor de embryonale ontwikkeling (embryotoxiciteit) is een model dat 
gebaseerd is op differentiatie van embryonale stamcellen (ESC) naar hartspiercellen, 
de Embryonale Stamcel Test (EST). Verstoring in het proces van embryonale stamceldif-
ferentiatie ten gevolge van blootstelling aan een stof kan gebruikt worden als maat voor 
embryotoxiciteit. De remming van de hartspierdifferentiatie kan beoordeeld worden 
onder de microscoop. Een nadeel van deze manier van beoordelen is dat deze subjec-
tief en tijdrovend is. Het doel van dit onderzoek was te bestuderen of een betrouwbare 
voorspelling voor embryotoxiciteit gedaan kan worden met behulp van de EST in com-
binatie met transcriptomics. Transcriptomics is een relatief nieuwe techniek waarmee 
de expressie van wel 20.000 genen in één keer gemeten kan worden. Met deze techniek 
kunnen veranderingen in genexpressie patronen in blootgestelde differentiërende 
cellen geïdentificeerd worden. Deze informatie kan vervolgens gebruikt worden voor 
voorspelling van embryotoxiciteit. De EST in combinatie met transcriptomics zal naar 
verwachting leiden tot een snellere, goedkopere en meer specifieke proefdiervrije test 
voor voorspelling van embryotoxiciteit.
Samenvatting
De eerste studie die uitgevoerd is in het kader van dit proefschrift is beschreven in 
hoofdstuk 2. Het doel van deze experimenten is om de relatie tussen proliferatie en 
differentiatie in het protocol van de EST op te helderen. Experimenten lieten zien dat 
celoverleving en proliferatie waren aangetast in celkweken die gedurende de eerste drie 
dagen van het protocol waren blootgesteld aan aspecifiek werkende embryotoxische 
stoffen (5-fluorouracil en 5-bromo-2’-deoxyuridine), terwijl specifiek werkende embry-
otoxische stoffen (monobutyl phthalaat (MBP) en 6-aminonicotinamide (6-AN)) deze 
parameters niet beïnvloedden. Een ander experiment toonde aan dat markers voor een 
vroeg stadium van ontwikkeling gedetecteerd werden rond dag 3. Samen wijzen deze 
Dorien BW v12.indd   223 12-05-11   14:08
224
bevindingen erop dat voor een verbeterde bepaling van effecten van stoffen op ESC 
differentiatie de blootstelling het beste kan starten vanaf dag 3 van de EST.
In hoofdstuk 3 was het ESC differentiatie proces in de EST in meer detail gekarakteri-
seerd met behulp van transcriptomics. De monsters, genomen 6, 12 en 24 uur na initiatie 
van differentiatie op dag 3, lieten een duidelijke inductie zien van bekende markers voor 
ontwikkeling. Dit bevestigde differentiatie van de cellen in de kweken. Alle genen die 
verhoogd tot expressie kwamen tijdens het differentiatie proces werden samengevoegd 
in een genenset (‘Van_Dartel_heartdiff_24h’). Voor detectie van subtiele genexpressie 
veranderingen werden additionele analyses uitgevoerd gebaseerd op verrijking van 
genensets. Hiervoor werden genenset collecties gebruikt die verkregen zijn uit databa-
ses en literatuur, maar ook de nieuw beschreven genenset ‘Van_Dartel_heartdiff_24h’ 
werd gebruikt. Deze analyses bevestigden ESC differentiatie in de controle kweken 
door suppressie van genensets gerelateerd aan pluripotentie en een samengaande 
verhoogde expressie van genensets gerelateerd aan ontwikkeling. Bovendien was er 
een grote overlap tussen de nieuwe genenset ‘Van_Dartel_heartdiff_24h’ en andere 
ontwikkeling gerelateerde genensets. Dit bevestigde dat de nieuwe genenset ‘Van_Dar-
tel_heartdiff_24h’ de vroege ESC differentiatie beschrijft. Tevens was in deze studie de 
genexpressie verandering ten gevolge van blootstelling aan de embryotoxische stof 
MBP bestudeerd. Ondanks dat morfologische evaluatie bevestigde dat de geteste con-
centratie de ESC differentiatie remde, werd geen enkel gen significant gereguleerd door 
de blootstelling. Echter, een analyse gebaseerd op verrijking van genensets liet zien dat 
de expressie van onze nieuwe genenset ‘Van_Dartel_heartdiff_24h’ significant verlaagd 
was. Deze vinding toonde direct bewijs dat MBP de ESC differentiatie moduleert. Dit 
resultaat werd verder ondersteunt door verhoogde expressie van pluripotentie-, proli-
feratie-, en non-mesodermale differentiatie gerelateerde genensets.
De genexpressie regulatie in ESC differentiatie in de tijd werd bestudeerd in hoofd-
stuk 4. De analyses onthulden zowel vroege, als middel en late genexpressie regulatie 
tijdens ESC differentiatie. Deze resultaten bevestigden het gedrag van bekende proces-
sen die gerelateerd zijn aan ontwikkeling; als vroege respons werd de expressie van 
genen gerelateerd aan pluripotentie en proliferatie verlaagd en als late respons werd de 
expressie van genen gerelateerd aan differentiatie verhoogd. Tevens werden ook twee 
clusters geïdentificeerd met een tijdelijke expressie op 24 en 48 uur. Het is aannemelijk 
dat de genen in deze twee genen clusters een rol spelen in ontwikkeling, toch is dit 
voor slechts een klein deel van deze genen bekend. We hebben laten zien dat Principal 
Component Analyse (PCA), gebruik makende van de genen die gereguleerd werden 
tijdens ESC differentiatie, gebruikt kon worden om het traject van ESC differentiatie te 
beschrijven. Dit traject werd de ‘differentiation track’ genoemd. De ‘differentiation track’ 
was een nuttige benadering om embryotoxische stoffen te identificeren. De stoffen MBP 
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en 6-AN weken significant af van de differentiation track, dit was in overeenstemming 
met de embryotoxische eigenschappen van deze stoffen.
De studie beschreven in hoofdstuk 5 bevestigde de mogelijkheid om embryo-
toxische stoffen te identificeren met behulp van de ‘differentiation track’ benadering. 
Vervolgens werd een kleine set bestaande uit 26 genen geïdentificeerd in deze studie. 
Deze 26 genen werden zowel in ESC differentiatie als door blootstelling aan embryo-
toxische stoffen gereguleerd. Samen vormden deze genen de set ‘EST biomarker genes’. 
De stoffen die geselecteerd waren in deze studie werden correct geïdentificeerd via de 
‘differentiation track’ benadering gebaseerd op de ‘EST biomarker genes’. Bovendien 
toonde cross validatie aan dat deze bevindingen erg robuust waren.
Identificatie van embryotoxische stoffen met behulp van de EST en de genensets 
beschreven in hoofdstuk 3 en 5, respectievelijk ‘Van_Dartel_heartdiff_24h’ en ‘EST bio-
marker genes’ was geëvalueerd in hoofdstuk 6 door het testen van 12 extra stoffen. De 
genenset ‘Van_Dartel_heartdiff_24h’ voorspelde 83% (10/12) van de stoffen goed. De 
goed voorspellende waarde was 67% (8/12) voor de genenset ‘EST biomarker genes’. 
Tevens werd aangetoond dat de remming van ESC differentiatie, wat gerelateerd is 
aan de concentratie van de stof, correleerde met de significantie van afwijking van de 
‘differentiation track’. Vanwege deze bevinding concludeerden we dat voor een juiste 
voorspelling van embryotoxiciteit de concentratie van de stof een grote rol speelt.
Het effect van concentratie op genexpressie regulatie in ESC differentiatie kweken 
was het onderwerp van de studie beschreven in hoofdstuk 7. De embryotoxische stof 
flusilazole werd geselecteerd als teststof. Deze studie bevestigde dat de significantie 
van afwijking van blootgestelde kweken van de ‘differentiation track’ afhankelijk is van 
de concentratie. Tevens liet deze studie zien dat effecten op processen gerelateerd aan 
ontwikkeling gedetecteerd werden bij alle geteste concentraties van flusilazole, zelfs 
nog voordat er remming van ESC differentiatie op het morfologisch eindpunt gevonden 
was. Bij de hoogst geteste concentratie werd een verstorend effect op celdeling gere-
lateerde processen gevonden. Tevens kon het farmacologische werkingsmechanisme 
van flusilazole, namelijk verstoring van sterol biosynthese, geïdentificeerd worden op 
genexpressie niveau. Onze data liet zien dat tengevolge van oplopende concentraties 
de genexpressie regulatie duidelijker te detecteren was door significantere expressie en 
sterkere regulatie van genen.
De mogelijkheid om verschillende klassen van stoffen met verschillende werkingsme-
chanismen te onderscheiden, met behulp van transcriptomic analyses, is beschreven in 
hoofdstuk 8. Voor deze studie is genexpressie data van zes verschillende stoffen beho-
rend tot twee stof klassen gebruikt, namelijk phthalaten en triazolen. Drie verschillende 
data analyse methoden toonden aan dat de karakteristieke genexpressie regulatie per 
klasse gebruikt kon worden om phthalaten en triazolen te discrimineren. Bovendien 
lieten onze analyses zien dat de niet embryotoxische phthalaat een ander genexpressie 
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profiel opleverde dan de embryotoxische phthalaten. Dit wijst er op dat toxiciteits-
ranking van stoffen binnen een klasse mogelijk zou kunnen zijn.
Een nieuwe analyse met de transcriptomic data van hoofdstuk 5, 6 en 7 werd uit-
gevoerd en beschreven in hoofdstuk 9. Deze analyse resulteerde in de identificatie 
van een genenset die een verbeterde voorspelling voor embryotoxiciteit liet zien. Het 
merendeel van de genen was gerelateerd aan processen die karakteristiek zijn voor 
ontwikkeling en stamcellen, wat de biologische robuustheid van de set illustreerde. 
Door middel van cross validatie bevestigde deze studie dat de voorspelling van embry-
otoxiciteit met deze genenset en de ‘differentiation track’ benadering een verbeterde 
correlatie opleverde met het kwantitatieve eindpunt van de EST.
In hoofdstuk 10 werd een co-regulatie netwerk geconstrueerd door identificatie van 
genen die gezamenlijk tot expressie komen. Genensets die eerder werden beschreven 
in de literatuur werden gebruikt om het netwerk te maken. Hierin waren twee grote 
subnetwerken aanwezig, waarvan er één overeenkwam met processen die actief zijn 
tijdens een vroeg stadium van differentiatie en het andere kwam overeen met proces-
sen die actief zijn tijdens late stadia van differentiatie. Deze scheiding van vroege en late 
differentiatie werd ondersteund door de genexpressie data van onze onafhankelijke stu-
die, beschreven in hoofdstuk 4, te koppelen aan het netwerk. Het co-regulatie netwerk 
bevatte verschillende genen die niet eerder geassocieerd waren met ESC differentiatie, 
maar waaraan een vermoedelijk nieuwe biologische functie is toegeschreven.
Conclusie
Uit de resultaten van dit proefschrift kan worden geconcludeerd dat embryotoxiciteit 
objectiever kan worden vastgesteld met de transcriptomics gebaseerde EST vergeleken 
met de ‘klassieke’ EST waar morfologische evaluatie een van de eindpunten is. Transcrip-
tomics is een gevoeligere methode om de verstoring van ESC differentiatie te detecte-
ren. Hierdoor is het mogelijk modulatie van ESC differentiatie al kort na aanvang van 
de blootstelling aan te tonen. Het gebruik van een genenset, die de dynamische fase 
van ESC differentiatie beschrijft, in combinatie met de beschreven ‘differentiation track’ 
methode heeft aangetoond een veelbelovende benadering te zijn om de verstoring op 
ESC differentiatie te detecteren. Het detecteren van embryotoxische verbindingen is 
echter afhankelijk van de gekozen test-concentratie.
Op dit moment wordt de EST voornamelijk gebruikt voor identificatie van toxiciteit. 
Om de test geschikt te maken voor risicobeoordeling is een uitgebreidere definitie van 
het toepassingsdomein en de voorspellende capaciteit van de test essentieel. In het 
bijzonder mechanistische validatie is een zeer belangrijk aandachtspunt. Hiervoor moet 
het toepassingsdomein van de EST met betrekking tot de ontwikkelings pathways die 
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aanwezig zijn in de EST nader opgehelderd worden. Een gedetailleerde definitie van 
deze actieve processen in de EST zal bijdragen aan een definitie van de biologische 
pathways en het stadium van embryonale ontwikkeling dat gedekt wordt door de EST. 
Deze informatie zal uiteindelijk leiden tot betrouwbare identificatie van embryotoxische 
stoffen die dat specifieke stadium van ontwikkeling beïnvloeden.
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Chapter 3, Figure 3. Clustering of differentially expressed genes after 24h of suspension culture. Cells 
were exposed for 6, 12 or 24h to monobutyl phthalate (MBP) or solvent control (CON). Per group the 
mean regulation of 7-8 replicates is shown. Gene expression changes are indicated by the color bar, where 
green represents down-regulation and red up-regulation. 
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Chapter 3, Figure 4. Molecular concept analysis of regulated gene sets in differentiation. Per set the top 
20% highest affected genes were used. The size of the gene set corresponds with the size of the node, and 
the boldness of the connecting lines indicates the degree of overlap between the respective gene sets.
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Chapter 3, Figure 5. Molecular concept analysis of regulated gene sets in monobutyl phthalate exposed 
differentiation cultures. Per set the top 20% highest affected genes were used. The size of the gene set 
corresponds with the size of the node, and the boldness of the connecting lines indicates the degree of 
overlap between the respective gene sets. 
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Chapter 4, Figure 2. Heatmap of all 1355 significantly regulated genes (fold ratio >1.5 and p<0.001) 
transcriptionally responsive to cardiac differentiation. Each row represents the relative expression of a 
single gene throughout the differentiation. Seven clusters are discriminated based on temporal gene 
expression of these regulated genes. The predominant function of each cluster is given.
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Chapter 4, Figure 3. Molecular concept analysis of regulated gene sets after 24h of differentiation. Per set 
the top 20% highest affected genes were used. The size of the gene set corresponds with the size of the 
node, and the width of the connecting lines indicates the degree of overlap between the respective gene 
sets. 
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Chapter 4, Figure 4. Principal Component Analysis (PCA) of the control cultures after 0, 24, 48, 72 and 
96h of differentiation, and cultures exposed to monobutyl phthalate (MBP) or 6-aminonicotinamide 
(6-AN) for 24 or 96 h. The PCA is based on the 1355 regulated genes. The mean values per experimental 
group are indicated by the large circles and the ‘differentiation track’ is shown by the dashed line. 
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Chapter 4, Figure 5. Molecular concept analysis of regulated gene sets (A) after 24h monobutyl phthalate 
exposure in differentiation cultures and (B) after 24h 6-aminonicotinamide exposure in differentiation 
cultures. Per set the top 20% highest affected genes were used. The size of the gene set corresponds with 
the size of the node, and the width of the connecting lines indicates the degree of overlap between the 
respective gene sets. 
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Chapter 5, Figure 3. (A) Clustering of the 3579 genes transcriptionally responsive to ESC differentiation 
between 0, 24 and 48 h. Each row represents the relative expression of a single gene throughout 
differentiation. (B) Principal Component Analysis of unexposed control cultures (CON) after 0, 24 and 48h 
of differentiation using the 3579 differentiation-related genes. The arrow connecting these experimental 
groups represents the differentiation track. 
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Chapter 5, Figure 4. (A) Clustering of the 26 genes that are both transcriptionally responsive to ESC 
differentiation with time and are also regulated by exposure to all developmental-toxic compounds 
tested. (B) Principal Component Analysis of the non-exposed cultures (CON) (individual samples, circles) at 
different stages of differentiation and compound-exposed cultures (mean of n=8 samples, asterisks) using 
the 26 biomarker genes. 
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Chapter 6, Figure 1. Heatmap of the mean gene expression values of the unexposed control samples at 
0, 24, and 48h of differentiation in our previous (_prev; van Dartel et al., 2010a) and present study using 
the differentiated-related genes identified in our previous study (3579 genes; A) and in the present study 
(3780 genes, B). PCA plots based on ESC differention-related genes in our previous study (C) and the 
present study (D). Unexposed ESC differentiation samples of the previous study (circles) and the current 
study (triangles) are presented. 
Dorien BW v12.indd   273 12-05-11   14:09
274  
Cbr3*
2210411K11Rik*
Dennd2c*
Depdc7*
Lgr4*
Rad51c*
Pxmp2*
Zfp518*
Cdca7*
Psmc3ip
Nfyb*
Rab25
Zcchc18
Unc13b
Cyp2s1*
Mlf1*
Dapk1*
Il18*
Manea*
Epb4.1l3*
Stxbp4*
H1f0*
Casd1*
Sept9*
Kdm4b*
Tmem9b*
Wnt3*
Fgf8*
Igfbp3*
Eomes*
Gsc*
Fst*
Car2*
Epha1*
Wnt8a*
Mixl1*
Nrarp*
1110067D22Rik*
4631416L12Rik*
S100a10*
Gas1*
Sp5*
Evx1*
Upp1*
Alox15*
Zfp105
Tceal8
Sln
Car4*
Nupr1*
Nkx2-9
Phox2a*
Egr2*
Cmklr1*
F3*
Ccnd2*
Hmga2*
Krt8*
Cer1*
T*
Cyp26a1*
Rspo3*
Frzb*
Mesp1*
-10 -3 ±1 3 10
CO
N
 0
h
CO
N
 2
4h
CO
N
 4
8h
CO
N
 0
h
CO
N
 2
4h
CO
N
 4
8h
PC
2
-2 -1 0 1 2
-2
-1
0
1
2
CON 0h
CON 24h
CON 48h
C
D
PC
2
-4 -2 0 2 4 6
-2
0
2
4
CON 0hCON 24h
CON 48h
A
B
PC1
PC1
Chapter 6, Figure 3. Mean gene expression of the ‘Van_Dartel_heartdiff_24h’ (A) and ‘EST biomarker 
genes’ (B) gene sets at 0 h, 24 h, and 48h of control ESC differentiation cultures (CON). * Indicate 
significantly differentially expressed genes among the 0 h, 24 h, and 48h CON groups. Principal 
Component Analysis of the control ESC differentiation cultures (individual samples, circles) at 0 h, 24 h, 
and 48h of ESC differentiation using the ‘Van_Dartel_heartdiff_24h’ (C) and ‘EST biomarker genes’ (D). 
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Chapter 7, Figure 2. (A) Concentration-related effect of flusilazole exposure in ESC differentiation cultures 
on absolute average fold change of a subset of enriched GOID. For comparability reasons the absolute 
average fold change was calculated using the significantly differentially expressed genes that contributed 
to the enrichment in at least one of the experimental groups. (B) Concentration-related effect of 
flusilazole exposure in ESC differentiation cultures on relative gene count associated with Gene Ontology 
Identifiers (GOID). GOID in red-yellow are related to development, in green to cell division and blue to 
lipid metabolism. ‘Total’ refers to total number of genes annotated to that GOID, and ‘regulated’ refers to 
total number of statistically significant genes that contributed to the enrichment of that GOID in at least 
one experimental group. Asterisks indicate statistically significantly enriched GOID. 
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Chapter 7, Figure 4. Mean gene expression of the ‘Van_Dartel_heartdiff_24h’ (A) and ‘EST biomarker 
genes’ (B) gene sets at 0 h, 24 h, and 48h of control ESC differentiation cultures (CON). * Indicate 
significantly differentially expressed genes among the 0 h, 24 h, and 48h CON groups. Principal 
Component Analysis of the control ESC differentiation cultures (individual samples, circles) at 0 h, 24 h, 
and 48h of ESC differentiation and flusilazole-exposed cultures (mean of n=8 samples, asterisks) using 
the ‘Van_Dartel_heartdiff_24h’ (C) and ‘EST biomarker genes’ (D). C’ and D’ present the enlargement of the 
CON 24h samples and the flusilazole-exposed cultures (FLU). 
Dorien BW v12.indd   276 12-05-11   14:09
Color figures 277
ES
C 
di
e
re
nt
ia
tio
n
G
O
ID
: R
es
po
ns
e 
to
 c
he
m
ic
al
 s
tim
ul
us
G
O
ID
: T
ra
ns
cr
ip
tio
n
G
O
ID
: D
ev
el
op
m
en
ta
l p
ro
ce
ss
ES
C 
di
e
re
nt
ia
tio
n
G
O
ID
: S
te
ro
id
 m
et
ab
ol
ic
 p
ro
ce
ss
G
O
ID
: T
ra
ns
cr
ip
tio
n
G
O
ID
: D
ev
el
op
m
en
ta
l p
ro
ce
ss
A B
M
M
P
M
M
P
FL
U
M
EH
P
H
EX
TD
I
-5 -3 ±1 3 5
M
M
P
M
M
P
FL
U
M
EH
P
H
EX
TD
I
Klf11
Plin2
Txnip
Zfp185
Six2
Klf10
Smad7
Trim6
Cd40
Mt2
Has2
Cytsb
Mt1
Epb4.1l1
Atp6v1h
2310014H01Rik
Pid1
Rbbp7
Wdr6
Pls1
Cadm1
Cd24a
D0H4S114
Epb4.1l3
Spef1
Lbh
Lhpp
Cth
Derl3
Rpl23
Sk25a38
Oxct1
Cbs
Zfp771
Lrrc56
Ccnd1
Rbmx
Sec14l4
Tox3
Lrrc4
Ppp1r1a
Foxa1
Ccno1
Ndrg1
Cd109
Ccdc96
Efcab10
Wnt8a
Zcchc18
Rsph9
Lrig1
Chrna9
Irx3
Hsd11b2
Kif27
Nme5
Ttc25
Chrd
Mak
Irx5
1700027A23Rik
1700009P17Rik
Lgr5
Foxj1
1110017D15Rik
Rsph4a
Foxd4
Hoxa1
Zfp503
Gbx2
Cdx1
B3gnt7
Sc4mol
Insig1
Irgm1
Lss
Fdft1
Foxb1
Ldlr
Utp14b
Id2
Pim1
Lrp8
Sqle
Pvrl2
Thbs2
Tcfap2c
Skap2
Sox13
Il17rd
Lphn2
Ctdsp2
Ubc
Eif1
Impdh2
Cdc42
Rab14
Dars
Sfrs11
Lsm11
Rgs19
Asf1b
Thap11
Wdr46
Bloc1s3
Hps6
Zfp410
0610009B22Rik
Ankrd10
Mrm1
Mett10d
Trim59
Jmjd6
Cebpg
Cbx8
Luc71
Prpf38b
Zfp322a
Hes1
Fam57a
Pdxp
Zfp647
Tdgf1
Pmaip1
Clk1
Jakmip1
Otx1
Ccne2
2810403A07Rik
Ccng2
Ddit4
Nl3
Ier3
D4Wsu53e
Mesp2
Chapter 8, Figure 3. Heatmap of the identified phthalate signature (A) and triazole signature (B). 
Responsiveness of the genes to early ESC differentiation and annotation of the genes to parent terms 
covering enriched GOID are indicated on the right of each figure. 
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Chapter 8, Figure 4. Discrimination of phthalates from triazoles using principal component plots of 
monomethyl phthalate (MMP), monobutyl phthalate (MBP), monoethylhexyl phthalate (MEHP), flusilazole 
(FLU), hexaconazole (HEX) and triadimefon (TDI) on the basis of the identified phthalate signature (A) 
and the triazole signature (B). The principal component analysis-based discrimination was validated by 
studying the projection of additional compounds (C), by evaluating the position of MBP tested in our 
previous study (MBP_PREV, D), and by performing leave-one-out analyses (E). 
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Chapter 8, Figure 5. Hierarchical clustering of control (CON), monomethyl phthalate (MMP), monobutyl 
phthalate (MBP), monoethylhexyl phthalate (MEHP), flusilazole (FLU), hexaconazole (HEX) and triadimefon 
(TDI) using all genes annotated to gene ontology identifiers (GOID) enriched in the phthalate signature 
(A) or triazole signature (B), using predefined gene sets (C), and using a negative control gene set (D). 
Asterisks indicate significant GOID enrichment (p-value<0.05) within the significantly regulated genes 
(p-value<0.001) of that compound. The color of the nodes indicates the confidence value (bootstrap 
value) for each node in the clustering tree. 
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Chapter 10, Figure 1. Network visualizations for three gene set collections. A, network for c2.cgp 
collection (591 genes, 1243 edges); B, network for lung-inflammation collection (133 genes, 930 edges); 
C, network for ESC-diff (embryonic stem cell differentiation) collection (927 genes, 7402 edges) with 
transitions between sub-networks indicated as dashed lines. 
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Chapter 10, Figure 2. Embryonic stem cell cardiomyocyte differentiation co-regulation network. A, 
biological process enrichment in network clusters containing novel functional candidates; B, peak gene 
expression for genes in a stem cell differentiation time series. 
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